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1chapter
general introdUction

1General IntroductIon
1.1 flavonoids 
Vitamin P
In the 1930s, Szent-Györgyi identified a substance in lemon peel that reduced capillary 
permeability, and called it ‘vitamin P’ 1. This vitamin status was never confirmed. Later, 
he reported that the substance contained, among others, the flavonoid hesperidin 2. 
Flavonoids belong to the large group of polyphenols which are abundantly present 
in all plant foods. Polyphenols may contribute to the beneficial health effects of fruits 
and vegetables, and therefore there is substantial interest in these dietary compounds. 
Flavonoids have been mostly studied for their preventive role against several diseases, 
like cancer and cardiovascular diseases (CVD) 3. However, still no conclusive underlying 
mechanism has been found which is targeted by these dietary compounds.
Flavonoid structure
The basic flavonoid structure is an aglycone that is characterized by two aromatic 
rings, called A and B that are linked by a heterocyclic pyrane ring (C). Flavonoids 
can be divided into six subclasses: anthocyanins, flavan-3-ols, flavanones, flavones, 
flavonols, and isoflavones, which are all present in our diet (Figure 1.1). The differences 
between the subclasses are determined by differences in oxidation state and pattern 
of substitution of the C ring. The individual flavonoids within a subclass differ in the 
level of substitution on the A and B rings 3,4.
Presence in food and intake of flavonoids
Anthocyanins, flavanones, flavones, flavonols, and isoflavones are present as glycosides 
in our food. In these glycosides sugars are covalently bound to the aglycone, in 
general at the hydroxyl moiety at position 3 or 7. The attached compound can be 
a rhamnose, glucose, glucorhamnose, galactose, arabinose or another sugar. Some 
flavonoids are found in all plant food products, such as fruits, vegetables, cereals, tea, 
and wine, whereas other flavonoids are mainly found in specific types of foods. For 
figure 1.1 basic structures of the six flavonoid subclasses.
9
Chapter 1
1
example, isoflavones are mainly present in soy and flavanones in citrus fruits. However, 
most foods contain a mixture of various flavonoids 4,5. 
It is difficult to estimate flavonoid intake from food intake. This is because the amount 
of flavonoids may vary widely within a product type. For example, within different varieties 
of apples and between yellow and red onions a 2-3 fold difference in the amount of 
flavonoids was found 6. Furthermore, in most foods flavonoids are not evenly distributed, 
with the peel or surface commonly containing most of the compounds 6,7. Furthermore, 
processing and storage will influence the amount of flavonoids in food 3. Table 1.1 shows 
the different subclasses of flavonoids and their main flavonoids, examples of foods in 
which they are present, and an estimation of the flavonoid concentrations in these foods. 
The estimated total dietary intake of flavonoids is between 100 and 1000 mg/day 4. 
However, when supplements are used the intake will be much higher. For example, for 
some quercetin containing supplements the intake can be about 1500 mg/day, which is 
far beyond the estimated dietary intake of quercetin of 16 mg/day 8. 
1.2  absorption, distribUtion, metabolism 
and excretion of flavonoids
For systemic effects of flavonoids it is essential that the flavonoids will enter the 
bloodstream, therefore the absorption, distribution, metabolism and excretion of 
flavonoids will be described in this paragraph.
table 1.1 Presence of flavonoids in foodsa.
flavonoid 
subclasses
flavonoids dietary sources concentrations  
(mg/kg) or (mg/l)
Anthocyanins Cyanidin
Delphinidin
Malvidin
Pelargonidin
Aubergine, Blackberry, Blueberry, 
Cranberry, Elderberry, Plum, Strawberry
20-10,000
Flavan-3-ols Catechin
Epicatechin
Epigallocatechin
Chocolate, Cocoa,  
Tea (black/white), Wine (red/white)
60-800
Flavanones Hesperetin
Naringenin
Grapefruit, Orange 100-650
Flavones Apigenin
Luteolin
Celery, Olive, Parsley 20-1850
Flavonols Myricetin
Kaempferol
Quercetin
Apple, Beans, Blueberry, Broccoli, 
Elderberry, Onion, Spinach, Tea
30-1200
Isoflavones Daidzein
Genistein
Soya Beans 200-900
aBased on 4,9.
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Absorption
When foods are ingested flavonoids are mostly present in the form of glycosides. There 
are some indications that already in the saliva of the mouth hydrolysis of the glycosides 
can take place 10. It was shown in rats that some flavonoids in their aglycone form can 
be absorbed in the stomach 11,12. Nevertheless, the intestines are the most important 
organs in absorption of flavonoids. In the small intestine, flavonoid glycosides can 
mostly not be absorbed, while aglycones and glucosides can be absorbed. Flavonoid 
glycosides are hydrophilic, which prevents passive diffusion across the intestinal wall. 
The Na+ dependent glucose co-transporter SGLT1 was shown to be able to transport 
quercetin glucoside across the small intestine 13. Furthermore, lactose phloridzin 
hydrolase (LPH) attached to the outside of the small intestinal cells was shown to work 
as a glucosidase, facilitating subsequent absorption of the aglycone 14. The flavonoid 
glycosides which cannot be transported via these mechanisms in the small intestine 
arrive in the colon. Here, glycosides should be hydrolysed by enzymes of the colonic 
microflora before they can be absorbed 15. However, it was also shown that aglycones 
can be (partly) degraded by the colonic microflora 16.
Tissue distribution and plasma concentrations
After consumption of flavonoid rich-foods, flavonoids first enter the gastro-intestinal 
tract, where the highest concentrations of flavonoids are expected. This was shown in 
studies with radiolabeled flavonoids which were found at the highest levels in stomach, 
intestine and liver 17-19. Studies on the tissue distribution of quercetin in pig and chicken 
found also the highest levels in the small intestine, followed by significant levels in liver 
and kidneys 20,21. Long-term exposure of rats to quercetin revealed appreciable amounts 
in lung and testis 22. Overall, flavonoids have been detected in very different tissues like 
brain, heart, kidney, lung, spleen, pancreas, prostate, uterus, ovary, mammary gland, 
testes, bladder, muscle, bone and skin 4. After uptake in the gastro intestinal tract, 
flavonoids enter the circulation via the portal vein and the liver. Alternatively, it was shown 
that some flavonoids can be absorbed into the circulation via the lymphatic system 23. 
The amount of flavonoids found in plasma after consumption of foods varies between 
nM and, rarely, low µM concentrations, consisting mainly of flavonoid conjugates, since 
flavonoids are intensively metabolised in the human body. For anthocyanins the plasma 
levels are even much lower, they can only be found in the low nM range in plasma 4,24,25. 
metabolism
Metabolism including especially conjugation of flavonoids takes place in the intestinal 
enterocytes and thereafter also in other organs. There are three types of conjugation 
that are relevant for flavonoids: glucuronidation by UDP-glucuronyltransferases 
(UGTs), sulfation by sulfotransferases (SULTs), and methylation by catechol-O-
methyltransferases (COMTs) 26. Glucuronidation of flavonoids by UGTs occurs at the 
11
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hydroxyl moieties at the 7, 3, 3’ and/or 4’ positions of the aglycone, and UGT activity 
for flavonoid conjugation was found in intestines, liver and kidney. During sulfation 
of flavonoids in liver and intestines a sulfate moiety is added likely to the hydroxyl 
moieties at position 3’ or 7 of the aglycone 27. Both SULTs and UGTs consist of a family 
of different isoforms of which some are predominately responsible for conjugation at 
a specific site or present in a specific tissue 3. Methylation will result in the addition of 
a methyl group mainly at the hydroxyl moieties at the 3’ and 4’ position of flavonoids. 
Methylation of flavonoids by COMTs was found in liver, kidney and small intestine. 
Conjugation can also occur at more than one position which normally leads to formation 
of di- or tri-conjugates containing different types of conjugating groups attached to 
the aglycone 3. The metabolism of flavonoids is dependent on the flavonoid, the dose, 
species, and sex. In general, the main conjugated forms found in human plasma are 
flavonoid glucuronides, however, numerous different glucuronidated, sulphated and 
methylated flavonoids are identified in plasma of rodents as well as in humans 4. 
excretion
Flavonoids present in the circulation can be excreted via the urine and via bile into the 
faeces. The main route can be different for different flavonoids. Urinary excretion has 
been shown in human studies for several flavonoids, excretion via urine are regularly the 
small conjugates for example the mono-sulfates. Furthermore, unabsorbed flavonoids 
are excreted via the faeces, these are mostly the large conjugated metabolites 4,28. 
1.3 beneficial health effects of flavonoids
Flavonoid-mediated health effects in human studies
Consumption of foods containing flavonoids has been associated with several 
beneficial health effect 29. Flavonoids are suggested to reduce the risk of CVD, cancer, 
diabetes, inflammatory and neuro generative disorders 3,30-32. Epidemiological studies 
have shown indications for the protective effects of flavonoids against cancer and 
CVD 30,33. Altogether available epidemiological data showed that most evidence was 
found for beneficial health effects of flavonoids on CVD 30. Epidemiological studies 
with foods rich in flavonoids suggested that daily consumption of three or more cups 
of tea per day decreased the risk of coronary heart disease by 11% or the risk of stroke 
by 21% 34,35. Similarly, high cocoa intake was associated with lowered mortality due to 
cardiovascular events by 40-50% 36,37. However, another study did not found such an 
effect 38. Most observational studies that calculated the intake of individual flavonoids 
focused on flavonols. A meta-analysis of these flavonol studies concluded that high 
flavonol intakes could reduce the incidence of stroke by 20% 39. Observational studies 
with other subclasses of flavonoids showed no clear indication of reduced risk on 
CVD 38,40-42. However, the number of studies is limited, which makes it difficult to draw 
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conclusions about the effects on CVD of these flavonoid subclasses 9. Randomized 
placebo controlled intervention studies were in general performed with flavonoid-rich 
foods or extracts and not with individual flavonoids. The studied risk factors related to 
CVD were blood pressure, endothelial dysfunction, and serum lipid profile. A meta-
analysis of 130 trials found that cocoa reduced blood pressure and that soy protein 
rich in isoflavones reduced LDL cholesterol 43. Overall, these human studies suggested 
effects by flavonoids on CVD risk factors, however the effects and possible underlying 
mechanisms are far from being completely known.
mechanisms underlying flavonoid-mediated health effects 
Several mechanisms are proposed to explain the health effects of flavonoids. 
Effects like scavenging free radicals, regulation of nitric oxide, decreasing leukocyte 
immobilization, induction of apoptosis, inhibition of cell proliferation and angiogenesis, 
and estrogenic activity were shown in vitro and in vivo 44. Mostly, the antioxidant and 
free radical scavenging activity of flavonoids were brought up as explanation for 
the health effects. Indeed, flavonoids showed strong antioxidant activities in vitro. 
However, it was demonstrated that these effects could not explain disease prevention 
in vivo, because absorption of flavonoids is low and they are extensively metabolised, 
which further reduces their antioxidant impact in the body 9. Therefore, other 
properties of flavonoids should underlie the beneficial health effects especially on 
CVD. Considering the low absorption and extensive metabolism of polyphenols, only 
biological effects that can be caused by low concentrations should be considered as 
relevant. Such effects may include effects on regulatory pathways, ultimately resulting 
in altered serum lipids or gene expression levels.
Flavonoids and serum lipids in rodents
Some observations in humans suggested an effect of flavonoids on serum lipid profiles. 
Lipid lowering effects of flavonoids are more established in rodents. Table 1.2 shows 
an overview of effects of individual pure flavonoids on serum and hepatic lipids found 
in rodents. Two studies showed that exposure of rats for several weeks to hesperetin 
or its glycoside hesperidin lowered serum triglycerides and cholesterol as well as 
hepatic lipids 45,46, while other hesperetin studies did not show such results in mice and 
rats 47,48. Naringenin and its glycoside naringin, also showed serum triglycerides and 
total cholesterol lowering effects in rodents 48-51. In some of these rodent naringenin 
studies hepatic triglycerides were not lowered, while hepatic cholesterol levels were 
lowered in some cases 49-51. Quercetin showed some lowering effects on serum and 
hepatic triglycerides in mice 52,53. Some other quercetin studies in mice did find 
lowering effects on other serum lipid fractions 53,54. For all of these compounds, these 
effects were not consistently found [37,38,43]. The effects on serum and hepatic lipids 
could be (partly) responsible for the CVD preventive effects of flavonoids, because 
high lipid levels in serum and liver are suggested risk factors for CVD 55-57. However, 
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table 1.2 Flavonoid-mediated effects on serum and hepatic lipids in rodents. 
flavonoids flavonoid in 
diet (w/w)
Weeks diet animal serum 
lipidsa
hepatic  
lipidsa
ref
Hesperidin 1% 4 Normal Streptozotocin-
induced 
marginal type 1 
diabetic rats
↓TG
↓TC 
↑HDL 
↓ LDL
↓Hepatic lipids 45
Hesperetin 0.02 % 6 High 
cholesterol 
Sprague-
Dawley rat
↓TG 
↓TC
↔Hepatic lipids
↓Hepatic TC
46
Hesperetin 1% 3 Normal ICR mice ↔TG 
↔ TC 
↔PL
↔Hepatic lipids 48
Hesperetin 1% 1.5 Orotic acid 
(1%) 
Sprague-
Dawley rat
↔TG 
↔TC 
↓PL
↓Hepatic lipids 47
Hesperetin 1% 1.5 Normal Sprague-
Dawley rat
↔TG 
↔ TC 
↔PL 
↔Hepatic lipids 47
Naringin 0.02% 3,6 High-fat high-
cholesterol
Sprague-
Dawley rat
↓TG 
↓TC (week 6)
↔Hepatic lipids
↓Hepatic TC
51
Naringenin 0.003,0.006, 
0.012%
6 Normal Male Long-
Evans hooded 
rats
↓TG 
↓TC (0.006%)
↔FFA
↔Hepatic TG
↓Hepatic TC 
(0.006%)
49
Naringenin 0.02% 5 High-
cholesterol
Sprague-
Dawley rat
↓TG 
↓TC 
↑HDL 
↔Hepatic TG
↓Hepatic TC
50
Naringenin 1% 3 Normal ICR mice ↓TG 
↓TC 
↓FFA
↓PC
↔Hepatic lipids
BW ↔
48
Quercetin 0.025% 9 High-fat C57BL/6J 
mice
↓TG ↓Hepatic TG
↓Total hepatic 
lipids
52
Quercetin 0.05% 4,8,20 High-fat C57BL/6J 
mice
↓TG
↓FFA (wk 
8,20)
↓Hepatic TG 
(wk 20)
↓Hepatic TC 
(wk 20)
53
Quercetin 0.03% 4 High-fat Wistar rats ↓TG
↑FFA
ND 61
Quercetin 1% 2 Normal ICR mice ↔TG 
↓TC 
↓PL
ND 54
Quercetin 0.05% 4,8,20 Normal C57BL/6J
mice
↔TG
↔TC
↔FFA
ND 53
aEffects could be overestimated, due to interference of flavonoids in the used enzymatic assays, as will be 
described in chapter 2. FFA free fatty acids, TG triglycerides, TC total cholesterol, PL phospholipids.
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the results are possibly compromised by interference of flavonoids with the enzymatic 
assays used, as described in chapter 2. For most flavonoids the lipid lowering effects 
were not conclusive and the mechanisms behind these effects are hardly understood.
1.4 safety of flavonoids
In line with the observed beneficial health effects of flavonoids, flavonoid intake is 
generally regarded as safe because these compounds are naturally present in food. 
However, since supplements of flavonoids are freely available in Western Europe and 
the United States, ingested doses of flavonoids may increase substantially. A human 
intervention trial with antioxidant vitamin supplements showed an increased mortality 
risk in supplement users 58. Therefore, the safety of flavonoids, especially at high dose 
levels, is an item of concern and should also be taken in consideration. 
Adverse effects of flavonoids 
Different types of potential adverse effects have been described for flavonoids. One 
potential adverse effect is based on the interaction of various flavonoids with trace 
elements. Interaction with iron, for example resulted in decreased iron absorption 59. 
This may be especially relevant in relation to flavonoid supplement use in people 
susceptible for deficiency in iron or other divalent metals.
Another potential adverse effect concerns especially isoflavones. Isoflavonoids can 
exert estrogenic and goitrogenic activities 60. The estrogenic properties were shown to 
lead to cancer in rodents 60. Effects on thyroid hormone biosynthesis and goitric effects 
are seen in humans 59. However, some human interventions showed no increased risk 
for hypothyroidism 59,60. Possible adverse effects of isoflavones and inconsistencies in 
the health benefits lead still to some concern for the use of isoflavone supplements. 
Finally, effects of flavonoids on phase 1 metabolism, such as cytochrome P450s 
and phase 2 metabolism enzymes, have been observed. This can cause complications 
due to interactions with drugs and may affect the detoxification capacity of the body 59.
Genotoxic properties of flavonoids
Overall, genotoxic properties of flavonoids are of highest concern with regard to 
safety of flavonoids. Some flavonoids tested positive in various in vitro genotoxicity 
tests. For example genotoxic properties were shown in the Ames test, a bacterial 
reverse mutation test, also after metabolic activation of flavonoids 62-66. Furthermore, in 
several cultured human and rodent cells, formation of micronuclei, DNA single strand 
breaks, and chromosomal aberrations were observed after flavonoid exposure 65,67-70. 
It was also shown that quercetin can generate DNA adducts in different cell types 
in vitro 71. This genotoxicity of flavonoids has been related to the quinone-quinone 
methide chemistry, implicitly connected to the structure of some flavonoids. Structural 
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requirements were shown to contribute to this effect; a free hydroxyl group at the 
3-position, a double bound at the 2,3 position, and a keto-group at the 4-position 62. 
The flavonoid quercetin meets all these requirements and has been shown to form 
quinone methide intermediates, which can bind to DNA. This is likely the mechanism 
of the observed genotoxicity of quercetin in vitro 72.
In vivo, genotoxicity of flavonoids was not shown in rodents after oral quercetin 
administration measured by, among others, micronuclei, chromosomal aberrations, 
and unscheduled DNA synthesis in bone marrow, liver, and gastric mucosa cells 73-77. 
However, quercetin was shown to be carcinogenic in two studies in rats fed a quercetin 
diet of 0.1%-4%, where tumours in intestine, bladder and/or kidney were found 78,79. 
The increased tumour incidence after flavonoid exposure observed in these studies 
have been criticized. Re-evaluations of the study of the National Toxicology Program 
which showed an increase of kidney tumours after quercetin exposure only in male 
F344/N rats 78 led to the conclusions that the observed tumours were specific for the 
rat strain used and probably related to α2u-globulin nephropathy, which occurs only 
in male rats 80,81. The other in vivo quercetin study 79 was also criticized 82 because the 
observed carcinogenicity could possibly be ascribed to the use of a specific rat strain 
and a whole grain diet in the study, which is however not fully understood. Moreover, 
several other long-term studies with even higher doses of quercetin (0.2%-10%), did 
not show carcinogenicity in rodents 83-86. An acute toxicity study in rodents with a 
proanthocyanidin extract also showed no toxicity 87. Finally, for green tea catechins no 
genotoxic or carcinogenic indications were found in rodents 88.
However, taking the high intake of supplementary flavonoids into account, the 
potential genotoxic activity of flavonoids, which is shown in vitro, still leads to concern 
for a possible genotoxic effect of flavonoids in vivo especially for tissues of first contact 
exposed to relatively high levels upon oral intake such as intestine and liver. 
1.5 mechanistic approach 
Several indications for health effect of flavonoids are found, however the mechanisms 
behind these effects are not fully elucidated. In studying the possible health effects of 
flavonoids, several important issues have to be considered. Human studies showing 
indications of flavonoid-mediated health effects are mostly based on flavonoid-rich 
food products, which could also contain other substances influencing the effects, 
like theobromine, and caffeine 89. Therefore, it is important that the pure individual 
compounds are taken along, since there is now only limited information on effects of 
the individual flavonoids. Furthermore, the absorption and metabolism of flavonoids 
should be taken into account when studying possible health effects of flavonoid in 
humans or animal models. 
Several health effect of flavonoids are associated with effects related to lipid 
metabolism. These include reducing effects of flavonoids on circulating lipids, lipid 
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accumulation in the liver and obesity, which are known to be associated with a lower risk 
for CVD 55-57. Liver is a key effector organ of lipid metabolism. Furthermore, reasonable 
concentrations of flavonoids are found in liver, and next to this the liver is involved in 
flavonoid metabolism. Therefore, studying the gene expression (transcriptomic) effects 
of flavonoids in liver will offer a good approach towards identification of mechanisms 
underlying health effects of flavonoids. Transcriptomic tools, which are nowadays widely 
used, allow for an unbiased genome-wide approach to identify effects in specific organs.
Since analysis of liver tissue is not easily arranged in human subjects, the mouse 
is a widely used alternative model. The C57BL/6J mouse strain is a respected model 
for diet-induced obesity, insulin resistance, cardiovascular diseases, and hepatic lipid 
accumulation 90-92, in which effects on lipid metabolism can be adequately studied 93-95. 
When using such an animal model it is important to consider that kinetics of flavonoids 
can be different between species. Various di- and tri-conjugates are found for quercetin 
in the circulation of rodents as well as in humans 96, suggesting a comparable pattern of 
conjugates formed after flavonoid metabolism in mice and humans. Mice are small and 
relatively cheap, there are many research tools available and suitable for use in mouse 
models (like gene expression microarrays and antibodies), highly controlled studies are 
possible, and the mouse genome has an overlap of over 90% with the human genome 97, 
making it a widely accepted and human relevant model for this type of research. 
A combination of transcriptomics and physiological data obtained in mice exposed 
to pure flavonoids will substantially contribute to the unravelling of the possible 
underlying mechanisms of the metabolic health effects of flavonoids. Furthermore, the 
identified targets could be used for translation into biomarkers for effects of flavonoids 
in animals and in humans. 
1.6 aims and oUtline of this thesis
Aims
The first aim of this thesis was to identify mechanisms underlying potential beneficial 
health effects by flavonoids in mice, with a specific focus on hepatic lipid metabolism 
and circulating lipids. These lipid metabolism related markers are associated with a 
reduction of CVD risk by flavonoids. Secondly, we aimed to study the potential in vivo 
genotoxic effects of quercetin in liver and small intestine, since these represent the 
tissues of first contact exposed to relatively high levels upon oral intake of flavonoids.
outline of this thesis
Serum lipid parameters are important CVD related risk markers that will be assessed 
in this thesis. Circulating lipids are in general determined with fast and simple enzyme 
based assays. We have first studied whether these assays can also be used in flavonoid 
research in a sensitive and reliable manner. This is described in chapter 2. 
17
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To unravel the underlying mechanisms of potential beneficial effects of flavonoids 
to CVD related risk factors, mechanistic and physiological effects on hepatic lipid 
metabolism and circulating lipids in mice were first studied for the flavonoid quercetin, 
and results obtained are described in chapter 3. 
Subsequently, the effects of quercetin on hepatic lipid metabolism were studied in mice 
by using a high-fat background diet. This diet was used, because it induces body weight 
gain and hepatic lipid accumulation, enabling potentially more sensitive detection of 
effects of quercetin on hepatic lipid metabolism. In chapter 4 the physiological and 
mechanistic effects of quercetin on hepatic lipid metabolism are described, with a focus 
on the influence of the background diet on the observed effects.
In chapter 5 we investigated if flavonoids from other subclasses could exert the 
same effects on hepatic lipid metabolism as quercetin showed. Furthermore, we 
have extended the investigations by studying whole body energy balance to obtain a 
complete overview of the metabolic effects of the different flavonoids. The effects of 
flavonoids representing five flavonoid subclasses were compared in a fully controlled 
intervention study in mice.
Apart from beneficial health effects of flavonoids, safety aspects have to be considered, 
because of potential genotoxic effects found for quercetin. In chapter 6 possible 
genotoxic effects of quercetin were studied by transcriptome analyses in liver and 
small intestine of quercetin exposed mice. 
Finally, in chapter 7, the general discussion, the outcomes of this thesis are discussed 
and recommendations for future research are given.
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abstract 
Flavonoids are bioactive food compounds with potential lipid lowering effects. 
Commercially available enzymatic assays are widely used to determine free fatty acids 
(FFA) and triglycerides (TG) levels, both in vivo in plasma or serum and in vitro in cell culture 
medium or cell lysate. However, we have observed that various flavonoids interfere with 
peroxidases used in these enzymatic assays, resulting in incorrect lower FFA and TG levels 
than actually present. Furthermore, addition of isorhamnetin or the major metabolite of 
the flavonoid quercetin in human and rat plasma, quercetin-3-O-glucuronide, to murine 
serum, also resulted in a significant reduction of the detected TG levels, while a trend was 
seen for FFA levels. It is concluded that when applying these assays vigilance is needed 
and alternative analytical methods, directly assessing FFA or TG levels, should be used for 
studying the biological effects of flavonoids on FFA and TG levels.
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2.1 introdUction
Free fatty acids (FFA) and triglycerides (TG) plasma levels are important factors which 
can give an indication of the metabolic health status and are therefore generally used 
as markers of lipid metabolism. Commercially available enzymatic kits are widely used 
to determine FFA and TG levels. There are many advantages for the use of these 
assays, including small sample volume, no need for extraction, and high sensitivity 
1. Flavonoids are natural food compounds which are suggested to have beneficial 
lowering effects on lipid status 2. Several studies investigated the effects of flavonoids 
on FFA and TG levels after dietary intervention or cell culture exposure and used these 
enzymatic kits to determine the lipid levels in serum cq. cell culture medium 3-9. FFA 
and TG assays are based on enzymatic reactions. Independent of the supplier of the 
kits, peroxidase catalyzes the final quantitative conversion to the colored compound, 
which is subsequently measured by absorbance in both of these assays. Furthermore, 
also other frequently used enzymatic assays for the determination of for example 
cholesterol and glucose are based on peroxidase reactions.
In the FFA assay, FFA are transformed into Acyl-coA, which is oxidized and generates 
hydrogen peroxide. In a quantitative oxidation reaction, hydrogen peroxide together 
with 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline and 4-aminoantipyrine (4-AA) are 
converted into a blue purple product by peroxidase activity. Absorbance is used to 
quantify the FFA levels. In the TG assay, TG are hydrolyzed with lipases generating 
glycerol, which is converted into glycerol-3-phosphate and oxidized generating 
hydrogen peroxide. Hydrogen peroxide and 4-AA are converted into quinoneimine 
catalyzed by peroxidase. Absorbance of quinoneimine is used to quantify the TG 
levels. It is clear that peroxidase has an important role in both assays, because it 
catalyzes the final quantitative reaction. Importantly, flavonoids are known to be 
inhibitors of peroxidase activity 10-12. Nevertheless, these assays are widely used in 
(nutritional) studies focusing on the effects of flavonoids. The inhibition of peroxidase 
by flavonoids may result in reduced peroxidase mediated color formation, which 
will result in apparently lower FFA and TG levels than actually present. Therefore, 
the aim of the present study was to investigate whether at physiologically relevant 
concentrations flavonoids do indeed interfere with these widely applied peroxidase-
based assays for the quantification of FFA and TG levels. 
2.2 materials and methods
sample preparation
Cell culture medium samples were prepared in 1x DMEM high glucose without phenol 
red (Invitrogen, Breda, The Netherlands), with 10% fetal bovine serum charcoal/dextran 
treated (Thermo Scientific, Logan, Utah, USA), 2% penicillin-streptomycin (Invitrogen), 
and 1% non-essential amino acids (Invitrogen). Medium was supplemented with 80 
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µM linoleic acid-oleic acid-albumin (Sigma, Zwijndrecht, The Netherlands) and 20 
mg/dL triglycerides standard. Quercetin, (+)-catechin (Sigma), naringenin, luteolin, 
kaempferol, and genistein (Extrasynthese, Lyon, France) were individually spiked to 
cell culture medium samples in different concentrations prior to measurements. 
Serum samples obtained from Harlan Laboratories (Horst, The Netherlands) were 
pooled serum of C57BL/6JOlaHsd male mice. Quercetin, quercetin-3-O-glucuronide 
(Phytolab, Vestenbergsgreuth, Germany) and isorhamnetin (Extrasynthese) were 
spiked to the murine serum. 
All flavonoids were dissolved in DMSO, except quercetin-3-O-glucuronide which 
was dissolved in ethanol, for controls only the solvent was added at equal volumes.
Free fatty acids assay
FFA kit reagents (Wako NEFA-HR(2) kit, Sopachem BV, Ochten, The Netherlands) 
were used according to the manufacturer’s protocol with some small adaptations. The 
protocol mentions several usually present compounds in serum or plasma that may 
interfere with the assay; however, information on flavonoids or other bioactive food 
ingredients is not provided. Briefly, 5 or 15 µl of sample plus 100 µl of the first reagent 
were incubated for 10 minutes at 37 °C. Then 50 µl of the second reagent was added 
and incubated for another 10 minutes at 37 °C. Oleic acid (Wako NEFA calibrator 
solution) was used for calibration curves. The absorbance was read at 550 nm using a 
Synergy HT plate reader (Biotek Instruments, Winooski VT, USA). 
Triglycerides assay
TG kit reagent (Triglycerides liquicolor kit, Human, Wiesbaden, Germany) was used 
according to the manufacturers protocol. The protocol mentions several usually present 
compounds in serum or plasma that may interfere with the assay; however, information on 
flavonoids or other bioactive food ingredients is not provided. Briefly, 5 µl of sample plus 
100 µl reagent were incubated for 10 minutes at room temperature. Triglycerides standard 
from the kit was used for calibration curves. The absorbance was read at 500 nm.
statistical analysis
Statistical analysis was performed by One-Way ANOVA followed by Dunnett’s post-hoc 
test, p-value<0.05 was considered significant. 
2.3 resUlts and discUssion
Individual spiking of quercetin, kaempferol and (+)-catechin to the cell culture medium 
prior to measurements resulted in a significant reduction in the FFA levels detected 
(Figure 2.1). The same flavonoids as well as luteolin caused also significant reductions 
in the TG levels detected. The apparent reduction in the levels of FFA and TG in these 
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assays was already present at concentrations (10-100 µM) which are generally used in 
in vitro studies, indicating that these peroxidase-based assays should be used with 
extreme caution under these circumstances. Different flavonoids are known to be able 
to inhibit peroxidase activity 10-12, and thus cause this unintentional reduction in the 
levels of FFA and TG detected by these assays. 
Inhibition of myeloperoxidase activity is dependent on the presence of hydroxyl 
group at the 3, 5 and 4’- positions in the structure of flavonoids and the C2-C3 double 
bond 12. As a consequence, quercetin, kaempferol and luteolin showed inhibition of 
myeloperoxidase in the following order: quercetin > kaempferol > luteolin 12. This 
corresponds with our results, which also showed an identical interference capacity in 
the FFA and TG assays. However, genistein can also inhibit the activity of peroxidase 13, 
while we found no interference of genistein in both assays (Figure 2.1).
In vivo, mainly metabolites of flavonoids are present in the circulation due to 
extensive intestinal and hepatic metabolism. Therefore, we analyzed the effect 
of individual spiking of quercetin, isorhamnetin and the metabolite quercetin-3-
O-glucuronide in murine serum. This also resulted in a significant reduction of the 
FFA and TG levels detected (Figure 2.2). Quercetin-3-O-glucuronide is the major 
metabolite found in human and rat plasma 12,14,15. It was previously shown that plasma 
concentrations of quercetin metabolites could inhibit myeloperoxidase 12. This result 
corresponds with our finding that besides quercetin also its metabolite quercetin-
3-O-glucuronide interferes with the TG and FFA assays. Addition of quercetin-3-
figure 2.1 interference of different flavonoids on the ffa (a) and tg (b) levels in cell culture 
medium measured by enzymatic assays. (+)-Catechin (■), quercetin (□), kaempferol (▲), luteolin 
(Δ), genistein (●), and naringenin (○). Results are mean ± SEM, n = 3 for FFA and n = 4 for TG. 
* indicates a significant difference (p<0.05) from the control (0 µM); B: quercetin has already a 
significant effect at 10 µM.
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figure 2.2 interference of quercetin (□) and its major metabolite quercetin-3-o-glucuronide (■), 
and isorhamnetin (●) in murine serum on ffa (a) and tg (b) levels measured by enzymatic assays. 
Results are mean ± SEM, n = 8. * indicates a significant difference (p<0.05) from the control (0 µM).
O-glucuronide resulted in a significant reduction in the detected TG levels, while 
at similar concentrations it did not have such a strong effect on the FFA assay. 
Furthermore, isorhamnetin seems to have a stronger effect on the FFA assay than 
on the TG assay at similar concentrations. Since the concentrations of quercetin-3-
O-glucuronide resulting in these reductions of FFA and TG levels detected are in the 
range that can be observed in in vivo serum samples upon oral intake of quercetin 16, 
these observations show that when these enzymatic assays are used for in vivo studies 
the results can also be unintentionally influenced. 
There are several recent rodent nutritional studies with quercetin supplementation 
using these enzymatic assays to measure FFA and/or TG levels in serum or plasma 3-9. 
The reported serum quercetin levels in these studies were between 10 µM and 45 µM. 
All studies reported decreased serum levels of FFA and/or TG after dietary quercetin 
supplementation, which could at least in part be due to the interference of quercetin 
with the FFA and TG assays as shown in the present study. The peroxidase-based 
assays for FFA and TG have also been used in human flavonoid intervention studies, 
although most of them found no lipid lowering effects, which could be partly due 
to lower plasma flavonoid levels 2,17. The present study showed a dose-dependent 
interference of various flavonoids and of an important in vivo quercetin metabolite 
with peroxidase-based assays for the detection of FFA and TG levels. Therefore, 
results of studies reporting a reduction in FFA and TG levels upon in vivo flavonoid-
supplementation should be interpreted with caution when these assays are used. 
Nevertheless, this does not exclude the biological effects on FFA and TG levels by 
flavonoids, as effects are also perceived by the use of other analytical techniques 18,19. 
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In conclusion, peroxidase-based enzymatic FFA and TG assays should be applied 
with caution in studies focusing on the effects of flavonoids. Interference of flavonoids 
and their metabolites with peroxidases used in these assays results in apparently 
lower levels of FFA and TG detected than actually present. Most likely this will also 
hold for other enzymatic kits using peroxidase reactions, such as total cholesterol 
and glucose assays. Vigilance is needed and alternative methods including LC-MS, 
gas chromatography, or 1H-NMR should be used in studies focusing on the effects of 
flavonoids on lipid status. 
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abstract 
Elevated circulating lipid levels are known risk factors for cardiovascular diseases (CVD). In 
order to examine the effects of quercetin on lipid metabolism, mice received a mild-high-
fat diet without (control) or with supplementation of 0.33% (w/w) quercetin for 12 weeks. 
Gas chromatography and 1H nuclear magnetic resonance were used to quantitatively 
measure serum lipid profiles. Whole genome microarray analysis of liver tissue was used 
to identify possible mechanisms underlying altered circulating lipid levels. 
Body weight, energy intake and hepatic lipid accumulation did not differ 
significantly between the quercetin and the control group. In serum of quercetin-fed 
mice, triglycerides (TG) were decreased with 14% (p<0.001) and total poly unsaturated 
fatty acids (PUFA) were increased with 13% (p<0.01). Palmitic acid, oleic acid, and 
linoleic acid were all decreased by 9-15% (p<0.05) in quercetin-fed mice. Both palmitic 
acid and oleic acid can be oxidized by omega (ω)-oxidation. Gene expression profiling 
showed that quercetin increased hepatic lipid metabolism, especially ω-oxidation. At 
the gene level, this was reflected by the up-regulation of cytochrome P450 (Cyp) 4a10, 
Cyp4a14, Cyp4a31 and Acyl-CoA thioesterase 3 (Acot3). Two relevant regulators, 
cytochrome P450 oxidoreductase (Por, rate limiting for cytochrome P450s) and the 
transcription factor constitutive androstane receptor (Car; official symbol Nr1i3) were 
also up-regulated in the quercetin-fed mice. 
We conclude that quercetin intake increased hepatic lipid ω-oxidation and lowered 
corresponding circulating lipid levels, which may contribute to potential beneficial 
effects on CVD.
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3.1 introdUction
Cardiovascular diseases (CVD) are globally the most important cause of mortality. High 
consumption of fruits and vegetables are thought to be protective against CVD 1. These 
protective effects have been suggested to be mediated by the flavonoid content of fruits 
and vegetables 2. Various classes of flavonoids are common in plant foods, one being the 
flavonols. Quercetin is the major dietary flavonol in the Western diet, which is present in, 
for example, apples, tea, red wine and onions. Epidemiological studies have shown that 
the intake of this dietary flavonoid is associated with a reduction of CVD risk 3-5. 
Elevated circulating levels of free fatty acids (FFA) and triglycerides (TG) are known 
risk factors for CVD 6-9. In particular, increased levels of FFA and TG are associated with 
atherosclerosis, ischemic damage, pro arrhythmia, myocardial infarction, and heart 
failure. Accumulation of toxic lipid intermediates, suppression of glucose usage, or 
mitochondrial dysfunction potentially play a role in these effects 9. Several studies 
showed that supplementation of quercetin to the diet decreased serum FFA and/or 
TG levels in rodents 10-12. The cardio protective properties of quercetin may therefore 
be explained by the lipid lowering effect of quercetin. However, in these studies the 
FFA and TG levels were measured with enzyme-based assays. Recently, we have shown 
that flavonoids interfere with these enzymatic FFA and TG assays, which will lead 
to incorrect, apparently lower FFA and TG levels 13. Therefore, it can be questioned 
whether quercetin has a true biological effect on lipid metabolism. Since various 
fatty acids are differently associated with CVD risk, it is also important to examine 
whether quercetin changes specific lipids 14. Furthermore, based on gene expression 
analysis some genes have been put forward to explain the effects of quercetin on lipid 
metabolism 11,12, but these results are not conclusive. The aim of the present study 
was to re-examine the effects of quercetin on lipid metabolism, with state-of-the-art 
analytical techniques, to exclude any interference of quercetin in the measeruments. 
Gas chromatography (GC) and a novel technique, 1H-nuclear magnetic resonance 
(1H-NMR) lipid profiling of mouse serum (based on 15,16), were used to profile and 
quantify different serum lipids. In addition, whole genome microarray gene expression 
analysis of liver tissues was applied to unravel the possible underlying mechanisms. 
For this gene expression analysis the liver was chosen as target organ, since it is one of 
the major effector organs of lipid metabolism. This principal combination of profiling 
of serum lipids and gene expression were used to investigate the mechanisms of 
action of quercetin on lipid metabolism.
The results show that a quercetin supplemented mild-high-fat diet in mice increased 
hepatic lipid metabolism, especially omega (ω)-oxidation and reduced corresponding 
circulating lipid levels. These results contribute to the understanding of the protective 
properties of quercetin on CVD. 
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3.2 materials and methods
Animals and treatments
Twenty-four male C57BL/6JOlaHsd mice (Harlan Laboratories, Horst, The Netherlands) 
were individually housed and maintained under environmentally controlled conditions 
(temperature 21°C, 12 h/12 h light-dark cycle, 45% humidity). The mice had ad-libitum 
access to food and water. The food was a pelletized diet (Research Diets Services B.V., 
Wijk bij Duurstede, the Netherlands) with a mild-high-fat content of 30 energy % (en%). 
The fat content (en% and fat composition) corresponds to the average human intake 
in the Netherlands (Dutch Food Consumption Survey, 1998). The mice entered the 
experiment at 10 weeks of age. After two weeks of adaptation, the quercetin group 
(n=12) received the mild-high-fat diet supplemented with 0.33% (w/w) quercetin (Sigma, 
Zwijndrecht, the Netherlands) for twelve weeks. The control group (n=12) was given the 
mild-high-fat diet without quercetin. The body weight and food intake of individual 
mice were monitored on a weekly basis. After 12 weeks of intervention all mice were 
fasted for two hours before anesthetisation by inhalation of 5% isoflurane. Blood was 
sampled via orbital extraction in collect serum tubes (Greiner Bio-one, Longwood, USA), 
which were centrifuged for 10 min at 3000 g 4 °C to obtain serum, which was stored 
at -80°C. After blood collection, the mice were killed using cervical dislocation and the 
liver was dissected, weighted and snap frozen in liquid nitrogen and stored at -80°C. 
The experiment was performed according to the Dutch Animal Experimentation Act 
(1996) and the experimental protocol was approved by the Animal Welfare Committee 
of Wageningen University, Wageningen, The Netherlands (DEC 2007080).
hPLc analysis of quercetin serum levels
HPLC with a coulometric array detector was used to measure the amount of quercetin 
in serum. For this 35 µl of serum was hydrolyzed by incubation with 15 μl of 12.5 mg/ml 
β-glucuronidase/sulfatase in 0.5 M sodium acetate (pH =5) with 5g/l ascorbic acid for 
two hours at 37°C to obtain deconjugated quercetin, isorhamnetin and tamarixetin. 
Subsequently, all samples were deproteinized by mixing with 100 μL acetonitrile and 
50 μL 20% H3PO4, with 3g/L ascorbic acid and centrifugation for 10 min at 13500 rpm 
at 5°C. Twenty μl of the supernatant was analyzed on a HPLC system consisting of 
two pumps (model L-2100; Hitachi, Tokyo, Japan), an autosampler (Model L-2200, 
Merck Hitachi), a CoulArray Module (Model 5600, ESA, Chelmsford, MA, USA) 
with electrochemical channels using carbon electrodes arranged in line and set to 
increasing specified potentials (1=20 mV; 2=100 mV; 3=250 mV; 4=500 mV) and a 
thermostatic column/cell chamber set at 30°C. The chromatography was performed 
on a Platinum C18 column (EPS; 150x4.6mm, 3μ, Grace Davison Sciences, Deerfield, 
IL, USA) equipped with a MPLC Newguard precolumn (Brownlee RP18 7μm 15x3.2mm, 
Perkin Elmer, Shelton, CT, USA), using a gradient elution with two mobile phases. 
Mobile phase A consisted of 15% acetonitrile in 25 mM H3PO4 buffer (pH 2.4). Mobile 
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phase B consisted of 50% acetonitrile in 25 mM H3PO4 buffer (pH 2.4). The gradient, 
at a flow rate of 1.0 ml/min, was as follows: 0–20 min, linear gradient from 0% to 100% 
mobile phase B; 20–22 min, isocratic at 100% B; 22– 30 min, linear return from 100 to 
0% B; the total runtime was 30.0 min. Quercetin, isorhamnetin and tamarixetin were 
quantified using calibration curves made with commercially available standards. 
hepatic lipid staining with oil Red o
Frozen liver sections (7 µm) were fixed with 3.7% buffered formalin. Neutral lipids 
were stained with Oil red O (Sigma). The stained areas were quantified based on 
a described method 17 using Photoshop software (version 12.0.4, Adobe). Briefly, 
contrast was enhanced with automatic contrast tool, red pixels were selected with the 
colour range selecting tool, and total selected area was measured in µm2. Ten to 16 
pictures per animal were quantified (n=6-8). Controls of hepatic lipid accumulation 
were liver of C57BL/6JOlaHsd mice fed a normal-fat diet (10 en% of fat) or a high-fat 
diet (40 en% of fat) for twelve weeks. 
serum lipid analysis with enzymatic assays
FFA assay (Wako NEFA-HR(2) kit, Sopachem BV, Ochten, The Netherlands) and TG 
assay (TG liquicolor kit, Human, Wiesbaden, Germany) were performed as described 
previously 13.
serum fatty acid analysis with Gc
Total serum fatty acids were extracted from 50 µl serum as described 18, using 
dichloromethane instead of chloroform 19. Ten µg of nonadecanoic acid methyl ester 
(NuCheck Prep, USA) was added to each sample before extraction, as an internal 
standard. Samples were transmethylated to fatty-esther methyl esthers (FAME) by 
incubation in 1M sodium methoxide in dry methanol for 20 min at 80°C. The reaction 
mixture was then cooled, acidified with 98% sulphuric acid and incubated for 1 hour 
at room temperature to methylate free acids. Lipid methyl esters were extracted with 
hexane, and the hexane extracts were subsequently dried under a nitrogen flow. Next, 
the residue was dissolved in 100 µl of n-heptane and stored at -20°C under nitrogen 
until analysed. All reactions were performed under nitrogen atmosphere. GC was 
performed with a Trace-GC gas chromatograph combined with AS 2000 autosampler 
(ThermoFinnigan, USA), equipped with a capillary split/splitless injector and a flame 
ionization detector. Analyses of FAME were performed on a fused-silica capillary 
column coated with chemically bond stationary phase CP-Sil 88 CB (100 m, 0.32 mm 
I.D.). The oven temperature was programmed as follows: from 80°C to 260°C at 
2°C/min, then to 280°C at 10°C/min, where it was maintained for 45 min. The injector 
and detector temperatures were set at 250°C and 270°C, respectively. Hydrogen 
carrier gas was maintained at a head pressure of 70 kPa and total flow of 44 ml/min, 
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with a split ratio of 1:35. Integration software Clarity version 2.4.1.57 (Data Apex Ltd. 
Prague, Czech Rep.) was used for data acquisition and handling. 
serum lipid analysis with 1h-NmR 
Total serum lipids were extracted from 20 µl of blood serum as described 18 based 
on 15,16 with some adaptations to optimise the protocol. Briefly, 20 µl of 150 mM sodium 
phosphate buffer with 0.04% azide (pH =3) was added per serum sample. Then 900 µl 
chloroform:methanol (2:1) v/v and 900 µl 0.15 M NaCl (pH =3) were added to the 
sample. Samples were shaken for 5 minutes on a horizontal shaker and centrifuged 
for 10 minutes at 4500 g to separate the organic and water phase. The lower organic 
phase was recovered and the aqueous layer was extracted again with 500 µl chloroform. 
The collected organic layers were combined and evaporated to dryness using argon. 
The samples were vacuum and freeze dried and dissolved in chloroform containing 
0.03% tetramethylsilane. 1H NMR was measured on a Bruker AVANCE spectrometer 
operating at 600 MHz. For each spectrum 256 (Free induction decays (FID)) transients 
were collected with a flip angle of 90°, with an acquisition time of 1.82 s, a relaxation 
delay of 4 s, a spectral width of 30 ppm and a standard noesy 1D pulse sequence, at 
25°C, and four dummy scans were used. The FID with 64K data points were once zero-
filled and multiplied by an exponential window function with a 0.2 Hz Line-broadening 
before a subsequent Fourier transformation. To all spectra a baseline correction was 
applied and the spectra were aligned on the chloroform peak at 7.24 ppm. 
The nature of the various resonances was based on the 1H NMR spectra as 
reported 15, 16. The regions selected to quantify the different lipid fractions were as 
follows; TG (4.300-4.250 ppm), total FFA (1.380-1.198 ppm), mono unsaturated fatty 
acids (MUFA) and PUFA (-CH=CH-)(5.41 to 5.27 ppm), other PUFA than 18:2 FA (2.862-
2.768 ppm), 18:2 FA including linoleic acid (18:2(n-6)) (2.767-2.721 ppm), 18:1 and 16:1 
FA including oleic acid (18:1(n-9)) (2.050-2.011 ppm), 22:6 FA including docosahexaenoic 
acid (22:6(n-3)) (2.379-2.342 ppm), ω-3 FA (0.957-0.947 ppm), phophoglycerides (PGLY) 
(5.258-5.190 ppm), phosphatidylcholine (PC) (3.787-3.738 ppm), esters of cholesterol 
(EC) (4.651-4.539 ppm) and total cholesterol (TC) (0.902-0.895 ppm). 
Fatty acid composition of diets
Fatty acids from the diets were extracted with accelerated solvent extraction according to 
the manufacturer’s protocol (Thermo Scientific) and dissolved in toluene. Subsequently, 
toluene was evaporated under nitrogen at 40°C and fatty acids were dissolved in iso-
octane (5 ml) and 200 µl 2 M KOH in methanol was added and the mixture was shaken 
for one minute. For neutralization, NaHSO4 was added and samples were shaken for 1 
minute. The iso-octane fraction (1 µl) was injected in the gas chromatograph equipped 
with a capillary split injector (split ratio 1:40) and flame ionization detector. Analyses 
were performed on a CP select column for FAME (50 m x 0.25 mm ID). The oven 
temperature was programmed from 100°C to 230°C at 6°C/min. 
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RNA isolation 
For RNA isolation, liver was homogenized in liquid nitrogen, total RNA was isolated using 
TRIzol reagent (Invitrogen, Breda, The Netherlands) followed by purification with RNeasy 
columns (Qiagen, Venlo, The Netherlands). RNA concentration and purity were measured 
using a Nanodrop spectrophotometer (IsoGen Life Science, Maarsen, The Netherlands); 
all RNA samples were of high purity. RNA quality was additionally checked on the Experion 
automated electrophoresis system (Bio-Rad, Veenendaal, The Netherlands).
microarray analysis
For global transcriptome analysis of liver samples, 4 x 44K Agilent whole-mouse genome 
microarrays (G4122F, Agilent Technologies Inc., Santa Clara, CA) were used. Preparation 
of the samples and the microarray hybridizations were carried out according to the 
manufacturer’s protocol with a few modifications as described previously 20. All materials 
and reagents were from Agilent Technologies, Palo Alto, USA unless stated otherwise. 
Briefly, cDNA was synthesized for each animal from 1 μg RNA using the Agilent Low-RNA 
Input Fluorescent Linear Amplification Kit without addition of spikes. Thereafter, samples 
were split into two equal amounts, to synthesize Cyanine 3-CTP (Cy3) and Cyanine 5-CTP 
(Cy5) labelled cRNA, using half the amounts per dye as indicated by the manufacturer. 
Labelled cRNA was purified using RNeasy columns (Qiagen). All samples had a cRNA 
yield higher than 825 ng and a specific activity of at least 8.0 pmol Cy-dye per µg cRNA. 
Cy3-labeled cRNA samples were pooled on an equimolar basis and used as a common 
reference pool. Individual 825-ng Cy5-labeled cRNA and 825-ng pooled Cy3-labeled 
cRNA were fragmented in 1x fragmentation and 1x blocking agent at 60°C for 30 min 
and thereafter mixed with GEx hybridization buffer (HI-RPM) and hybridized in a 1:1 ratio 
at 65°C for 17h in the Agilent Microarray Hybridization Chamber rotating at 10 rpm. After 
hybridization, slides were washed according to the manufacturers’ wash protocol. Arrays 
were scanned with an Agilent scanner with 10 and 100% laser-power intensities. 
Normalisation and microarray data analysis
Signal intensities for each spot were quantified using Feature Extraction version 9.1 
(Agilent Technologies). Median density values and background values of each spot 
were extracted for both the experimental samples (Cy5) and the reference samples 
(Cy3). Quality control for every microarray was performed visually by using ‘Quality 
control graphs’ from Feature extraction and M-A plots and box plots, which were 
made using limmaGUI in R (Bioconductor, Wettenhal, 2004). Data were imported 
into GeneMaths XT 2.0 (Applied Maths, Sint-Martens-Latem, Belgium). Spots with 
an average Cy5 and Cy3 signal twice above background were considered expressed 
and log transformed. The Cy5 signal was normalized against the Cy3 intensity as 
described before 21. Pathway analysis was performed using MetaCore (GeneGo, St. 
Joseph, Michigan, USA) and Ingenuity Systems (Ingenuity, Redwood City, California, 
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USA). Fold change was expressed as the ratio of the quercetin group versus the control 
group. Microarray data has been deposited in NCBI Gene Expression Omnibus (GEO) 
under accession number GSE39140.
Real time quantitative polymerase chain reaction (RT-qPcR)
RT-qPCR was performed using the RNA of the liver samples to validate the microarray 
data. One microgram of RNA of all individual samples was used for cDNA synthesis 
using the iScript cDNA synthesis kit (Bio-Rad). RT-qPCR reactions were performed 
with iQ SYBR Green Supermix (Bio-Rad) using the MyIQ single-colour real-time 
PCR detection system (Bio-Rad). Individual samples were measured in duplicate. 
Data were normalized against reference genes beta-2 microglobulin (B2m) and 
hypoxanthine phophoribosyltransferase 1 (Hprt1) which were chosen based on 
stable gene expression levels (geNorm, Ghent University Hospital, Ghent, Belgium) 
and the microarray data. Primers were designed using the NCBI Primer-Blast (NCBI 
Web site). Sequences of the used primes were as follows: cytochrome P450 4a14 
(Cyp4a14); 5’-TTCTTTCGCCTGCGGAATGC-3’ and 5’-CACTCCATCTGTGTGCTC 
GTGA-3’, cytochrome P450 4a10 (Cyp4a10); 5’-TCTACCCACCTGTCCCAGGC-3’ 
and 5’-ACACCTCTGGATTTGGCCACA-3’, acyl-CoA thioesterase 3 (Acot3); 5’-GC 
TGTGACCTACCTGCTCAGTCA-3’ and 5’-ATATAGAGCCATTGATGATGACAGCGG-3’, 
cytochrome P450 oxidoreductase (Por); 5’-CGAGGGCAAGGAGCTGTACC-3’ and 
5’-CACAGGTGGTCGATGGGTGG-3’, constitutive androstane receptor (Car; official 
gene symbol Nr1i3); 5’-CCGTGTTGCCTCTGCTCACA-3’ and 5’-GGTTAGGGACC 
GGAAGAGCG -3’, beta-2-microglobulin (B2m); 5’-CCCCACTGAGACTGATACATAC 
GC-3’ and 5’-AGAAACTGGATTTGTAATTAAGCAGGTTC-3’, hypoxanthine-guanine 
phosphoribosyltransferase (Hprt1); 5’-TGACACTGGTAAAACAATGCAAACTTTG-3’ 
and 5’-GAGGTCCTTTTCACCAGCAAGCT -3’. 
statistical analysis
For microarray analysis, Student’s t tests were used with false discovery rate (FDR) 
adjustment for multiple testing correction according to Benjamini-Hochberg 22. GraphPad 
Prism version 5.03 (Graphpad Software, San Diego, USA) was used for other statistical 
analysis, with Student’s t test being used to compare the two groups. Two-way ANOVA 
was used for analysis of the lipid profiles in serum and diets, followed by a Bonferroni post 
hoc test. P-values smaller than 0.05 were considered statistically significant.
3.3 resUlts
Body weight, energy intake and quercetin uptake
Body weight (BW) and energy intake of the adult male mice, which were fed a mild-
high-fat diet with or without quercetin supplementation, were not significantly different 
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between the quercetin and the control group during all 12 weeks. Final body weight 
was 27.9 ± 1.9 and 28.5 ± 1.6 (mean ± SD) gram, and cumulative total energy intake 
was 4580 ± 172 and 4636 ± 207 kJ for the quercetin and control group, respectively. 
The calculated quercetin intake for the quercetin-fed mice was ~ 400 mg/kg BW/
day. The sum of quercetin and isorhamnetin after deconjugation in serum was 13.5 ± 3.1 
µM expressed as aglycone (quercetin was 6.7 ± 0.9 µM, isorhamnetin was 6.8 ± 2.6 µM, 
and no tamarixetin was found). No quercetin was found in serum of the control animals. 
Relative liver weight was significantly lower in the quercetin-fed mice (3.80% ± 0.20; 
p=0.007) compared to the control mice (4.08%± 0.26), while no significant differences 
were found for other organs, including white adipose tissue, brown adipose tissue, 
lung, heart, muscles (data not shown). Hepatic lipid staining showed no significant 
differences between the quercetin and control group (Figure 3.1a and b); the Oil red O 
recorded areas were 480 ± 493 µm2 and 321 ± 440 µm2, respectively. The hepatic lipid 
levels were much lower than a positive control of hepatic lipid accumulation (13,151 
± 4,410 µm2) and in the same range of hepatic lipid levels found in liver of mice fed a 
normal-fat diet (516 ± 271 µm2) (Figure 3.1c and d).
serum lipids as determined by enzymatic assays
Quantification of serum FFA and TG levels was performed using the enzymatic FFA 
and TG assays, which showed a significant decrease of 13% FFA (p<0.05) and 27% 
TG (p<0.05) due to the quercetin diet. However, since quercetin has been shown to 
interfere with these enzymatic assays resulting in incorrect, apparently lower FFA and 
TG levels 13, two additional analytical techniques were applied to assess serum lipid 
figure 3.1 representative pictures of hepatic lipid staining with oil red o. There were no 
significant differences in lipid accumulation between the control (A) and the quercetin (B) group. 
The lipid levels were comparable to mice fed a normal-fat diet (C) and much lower than the positive 
control of hepatic lipid accumulation from mice fed a high-fat diet (D).
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profiles, and to check if the decreased FFA and TG levels detected by the enzymatic 
assays represent real biological effects.
serum fatty acid profile as determined by Gc
GC fatty acid profiles reveales fatty acids originating from TG, FFA, cholesteryl 
esters and phospholipids. The serum fatty acid profile showed a total decrease of 
7% (p<0.001) in the quercetin-fed mice. The levels of palmitic acid (16:0), oleic acid 
(18:1(n-9)) and linoleic acid (18:2(n-6)) were 9-15% lower (p<0.001) in the quercetin 
group (Figure 3.2). These are the main fatty acids in the quercetin diet and the control 
diet, which were similar in terms of fatty acid composition (Table 3.1). All other fatty 
acids that were present in the serum showed a tendency of decreased levels due to 
the quercetin treatment, except for some poly unsaturated fatty acids (PUFA), such as 
arachidonic acid (20:4(n-6)) and docosahexaenoic acid (22:6(n-3)) which were slightly, 
but non significantly, increased in the serum of quercetin-supplemented mice.
serum lipid profile as determined by 1h NmR
1H NMR measurement reveals total TG, FFA, cholesterol and phospholipids that are 
present in serum, separately. Figure 3.3 presents the 1H NMR difference spectrum, that 
is composed of the 1H NMR spectra of serum samples from mice exposed to quercetin 
(n=12) minus the 1H NMR spectra of the sera from control mice (n=12). The different 
figure 3.2 cumulative serum profile of fatty acids originating from total lipids. Fatty acids were 
measured with GC. The levels of palmitic acid (16:0), oleic acid (18:1(n-9)), and linoleic acid (18:2(n-
6)) were significant lower in the quercetin group. Data is presented as mean ± SEM. Asterisks 
indicates a significant difference between the control and the quercetin group; *** p < 0.001.
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table 3.1 Fatty acid composition of the control and quercetin diet 
in percentages. 
lipids control diet
(%)
Quercetin diet
(%)
C12:0 0.09 0.08
C14:0 1.11 1.09
C14:1 0.06 0.06
C15:0 0.08 0.08
C16:0 22.40 22.26
C16:1 1.25 1.25
C17:0 0.30 0.30
C17:1 0.19 0.15
C18:0 10.79 10.87
C18:1 trans 0.46 0.47
C18:1 33.87 33.94
C18:1 1.60 1.61
C18:2 24.23 24.21
C18:3(n-6) 0.01 0.01
C18:3 0.71 0.72
C20:0 0.23 0.22
C20:1 0.55 0.56
C20:2 0.29 0.30
C20:3(n-6) 0.05 0.05
C22:0 0.06 0.06
C20:3(n-3) 0.20 0.20
C24:0 0.06 0.06
C22:5(n-3) 0.00 0.07
C22:6(n-3) 0.02 0.03
Saturated FA 35.12 35.02
MUFA 37.98 38.04
PUFA 25.51 25.59
regions (based on 15,16) were selected to obtain information on several subsets of FFA 
and/or TG, as shown in Figure 3.3. Integration of the respective peak areas in the 1H 
NMR spectra of the individual serum samples resulted in the amounts of the various 
lipids. The data are presented in Figure 3.4 as the mean ratio of percentages of lipids 
present in serum of quercetin-fed mice as compared to control mice. From these data 
it follows that upon quercetin exposure the levels of TG are significantly decreased 
with 14% (p<0.001), while some specific poly unsaturated FFA levels were increased 
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figure 3.3 1h nmr difference spectrum of the quercetin-fed mice minus the control mice. Serum 
samples from mice exposed to quercetin minus the 1H NMR spectra of the sera from control mice is 
represented by the top line. The control group is represented by the middle line and the quercetin group 
is represented by the lowest line. Two representative parts of the spectrum are presented in the figure. 
PUFA, poly unsaturated fatty acids; MUFA, mono unsaturated fatty acids; FA, fatty acids; TG, triglycerides; 
PGLY, phosphoglycerides; PC phosphatidylcholine; EC, esterified cholesterol; TC total cholesterol.
figure 3.4 percentages of lipids present in serum per mouse plotted for quercetin mice to control 
mice. Lipids were measured with 1H NMR. Data is presented as the mean ratio of percentages of lipids 
present in serum per mouse plotted for quercetin-fed (Q) mice over control (C) mice. Total FFA were not 
changed, while other PUFA than 18:2 FA, 22:6 FA, and, w-3 FA were significantly increased. TG were 
significantly decreased by the quercetin diet. Data is presented as mean ± SEM. Asterisks indicates a 
significant difference between the control and the quercetin group; * p < 0.05, **p < 0.01, *** p < 0.001. 
PUFA, poly unsaturated fatty acids; MUFA, mono unsaturated fatty acids; FA, fatty acids; TG, triglycerides; 
PGLY, phosphoglycerides; PC phosphatidylcholine; EC, esterified cholesterol; TC total cholesterol.
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with 11-16%; these were PUFA other than 18:2 FA (p<0.01), 22:6 FA (p<0.001), and 
ω-3 FA (p<0.05). The total amount of FFA was the same in both groups, the levels 
of PGLY and PC showed no change and the EC and TC showed a slight increase, 
although not significant. This implies that the overall decrease in lipid levels that are 
observed in the GC analysis are due to a decrease in TG.
Quercetin altered the expression of genes involved in lipid metabolism 
Gene expression was analysed using whole genome gene expression microarrays. Of 
the 23,256 probes being expressed, 415 probes were significantly differently expressed 
by quercetin treatment (p<0.05, FDR-adjusted). Regulation of lipid metabolism by 
quercetin was found by pathway analysis of the differently expressed genes using 
the two major analysis programs, Metacore and Ingenuity. ‘Phospholipid metabolism’ 
was the most significantly regulated pathway in Metacore with a p-value of 4.8E-05 
(with 3 down-regulated and 1 up-regulated gene out of 33 genes). Ingenuity pathway 
analyses identified: ‘LPS/IL-1 Mediated Inhibition of RXR Function’ as the most 
regulated pathway (p-value of 5.46 E-05, with 13 up-regulated genes out of 187).
In this pathway Car is the central transcription factor and the genes, in particular 
cytochromes P450, overlap partly with the ‘linoleic acid pathway’, which is the number 
3 pathway (p-value of 1.7E-03 with 4 up-regulated genes out of 83 genes) in Metacore. 
Although, in each of these pathways a relative small number of genes were regulated 
out of the total number of genes present, it was clear that these regulated genes 
corresponded with the top significantly regulated genes. The ten most regulated 
genes (absolute fold change > 1.75 and a FDR adjusted p-value < 0.01), where almost 
all involved in lipid metabolism, particularly in ω-oxidation of fatty acids (Figure 3.5, 
Table 3.2). These genes involved in ω-oxidation included Cyp4a14, Cyp4a10, Cyp4a31, 
Acot3 and Por. Altogether, lipid metabolism, and in particular ω-oxidation, were 
identified as being regulated by quercetin in the liver. 
confirmation with RT-qPcR 
The quercetin induced changes in expression of Cyp4a14, Cyp4a10, Acot3, Car, and Por 
that were identified by microarray analysis, were confirmed with RT-qPCR (Figure 3.6). 
Cyp4a14, Cyp4a10, Acot3 and Por were significantly up-regulated in the quercetin group, 
while the up regulation of Car followed the same trend, but did not reach significance.
3.4 discUssion
This study showed that chronic intake of quercetin in mice lowered serum lipid levels 
which are risk factors for CVD. Microarray analysis indicated that hepatic genes involved 
in lipid metabolism, in particular in ω-oxidation of fatty acids, could be responsible for 
these quercetin-induced effects. 
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figure 3.5 volcano plot of all expressed probes by global hepatic gene expression analysis. 
Volcano plot of all probes showing statistics FDR-adjusted p-values plotted against the fold change 
of each probe (quercetin vs. control). Frames outline genes that are regulated with absolute fold 
change >1.75 and a FDR-adjusted p-value <0.01; these gene symbols, names and functions are 
also represented in table 3.1.
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Other studies have also observed that supplementation of quercetin to a high-fat diet 
decreases serum FFA and/or TG levels in mice 10-12. However, these circulating FFA and 
TG levels were measured with commercial enzymatic assays, which have recently been 
found to be sensitive to interference of quercetin and its major metabolite quercetin-
3-O-glucuronide, resulting in apparently incorrect lower detected levels 13. Here, 
besides these enzymatic assays, we also used two independent analytical methods for 
quantification of serum lipid profiles; GC and 1H NMR techniques. The observed effect 
of quercetin on lipid levels measured with the enzymatic FFA and TG assays (FFA -13% 
and TG -27%) was higher than measured with the two analytical techniques (GC: total 
fatty acids -7% and 1H NMR: FFA -2%, TG -14%).
This confirms interference of quercetin in the enzyme based assays 13 in the physiological 
range of quercetin exposure and as a consequence overestimate the lipid lowering 
effect of quercetin. Nevertheless, with GC and 1H NMR a significant reduction in serum 
lipid levels was found, proving that lipid lowering is a real biological effect of quercetin. 
The GC data revealed that the specific serum fatty acids palmitic acid (16:0), oleic acid 
(18:1(n-9)) and linoleic acid (18:2(n-6)), originating from total lipids, were all significantly 
decreased in the quercetin-fed mice. Moreover, with 1H NMR, serum lipids were measured 
separately, which revealed that serum TG levels of the quercetin group were significantly 
decreased, while total FFA, cholesterol and phospholipid levels remained unchanged. 
This indicates that the decreased levels of palmitic acid (16:0), oleic acid (18:1(n-9)) and 
linoleic acid (18:2(n-6)) found by GC originated from TG. Moreover, the 1H NMR data 
showed unchanged levels of total FFA and increased levels of PUFA in the serum of the 
mice on the quercetin diet, which indicate a shift from saturated fatty acids to PUFA, which 
are known as the more healthy fatty acids. Together, these data proved that quercetin 
significantly reduced serum lipid levels and resulted in a more beneficial lipid profile. 
The increased levels of PUFA and the decreased levels of saturated fatty acids 
cannot be fully explained by the microarray data. Genes involved in beta oxidation or 
specific desaturases were not differentially regulated by the quercetin diet. 
There were no significant differences found in the serum phospholipid levels, while 
pathway analysis revealed phospholipid metabolism as a regulated pathway. However, 
based on gene expression it was not clear how phospholipid metabolism would be 
affected, since up as well down regulated genes were observed in different parts of 
this pathway, and a relative small number of genes of the total pathway was regulated. 
Therefore, it was concluded that this was not a crucial pathway in this study. Quercetin 
induced a decrease in relative liver weight in our study. This decrease cannot be 
explained by a decrease in hepatic lipid accumulation, because hepatic lipid levels 
were not affected by quercetin. Other studies 11,12 have shown a decrease in lipid 
accumulation in liver upon dietary administration of quercetin and thus seem to be 
in contrast with our study. While a study with mulberry leaves, high in quercetin, did 
report unmodified lipid accumulation in the liver 23 and is thus in line with our data. The 
differences may be explained by the diets used in the different studies. We have used 
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a mild-high-fat diet rich in unsaturated fatty acids, which did not result in extensive 
lipid accumulation in the liver, since the found hepatic lipid levels were in the same 
range as found for mice fed a normal-fat diet. The other studies that show a quercetin 
induced decrease in lipid accumulation used a high saturated fatty acid rich diet which 
induced lipid accumulation in the liver 11,12. This suggests that quercetin may prevent 
lipid accumulation in the liver under adverse dietary conditions, but not with relatively 
healthy diets. In general, quercetin induced altered lipid metabolism on a mild-high-
fat diet (our study), a normal-fat diet [10], and different high-fat diets 11,12. Suggesting, 
that quercetin can affect lipid metabolism independent of the diet, although the 
impact of this effect can be different. 
Using whole genome microarrays and confirmation by RT-qPCR, we showed that 
quercetin up-regulates Cyp4a10, Cyp4a14, Cyp4a31, Acot3, Por, and, possibly Car. 
An integration of these genes into a single ‘hepatic pathway’ differentially expressed 
by quercetin treatment is proposed in Figure 3.7. 
Normally, fatty acids are mainly metabolized by β-oxidation first in peroxisomes 
(very long chain FFA) and subsequently in mitochondria (long, medium, and short 
chain FFA). Another type of fatty acid oxidation is ω-oxidation, which occurs in the 
endoplasmatic reticulum by members of the cytochrome P450 4A family 24. Omega-
oxidation becomes more important during periods of increased influx of fatty acids 
figure 3.7 schematic representation of the quercetin-regulated genes involved in ω-oxidation. 
Microarray and RT-qPCR analysis showed an up regulation of Cyp4a14, Cyp4a10, Acot3, Por 
and Car. Quercetin is suggested to activate Car and/or Por (dashed arrow). Activation of the 
transcription factor CAR can induce the microsomal cytochrome P450 enzymes, CYP4a14, CYP4a10 
and CYP4a31, which are important enzymes involved in ω-oxidation. POR is the electron donor for 
the microsomal cytochrome P450 mixed-function oxidase system. Formed DCA by ω-oxidation are 
further degraded by peroxisomal β-oxidation to shorter chain fatty acids. ACOT3 is involved in the 
transport of DCA into the peroxisomes by hydrolysis of long-medium chain fatty acyl-CoA esters 
to FFA, which can be further transported out of peroxisomes to mitochondria for β-oxidation or 
excreted in the urine. FA, fatty acids; DCA, dicarboxylic acids.
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into the liver, for example in our high-fat diet mice study, in obesity, and when the 
mitochondrial oxidation system is insufficient to metabolize fatty acids 25,26. In these 
situations ω-oxidation can prevent lipid toxicity 27. Fatty acids oxidized by ω-oxidation 
result in ω-hydroxy fatty acids which are then dehydrogenated to a dicarboxylic 
acid in the cytosol. These dicarboxylic acids are further degraded by peroxisomal 
β-oxidation to shorter chain dicarboxylic fatty acids, which can be excreted in the 
urine, metabolized by the peroxisomal oxidation system to succinate and acetyl CoA, 
or completely oxidized after transport into the mitochondrial β-oxidation system 28. A 
small increase of ketone bodies was found in the quercetin-fed mice suggesting an 
increase of β-oxidation (292.5 ± 199.2 versus 185.6 ± 118.1 µM, p=0.12). 
Acot3 was also up-regulated in our study, and the enzyme ACOT3 hydrolyses 
long-medium chain fatty acyl-CoA esters to FFA, and thus facilitate transport into 
peroxisomes. The FFA can subsequently be transported out of peroxisomes to 
mitochondria for further β-oxidation 29,30. 
It has been described that, among others, palmitic acid (16:0) and oleic acid 
(18:1(n-9)) can be hydroxylated by CYP4A11, the human variant of murine Cyp4a10 31. 
This is especially consistent with the serum fatty acid profile obtained in the present 
study (Figure 3.2), where levels of palmitic acid (16:0) and oleic acid (18:1(n-9)) were 
significantly lower in the quercetin-fed mice. The significant up regulation of Cyp4a10, 
Cyp4a14, Cyp4a31 and Acot3 therefore explains the observed reduced serum levels 
for these specific fatty acids.
In humans, various polymorphisms are described in the genes of cytochromes 
P450s and they can be considered as one of the major determinants of individual 
susceptibility to CVDs 32. Allelic variations in CYP4A11 are suggested to result in an 
increased risk for hypertension 25,32. Hypertension can be caused by increased serum 
lipid levels6, which were decreased by quercetin in our study with concomitant up 
regulation of Cyp4a genes.
The up regulation of the Cyp4a genes is consistent with the significant, 1.97 fold up 
regulation of Por by quercetin. POR is an enzyme that is required for electron transfer 
to cytochrome P450 enzymes and is therefore rate limiting for P450 enzymes. Deletion 
of the Por gene in a mouse model reduced hepatic P450 activity by more than 95%. 
Moreover, hepatic Por knockout (Por-KO) mice showed decreased CYP4A protein 
levels, and an enlarged and fatty liver. Based on these observations, it was concluded 
that the P450 system plays a major role in regulating lipid homeostasis and hepatic 
lipid levels 33,34. Two to three-fold more genes were significantly regulated when WT 
mice were exposed to quercetin compared to Por-KO mice. These genes were, among 
others, involved in fatty acid metabolism pathways. This suggests that hepatic POR 
mediates many of the biological effects of quercetin, including fatty acid metabolism 35. 
These results underscores our data, which showed an up regulation of Por. 
It is also suggested that P450 expression can be mediated via a CAR-dependent 
signaling pathway 36. CAR is a transcription factor that is highly expressed in the liver. It is 
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shown that ligand dependent activation of CAR increased lipid metabolism in rodents 37,38 
and it is also shown that this can lead to specifically increased expression of genes involved 
in ω-oxidation 39. Furthermore, exposure of quercetin to HepG2 cells transfected with 
CAR showed that CAR can be activated by quercetin 40,41. Our data showed significant up 
regulation of Car (FC = 1.37, FDR adjusted p-value = 0.005), which suggests that Car has 
an important role in quercetin mediated regulation of lipid metabolism. 
This study used male mice, therefore caution is needed in translating these data 
to female mice. It is known that there are sex differences in the sensitivity to CAR 
activators and also Cyp4a genes can be under sex-dependent control 42,43. 
In conclusion, quercetin can affect hepatic lipid metabolism, especially ω-oxidation. 
This is shown by the up regulation of Cyp4a10, Cyp4a14, Cyp4a31, Acot3, Por and the 
transcription factor Car. These effects are associated with decreased corresponding 
circulating lipid levels, which may contribute to potential beneficial effects on CVD. 
Acknowledgments 
We thank Henk van der Kamp for his help with the dietary fatty acid composition 
determinations, Peter van Baarlen for his help by the microarray analysis with Ingenuity, 
and Lonneke Janssen Duijghuijsen for her help with the ketone bodies measurements.
3.5 references 
1. van’t Veer P, Jansen MC, Klerk M, Kok FJ. 
Fruits and vegetables in the prevention of 
cancer and cardiovascular disease. Public 
Health Nutr 2000;3:103-7.
2. Mink PJ, Scrafford CG, Barraj LM, Harnack L, 
Hong C-P, Nettleton JA, Jacobs DR. Flavonoid 
intake and cardiovascular disease mortality: 
a prospective study in postmenopausal 
women. The American Journal of Clinical 
Nutrition 2007;85:895-909.
3. Arts IC, Hollman PC. Polyphenols and 
disease risk in epidemiologic studies. Am J 
Clin Nutr 2005;81:317S-25S.
4. Hertog MG, Feskens EJ, Hollman PC, Katan MB, 
Kromhout D. Dietary antioxidant flavonoids 
and risk of coronary heart disease: the Zutphen 
Elderly Study. Lancet 1993;342:1007-11.
5. Hollman PC, Geelen A, Kromhout D. Dietary 
flavonol intake may lower stroke risk in men 
and women. J Nutr 2010;140:600-4.
6. Boden G. Obesity and Free Fatty Acids. 
Endocrinology & Metabolism Clinics of 
North America 2008;37:635-46.
7. Harchaoui KE, Visser ME, Kastelein JJ, 
Stroes ES, Dallinga-Thie GM. Triglycerides 
and cardiovascular risk. Curr Cardiol Rev 
2009;5:216-22.
8. Jouven X, Charles MA, Desnos M, Ducimetiere 
P. Circulating nonesterified fatty acid level as a 
predictive risk factor for sudden death in the 
population. Circulation 2001;104:756-61.
9. Pilz S, Scharnagl H, Tiran B, Seelhorst U, 
Wellnitz B, Boehm BO, Schaefer JR, Marz W. 
Free Fatty Acids Are Independently Associated 
with All-Cause and Cardiovascular Mortality in 
Subjects with Coronary Artery Disease. J Clin 
Endocrinol Metab 2006;91:2542-7.
10. de Boer VC, van Schothorst EM, Dihal AA, 
van der Woude H, Arts IC, Rietjens IM, 
Hollman PC, Keijer J. Chronic quercetin 
exposure affects fatty acid catabolism in rat 
lung. Cell Mol Life Sci 2006;63:2847-58.
11. Jung CH, Cho I, Ahn J, Jeon TI, Ha TY. 
Quercetin Reduces High-Fat Diet-Induced Fat 
Accumulation in the Liver by Regulating Lipid 
Metabolism Genes. Phytother Res 2012.
12. Kobori M, Masumoto S, Akimoto Y, Oike H. 
Chronic dietary intake of quercetin alleviates 
hepatic fat accumulation associated with 
consumption of a Western-style diet in C57/
53
Chapter 3
3
BL6J mice. Mol Nutr Food Res 2011;55:530-
40.
13. Hoek-van den Hil EF, Beekmann K, Keijer J, 
Hollman PC, Rietjens IM, van Schothorst EM. 
Interference of flavonoids with enzymatic 
assays for the determination of free fatty 
acid and triglyceride levels. Anal Bioanal 
Chem 2012;402:1389-92.
14. Baum SJ, Kris-Etherton PM, Willett WC, 
Lichtenstein AH, Rudel LL, Maki KC, 
Whelan J, Ramsden CE, Block RC. Fatty 
acids in cardiovascular health and disease: 
A comprehensive update. J Clin Lipidol 
2012;6:216-34.
15. Tukiainen T, Tynkkynen T, Makinen VP, 
Jylanki P, Kangas A, Hokkanen J, Vehtari 
A, Grohn O, Hallikainen M, Soininen H, 
Kivipelto M, Groop PH, Kaski K, Laatikainen 
R, Soininen P, Pirttila T, Ala-Korpela M. A 
multi-metabolite analysis of serum by 1H 
NMR spectroscopy: early systemic signs of 
Alzheimer’s disease. Biochem Biophys Res 
Commun 2008;375:356-61.
16. Vinaixa M, Rodriguez MA, Rull A, Beltran 
R, Blade C, Brezmes J, Canellas N, Joven 
J, Correig X. Metabolomic assessment 
of the effect of dietary cholesterol in the 
progressive development of fatty liver 
disease. J Proteome Res 2010;9:2527-38.
17. Fiorini RN, Kirtz J, Periyasamy B, Evans Z, 
Haines JK, Cheng G, Polito C, Rodwell 
D, Shafizadeh SF, Zhou X, Campbell C, 
Birsner J, Schmidt M, Lewin D, Chavin KD. 
Development of an unbiased method for the 
estimation of liver steatosis. Clin Transplant 
2004;18:700-6.
18. Folch J, Lees M, Sloane Stanley GH. A simple 
method for the isolation and purification of 
total lipides from animal tissues. J Biol Chem 
1957;226:497-509.
19. Carlson LA. Extraction of lipids from human 
whole serum and lipoproteins and from 
rat liver tissue with methylene chloride-
methanol: a comparison with extraction 
with chloroform-methanol. Clin Chim Acta 
1985;149:89-93.
20. van Schothorst EM, Pagmantidis V, de 
Boer VC, Hesketh J, Keijer J. Assessment 
of reducing RNA input for Agilent oligo 
microarrays. Anal Biochem 2007;363:315-7.
21. Pellis L, Franssen-van Hal NL, Burema J, 
Keijer J. The intraclass correlation coefficient 
applied for evaluation of data correction, 
labeling methods, and rectal biopsy 
sampling in DNA microarray experiments. 
Physiol Genomics 2003;16:99-106.
22. Hochberg Y, Benjamini Y. More powerful 
procedures for multiple significance testing. 
Stat Med 1990;9:811-8.
23. Kobayashi Y, Miyazawa M, Kamei A, Abe K, 
Kojima T. Ameliorative effects of mulberry 
(Morus alba L.) leaves on hyperlipidemia 
in rats fed a high-fat diet: induction of fatty 
acid oxidation, inhibition of lipogenesis, 
and suppression of oxidative stress. Biosci 
Biotechnol Biochem 2010;74:2385-95.
24. Lavoie JM, Gauthier MS. Regulation of fat 
metabolism in the liver: link to non-alcoholic 
hepatic steatosis and impact of physical 
exercise. Cell Mol Life Sci 2006;63:1393-409.
25. Hsu MH, Savas U, Griffin KJ, Johnson EF. 
Human cytochrome p450 family 4 enzymes: 
function, genetic variation and regulation. 
Drug Metab Rev 2007;39:515-38.
26. Reddy JK, Rao MS. Lipid metabolism and 
liver inflammation. II. Fatty liver disease 
and fatty acid oxidation. Am J Physiol 
Gastrointest Liver Physiol 2006;290:G852-8.
27. Hardwick JP, Osei-Hyiaman D, Wiland H, 
Abdelmegeed MA, Song BJ. PPAR/RXR 
Regulation of Fatty Acid Metabolism and 
Fatty Acid omega-Hydroxylase (CYP4) 
Isozymes: Implications for Prevention of 
Lipotoxicity in Fatty Liver Disease. PPAR Res 
2009;2009:952734.
28. Hardwick JP. Cytochrome P450 omega 
hydroxylase (CYP4) function in fatty acid 
metabolism and metabolic diseases. 
Biochem Pharmacol 2008;75:2263-75.
29. Hunt MC, Yamada J, Maltais LJ, Wright 
MW, Podesta EJ, Alexson SE. A revised 
nomenclature for mammalian acyl-CoA 
thioesterases/hydrolases. J Lipid Res 
2005;46:2029-32.
30. Kirkby B, Roman N, Kobe B, Kellie S, Forwood 
JK. Functional and structural properties of 
mammalian acyl-coenzyme A thioesterases. 
Prog Lipid Res 2010;49:366-77.
31. Hoch U, Zhang Z, Kroetz DL, Ortiz de 
Montellano PR. Structural determination 
of the substrate specificities and 
regioselectivities of the rat and human fatty 
acid omega-hydroxylases. Arch Biochem 
Biophys 2000;373:63-71.
32. Zordoky BN, El-Kadi AO. Effect of cytochrome 
P450 polymorphism on arachidonic acid 
54
3Quercetin induces hepatic lipid omega-oxidation
metabolism and their impact on cardiovascular 
diseases. Pharmacol Ther 2010;125:446-63.
33. Henderson CJ, Otto DM, Carrie D, Magnuson 
MA, McLaren AW, Rosewell I, Wolf CR. 
Inactivation of the hepatic cytochrome P450 
system by conditional deletion of hepatic 
cytochrome P450 reductase. J Biol Chem 
2003;278:13480-6.
34. Mutch DM, Klocke B, Morrison P, Murray 
CA, Henderson CJ, Seifert M, Williamson G. 
The disruption of hepatic cytochrome p450 
reductase alters mouse lipid metabolism. J 
Proteome Res 2007;6:3976-84.
35. Mutch DM, Crespy V, Clough J, Henderson 
CJ, Lariani S, Mansourian R, Moulin J, Wolf 
CR, Williamson G. Hepatic cytochrome 
P-450 reductase-null mice show reduced 
transcriptional response to quercetin and 
reveal physiological homeostasis between 
jejunum and liver. Am J Physiol Gastrointest 
Liver Physiol 2006;291:G63-72.
36. Finn RD, Henderson CJ, Scott CL, Wolf 
CR. Unsaturated fatty acid regulation 
of cytochrome P450 expression via a 
CAR-dependent pathway. Biochem J 
2009;417:43-54.
37. Dong B, Saha PK, Huang W, Chen W, 
Abu-Elheiga LA, Wakil SJ, Stevens RD, 
Ilkayeva O, Newgard CB, Chan L, Moore 
DD. Activation of nuclear receptor CAR 
ameliorates diabetes and fatty liver disease. 
Proc Natl Acad Sci U S A 2009;106:18831-6.
38. Venkatesan N, Davidson MB, Simsolo RB, 
Kern PA. Phenobarbital treatment enhances 
insulin-mediated glucose metabolism and 
improves lipid metabolism in the diabetic 
rat. Metabolism 1994;43:348-56.
39. Baskin-Bey ES, Anan A, Isomoto H, Bronk 
SF, Gores GJ. Constitutive androstane 
receptor agonist, TCPOBOP, attenuates 
steatohepatitis in the methionine choline-
deficient diet-fed mouse. World J 
Gastroenterol 2007;13:5635-41.
40. Li L, Stanton JD, Tolson AH, Luo Y, Wang H. 
Bioactive terpenoids and flavonoids from 
Ginkgo biloba extract induce the expression 
of hepatic drug-metabolizing enzymes 
through pregnane X receptor, constitutive 
androstane receptor, and aryl hydrocarbon 
receptor-mediated pathways. Pharm Res 
2009;26:872-82.
41. Yao R, Yasuoka A, Kamei A, Kitagawa Y, Tateishi 
N, Tsuruoka N, Kiso Y, Sueyoshi T, Negishi M, 
Misaka T, Abe K. Dietary flavonoids activate 
the constitutive androstane receptor (CAR). J 
Agric Food Chem 2010;58:2168-73.
42. Hernandez JP, Mota LC, Baldwin WS. Activation 
of CAR and PXR by Dietary, Environmental 
and Occupational Chemicals Alters Drug 
Metabolism, Intermediary Metabolism, and 
Cell Proliferation. Curr Pharmacogenomics 
Person Med 2009;7:81-105.
43. Sundseth SS, Waxman DJ. Sex-dependent 
expression and clofibrate inducibility of 
cytochrome P450 4A fatty acid omega-
hydroxylases. Male specificity of liver 
and kidney CYP4A2 mRNA and tissue-
specific regulation by growth hormone and 
testosterone. J Biol Chem 1992;267:3915-21.
55

4chapter
QUercetin decreases high-fat 
diet-indUced body Weight 
gain and accUmUlation 
of hepatic and circUlating 
lipids in mice
Elise F. Hoek-van den Hil1,2,3, 
Evert M. van Schothorst1, Inge van der Stelt1, 
Hans J.M. Swarts1, Dini Venema3, Manuela Sailer4, 
Jacques J.M. Vervoort5, Peter C.H. Hollman3, 
Ivonne M.C.M. Rietjens2, and Jaap Keijer1.
1 Human and Animal Physiology, Wageningen University, 
Wageningen, The Netherlands 
2 Division of Toxicology, Wageningen University, 
Wageningen, The Netherlands 
3 RIKILT, Wageningen UR, Wageningen, The Netherlands 
4 Molecular Nutrition Unit, Research Center for Nutrition 
and Food Sciences, Technische Universität München, 
Freising- Weihenstephan, Germany 
5 Laboratory of Biochemistry, Wageningen University, 
Wageningen, The Netherlands
GeneS nutr 2014;9:418
Chapter 4
4
abstract
Dietary flavonoids may protect against cardiovascular diseases (CVD). Elevated 
circulating lipid levels and hepatic lipid accumulation are known risk factors for CVD. 
The aim was to investigate the effects and underlying molecular mechanisms of the 
flavonoid quercetin on hepatic lipid metabolism in mice with high-fat diet-induced 
body weight gain and hepatic lipid accumulation.
Adult male mice received a 40 energy% high-fat diet without or with supplementation 
of 0.33% (w/w) quercetin for 12 weeks. Body weight gain was 29% lower in quercetin 
fed mice (p<0.01), while the energy intake was not significantly different. Quercetin 
supplementation lowered hepatic lipid accumulation to 29% of the amount present 
in the control mice (p<0.01). 1H nuclear magnetic resonance serum lipid profiling 
revealed that the supplementation significantly lowered serum lipid levels. Global 
gene expression profiling of liver showed that cytochrome P450 2b (Cyp2b) genes, 
key target genes of the transcription factor constitutive androstane receptor (Car; 
official symbol nr1i3), were down-regulated.
Quercetin decreased high-fat diet-induced body weight gain, hepatic lipid 
accumulation and serum lipid levels. This was accompanied by regulation of 
cytochrome P450 2b genes in liver, which are possibly under transcriptional control of 
CAR. The quercetin effects are likely dependent on the fat content of the diet. 
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4.1 introdUction
High consumption of fruits and vegetables is protective against cardiovascular diseases 
(CVD) 1. Flavonoids in fruits and vegetables are suggested to contribute to these 
protective effects 2. Moreover, epidemiological studies have shown that the intake of 
the flavonoid quercetin is associated with a reduction of CVD risk 3-5. In the Western 
diet, quercetin is the major dietary flavonol, a subclass of the flavonoids, and is present 
in, for example, apples, tea, red wine, and onions. Our previous results in mice showed 
that a quercetin supplemented mild-high-fat diet, increased hepatic lipid metabolism, 
especially omega (ω)-oxidation, and reduced corresponding circulating lipid levels 6. 
The cardiovascular protective properties of quercetin might therefore be explained by 
the lipid lowering effect of quercetin, since elevated circulating levels of free fatty acids 
and triglycerides are known risk factors for CVD 7-9. Furthermore, growing evidence 
shows that increased lipid accumulation in the liver also increased the risk of CVD 10,11. 
The mechanisms behind these effects of quercetin are neither fully understood 
nor conclusive. Other rodent studies with quercetin supplementation that investigated 
lipid lowering effects showed reduction in body weight, serum lipid levels, hepatic lipid 
accumulation, and/or white adipose tissue mass. However, these effects were not seen 
in all studies and were sometimes conflicting 6,12-17. It is not clear which combination 
of factors, like dose of quercetin, dietary en% of fat or duration causes these effects 
on lipids. Previously, we have observed an effect of quercetin on serum lipid lowering 
and hepatic lipid ω-oxidation using a mild-high-fat diet (30 en%) for 12 weeks 6. Here, 
we examined whether the same effects would be observed using the same amount of 
quercetin and the same duration, but using a high-fat diet (40 en%), which is expected 
to induce body weight gain as well as hepatic lipid accumulation. This high-fat diet 
is a fully standardised diet with a fatty acid composition that provides a balance of 
essential fatty acids and a healthy polyunsaturated to saturated ratio 18. The main focus 
was on the effects of quercetin on hepatic lipid metabolism, since the liver is the major 
effector organ of lipid metabolism. We assessed hepatic lipid accumulation and profiled 
serum lipids. Based on previous results, expression of genes involved in ω-oxidation was 
studied. In addition, we performed whole genome gene expression analysis to obtain 
an overview of the molecular changes induced by quercetin on this dietary background. 
4.2 materials and methods
Animals and treatments 
Twenty-four male C57BL/6JOlaHsd mice (Harlan Laboratories, Horst, The Netherlands) 
were individually housed and maintained under environmentally controlled conditions 
(temperature 21°C, 12 h/12 h light-dark cycle, 55 ± 15 % humidity), with ad libitum 
access to food and water. At arrival, the mice were 9 weeks old and were adapted 
for 3 weeks. The first five days of adaptation were on standard chow diet, which was 
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followed by a standardised semi-synthetic normal fat diet (10 en% fat) with the same 
dietary constituents as the control high-fat diet 18,19 (Research Diets Services B.V., Wijk 
bij Duurstede, the Netherlands; Supplementary Table S4.1). During the intervention, 
the mice (n=12) received high-fat diet (40en% fat) without or with supplementation 
of 0.33% (w/w) quercetin (Sigma, Zwijndrecht, the Netherlands). The percentage of 
quercetin in the diet was identical to that used in our previous study 6. Body weight 
and food intake of individual mice were weekly monitored. Faeces was collected in 
weeks 11 and 12 (n=4). One quercetin fed mouse was excluded from all analyses, 
because a nasal abscess developed in week 6. After 12 weeks of intervention, all 
mice were fasted for 2-4 hours during the light phase and anesthetized by inhalation 
of 5% isoflurane using O2 as a carrier. Blood was sampled via orbital extraction in 
collect serum tubes (Greiner Bio-one, Longwood, USA), kept on ice for max 2 hours, 
and centrifuged for 10 min at 3000g at 4 °C to obtain serum, aliquoted, and stored 
at -80°C. After blood collection, mice were killed by cervical dislocation, and liver 
was dissected, weighted and snap frozen in liquid nitrogen and stored at -80°C. The 
experiment was performed according to the Dutch Animal Experimentation Act (1996) 
and the experimental protocol was approved by the Animal Welfare Committee of 
Wageningen University, Wageningen, The Netherlands (DEC 2011079).
energy content of faeces and diet
Bomb calorimetry was used to determine energy content of diet and faeces (n=4) 
(Calorimeter C7000, IKA, Staufen, Germany). Measured faecal energy content was 
extrapolated to calculate with the measured dietary energy content and the weekly 
measured food intake the total digestible energy intake over 12 weeks. Digestible energy 
intake is assumed to be comparable with metabolisable energy intake, as dietary protein 
content is equal for both diets and no differences in urinary energy losses were expected.
hPLc analysis of quercetin levels in serum
Quercetin levels in serum (n=6) were measured using HPLC with coulometric array 
detection as described 6. Before analysis, samples were hydrolysed by β-glucuronidase/
sulfatase to obtain deconjugated quercetin, isorhamnetin and tamarixetin. 
serum and tissue lipid measurements
Because quercetin was previously shown to interfere with commonly used commercially 
available enzymatic lipid assays 20, alternative methods were used. Neutral lipids 
were stained in frozen liver sections (n=6) with Oil red O (Sigma) and quantified as 
described 6. Ten to 16 pictures per animal were quantified (n=6). Serum lipids were 
extracted and analysed with 1H nuclear magnetic resonance (1H-NMR) as described 6. 
Serum insulin levels were quantified by sandwich-type ELISA (Shibayagi Co., Ltd., 
Gunma, Japan) and blood glucose levels using ADC Freestyle blood glucose system 
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(Abbott Diabetes Care, Hoofddorp, the Netherlands). The homoeostasis model 
assessment–insulin resistance (HOMA-IR) was calculated using the following formula: 
fasting plasma insulin (mIU/l) × fasting glucose (mmol/l) / 22.5. Taurine levels in 
serum and hepatic tissues were quantified as described 21 using the aTRAQ® reagent 
(aTRAQTM Reagent Kit, ABSciex, Foster City, USA). 
Real time quantitative polymerase chain reaction (RT-qPcR)
RNA from liver was isolated using RNeasy columns (Qiagen, Venlo, The Netherlands) 
and used for RT-qPCR and microarray analysis. RNA purity and quality was verified 
using a Nanodrop spectrophotometer (IsoGen Life Science, Maarsen, The Netherlands) 
and on Experion automated electrophoresis system (Bio-Rad, Veenendaal, The 
Netherlands). RT-qPCR was performed as previously described 6 according to the MIQE 
guidelines 22. Data were normalised against reference genes beta-2 microglobulin 
(B2m) and hypoxanthine phophoribosyltransferase 1 (hprt1) which were chosen 
based on stable gene expression levels (geNorm, Ghent University Hospital, Ghent, 
Belgium). Sequences of the used primers can be found in Supplementary Table S4.2. 
microarray analysis 
For global transcriptome analysis liver samples of individual mice and 8x60K Agilent 
whole-mouse genome microarrays (G4852A, Agilent Technologies Inc., Santa Clara, 
CA) were used according to the manufacturer’s protocol with a few modifications as 
described previously 23. cDNA was synthesised for each animal from 200 ng RNA. 
Normalisation and data analysis were performed as published 24 using Feature 
Extraction version 10.7.3.1 (Agilent Technologies). Based on visual inspection three 
arrays were excluded in which hybridisation was not homogenous. Fold change was 
expressed as ratio of quercetin group (n=10) versus control group (n=11). Pathway 
analysis was performed using MetaCore (GeneGo, St. Joseph, Michigan, USA). 
Microarray data have been deposited in NCBI Gene Expression Omnibus under 
accession number GSE51343. 
statistical analysis
GraphPad Prism version 5.03 (Graphpad Software, San Diego, USA) was used for 
statistical analysis, with Student’s t test being used to compare the two groups if 
normally distributed. Two-way ANOVA (repeated measures, matched values) followed 
by a Bonferroni post hoc test was used for body weight in time analysis. Two way 
ANOVA (no repeated measures) was used for analysis of the lipid profiles in serum. 
P-values smaller than 0.05 were considered significantly different.
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4.3 resUlts
Quercetin lowered high-fat diet-induced body weight gain and food 
efficiency
Mice received a 40 en% high-fat diet without (control) or with supplementation 
of quercetin for 12 weeks. Body weight of the mice was significantly lower upon 
quercetin supplementation compared to the high-fat diet from week 7 onwards 
(Figure 4.1a). Total body weight gain after 12 weeks was 29% lower in the quercetin 
fed mice compared to the control mice (p<0.01; Figure 4.1b), while digestible (equals 
metabolisable) energy intake over 12 weeks was not significantly different (Figure 
4.1c). Consequently, the calculated food efficiency was 26% lower for the quercetin 
fed mice (p<0.001) (Figure 4.1d). The weekly food intake and energy content of faeces 
used for the calculation is provided in Supplementary Figure S4.1.
figure 4.1 Quercetin reduces body weight gain and food efficiency. Body weight of control 
(n=12) and quercetin (n=11) fed mice during 12 weeks on high-fat diet (A). Cumulative body weight 
gain over 12 weeks (B). Cumulative metabolisable energy intake over 12 weeks (C). Calculated 
total food efficiency in body weight gain per kJ consumed (D). Data are presented as mean ± SEM. 
White bars indicate the control group (C) and black bars indicate the quercetin group (Q). Asterisks 
indicates a significant difference between both groups, *p<0.05, **p<0.01, ***p<0.001.
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concentration of quercetin in serum
The sum of quercetin and isorhamnetin after deconjugation in serum was 6.5 ± 1.4 µM 
(quercetin 2.8 ± 1.4 µM, isorhamnetin 3.7 ± 0.8 µM, and no tamarixetin was found). No 
quercetin was found in serum of control animals. The calculated quercetin intake based 
on the food intake of the quercetin fed mice was ~325 mg kg-1 body weight day-1 .
Quercetin decreased high-fat diet-induced serum and hepatic lipid levels
Because quercetin was previously shown to interfere with many commercially available 
enzymatic assays including the ones commonly used for measurement of serum and 
hepatic lipids 20, we quantified various serum lipid fractions with 1H NMR and hepatic 
lipid accumulation with histological Oil red O staining. Two-way ANOVA analysis 
revealed that quercetin supplementation has a significant lowering effect on the 
high-fat diet-induced serum lipid levels (Figure 4.2a). 
Relative liver weight was not significantly different between both groups. Oil red 
O stained liver sections showed that hepatic lipid accumulation in quercetin fed mice 
was significantly lower amounting to 29% (measured as area) of the value observed for 
control mice fed the high-fat diet, and lipid droplet number in the quercetin fed mice 
was 69% (p<0.05) of the value observed in control mice (Figure 4.2). 
Serum insulin (0.60 ± 0.46 and 0.98 ± 0.58 ng/ml, resp.), blood glucose (8.4 ± 1.2 
and 9.1± 0.7 mM, resp.) and calculated HOMA-IR (5.9 ± 4.8 and 10.5 ± 6.8, resp) were 
not significantly different between the quercetin and the control group.
Quercetin regulated hepatic gene expression
First, hepatic expression levels of genes involved in ω-oxidation, identified in our 
previous study where quercetin was supplemented to a mild high-fat diet 6, were 
studied. However, RT-qPCR analysis indicated no significant regulation of Cyp4a14, 
Cyp4a10, Acot3, nor Por (Table 4.1). 
Subsequently, we profiled gene expression in the liver using whole genome 
microarrays, since we observed large differences in hepatic lipid accumulation between 
table 4.1 Gene expression of genes related with lipid ω-oxidation measured with RT-qPCR in liver.
gene  
symbol
gene name accession  
number
rt-qpcr
fc p
Acot3 acyl-CoA thioesterase 3 NM_134246 1.07 0.68
Cyp4a10 cytochrome P450, family 4a10 NM_010011 -1.09 0.82
Cyp4a14 cytochrome P450, family 4a14 NM_007822 1.11 0.47
Por P450 (cytochrome) oxidoreductase NM_008898 1.08 0.57
Fold Changes are depicted as the expression values of quercetin over control animals. FC, Fold 
Change; p, p-value.
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figure 4.2 Quercetin decreased high-fat diet-induced serum lipid levels and hepatic lipid 
accumulation. A. Serum lipid fractions are shown as ratio of quercetin fed mice (n=11) over the 
average value of the control mice (n=12).Two-way ANOVA; diet significant (p<0.01). B. Representative 
pictures of hepatic lipid staining with Oil red O for control and quercetin fed mice on a high-fat 
diet (n=6). Quantification of mean total area of lipids per picture (C) and mean lipid droplet number 
per picture (D). Data are presented as mean ± SEM. White bars indicate the control group (C) and 
black bars indicate the quercetin group (Q). Asterisks indicate a significant difference between both 
groups, *p<0.05, **p<0.01. PUFA, poly unsaturated fatty acids; MUFA, mono unsaturated fatty 
acids; FA, fatty acids; TG, triglycerides; PGLY, phosphoglycerides; PC phosphatidylcholine; EC, 
esterified cholesterol; TC total cholesterol. 
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the two groups. Of the 34,373 probes showing expression, 462 probes showed 
differential expression upon quercetin supplementation to a high-fat diet as compared to 
the high-fat diet alone (p<0.01). Similar to RT-qPCR, microarrays did not show regulation 
of the ω-oxidation related genes. Pathway analysis of the differentially expressed genes 
revealed no reliable regulated pathways. In the volcano plot, four major regulated genes 
(absolute fold change >2.0 with p<0.01), were observed (Figure 4.3). Cysteine sulfinic acid 
decarboxylase (Csad), encoding the rate limiting enzyme in taurine biosynthesis, was up-
regulated with a fold change of 2.3. However, taurine levels in serum and in hepatic tissue 
were not significantly affected by the quercetin diet (Supplementary Table S4.3).
Three cytochrome P450 enzyme encoding genes, Cyp2b9, Cyp2b10, and 
Cyp2b13, were all down regulated with fold changes between -2.3 and -2.6. These 
genes are known to be transcriptionally regulated by Car (official symbol nr1i3), 
which we previously postulated to be an important transcription factor affected by 
quercetin supplementation 6. The top regulated genes (p<0.01 and absolute fold 
change >1.5) and confirmation of these genes by RT-qPCR are shown in 4.2. This list 
includes another cytochrome P450 and two genes involved in lipid metabolism: fatty 
acid binding protein 5 (Fabp5) and hydroxyacid oxidase 2 (hao2). 
4.4 discUssion
This study shows that quercetin attenuated the increase of circulating lipids, hepatic 
lipid accumulation, and body weight gain, all dietary risk factors for CVD, caused by 
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figure 4.3 volcano plot of all expressed probes by global hepatic gene expression analysis. 
P-values of all probes are plotted against the fold change of each probe, quercetin (n=10) vs. 
control (n=11). Dotted lines indicate used cut-off value of an absolute fold change >2.0. Selected 
gene symbols are depicted in the figure; cytochrome P450 (Cyp) enzymes Cyp2c9, Cyp2c10, and 
Cyp2c13, and cysteine sulfinic acid decarboxylase (Csad).
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a chronic high-fat diet. These effects of quercetin were accompanied by regulation of 
cytochrome P450s. 
The significant lower body weight gain of mice induced by high-fat diet upon 
0.33% quercetin supplementation cannot be explained by a lower food intake or 
higher faecal energy losses. The quercetin fed mice gained less weight with a similar 
digestible energy intake resulting in a significantly lower calculated food efficiency. 
The high-fat (40 en%) diet-induced body weight gain and hepatic lipid accumulation. 
In case of a normal fat (10 en%) diet, body weight gain over 12 weeks was 40-50% 
of the body weight gain by high-fat diet feeding 18,25. The observed body weight 
gain in mice fed the high-fat diet supplemented with quercetin was lowered with 
29% compared to high-fat diet feeding, thus decreasing it towards a more normal 
level. Hepatic lipids level after normal fat feeding for 12 weeks was only around 4% 
of the value after high-fat feeding and the high-fat supplemented with quercetin 
decreased the hepatic lipid level to 27% of the high-fat values. Both parameters show 
that quercetin supplementation reduced the effects of the high-fat diet substantially, 
changing these parameters into the direction of values that are observed upon a more 
normal healthy (10 en%) fat diet.
Our results were in line with other studies performed with supplementation of 0.025% 
and 0.05% quercetin to 40 en% high-fat diets 13,17, which also resulted in lowering of 
body weight gain and hepatic lipid accumulation. Other studies with doses of quercetin 
ranging between 0.05% and 1% were shorter or used a diet with a lower energy% 
of fat. Consequently, body weight gain was lower in these studies and as a result, 
table 4.2 Top regulated genes from microarray analysis in liver with an absolute fold change >1.5 
and p<0.01.
gene 
symbol
gene name accession 
number
microarray rt-qpcr
fc p fc p
Csad Cysteine sulfinic acid decarboxylase NM_144942 2.33 0.0045 2.73 0.001
Cib3 Calcium and integrin  
binding family member 3
NM_001080812 1.88 0.0004 n.a.
Fabp5 Fatty acid binding protein 5, epidermal NM_010634 1.59 0.0075 1.37 0.173
Tfrc Transferrin receptor NM_011638 1.52 0.0069 1.45 0.016
Cyp3a59 Cytochrome P450, subfamily 3a59 NM_001105160 -1.51 0.0038 n.a.
Hao2 Hydroxyacid oxidase 2 NM_019545 -1.67 0.0022 -2.81 0.006
Cyp2b9 Cytochrome P450, family 2b9 NM_010000 -2.30 0.0009 -8.2 0.0003
Cyp2b13 Cytochrome P450, family 2b13 NM_007813 -2.39 0.0006 n.a.
Cyp2b10 Cytochrome P450, family 2b10 NM_009999 -2.63 0.0028 n.a.
Not assigned probes were not mentioned in the table; NAP111439-1 (FC=1.64, p=0.009), 
NAP114472-1 (FC=1.59, p=0.007), Gm10804 (FC=-1.83, p=0.0069), A_55_P2071906 (FC=-1.9, 
p=0.002). Fold Changes are depicted as the expression values of quercetin over control animals. 
FC, Fold Change; p, p-value; n.a., not assessed.
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quercetin did not show a decrease in bodyweight gain 6,12-16. Our previous data (30en% 
fat diet) 6, showed also no effects on body weight gain and hepatic lipid accumulation, 
which study was identical to the present study except for the used background diet. 
Taking this together, we conclude that the observed effects of quercetin on body 
weight gain and hepatic lipid accumulation are dependent on the en% fat in the diet. 
The magnitude of body weight gain and hepatic lipid accumulation caused by the diet, 
which is dependent on the dietary fat content, seems to be important for the outcomes 
obtained in these quercetin supplementation studies.
In our previous study we have shown that quercetin induced hepatic lipid 
ω-oxidation and lowered corresponding serum triglyceride levels, possibly under 
transcriptional control of CAR 6. These specific changes in serum triglyceride le vels 
and genes involved in lipid ω-oxidation were not seen in the present study, which also 
suggests an influence of the used diet on these effects. Omega-oxidation is known to 
be induced by a high-fat diet and in case of induced nonalcoholic fatty liver disease 26. 
Here, the high-fat diet-induced a fatty liver, thus ω-oxidation and especially Cyp4a 
transcripts are expected to be up regulated, already in the high-fat control group, 
possibly diminishing further stimulation by quercetin.
Whole genome microarray analysis of liver revealed that Cyp2b9, Cyp2b10, and 
Cyp2b13 were the most evident genes regulated by quercetin. These three genes comprise 
the hepatic cyp2b genes of mice. Besides metabolism of endogenous and xenobiotic 
compounds, cytochrome P450s are also important in hepatic lipid homeostasis 27. 
Importantly, these Cyp2b genes are known to be under control of CAR 27,28. Thus, although 
differences in liver gene expression are seen in this study compared to our previous study 6, 
in both cases lipid metabolizing genes that are under control of CAR were modulated, and 
the changes were accompanied by changes in serum lipids. 
CAR is involved in the regulation of genes which are involved in lipid homoeostasis. 
CAR mediates the induction of cytochrome P450 enzymes, including Cyp2b10, dietary 
linoleic acid is shown to be a regulator of P450 expression via CAR 29. Linoleic acid is 
also abundantly present in the high-fat diet used in the present study, at double the 
amount compared to our previous study (Supplementary Table S4.1). Fabp5, the fourth 
gene among the top up regulated genes (p<0.01) with a fold change of 1.59, can bind 
and transport long-chain fatty acids and it has a high affinity for linoleic acid 30. This may 
suggest that linoleic acid transport into the liver of quercetin fed animals is increased. 
Furthermore, activation of CAR as well as induction of Cyp2b mRNA by the known 
inducer phenobarbital can be attenuated by PUFAs 31,32. Altogether, this information 
suggests that possible activation of CAR by quercetin can be possibly attenuated 
by dietary linoleic acid. Although, this has to be further investigated in detail, our 
results indicate that it is important to take the composition of the dietary background 
into account in evaluation effects of quercetin and, most likely, of other polyphenols. 
Indeed, also for the polyphenol resveratrol, marked differences in functional effects 
were observed dependent on standard or high-fat dietary backgrounds 33. 
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In conclusion, high-fat diet-induced hepatic lipid accumulation, circulating lipids 
and weight gain were reduced by chronic intake of quercetin in mice. Also cytochrome 
P450s were regulated in liver, which are under transcriptional control of the nuclear 
receptor CAR. Our data newly suggest that these effects may depend on dietary 
fat content and composition. This novel notion may provide an explanation for the 
apparent contradictions in the outcomes of studies with quercetin and potentially has 
important implications for the analysis and interpretation of human studies.
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table s4.1 Dietary composition of the diets used in previous and present study.
components previous studya present studyb
% of total 
amount of lipids, 
proteins or 
carbohydrates 
g/kg  
diet
en% kcal/
kg  
diet
% of total 
amount of lipids, 
proteins or 
carbohydrates 
g/kg  
diet
en% kcal/
kg  
diet
Lipids
C8:0 - - 1.3 2.73
C10:0 - - 1.1 2.31
C12:0 0.09 0.13 8.5 17.85
C14:0 1.11 1.61 3.4 7.14
C14:1 0.06 0.09 - -
C15:0 0.08 0.12 - --
C16:0 22.40 32.48 6.7 14.07
C16:1 1.25 1.81 - -
C17:0 0.30 0.44 - -
C17:1 0.19 0.28 - -  
C18:0 10.79 15.65 3.9 8.19
C18:1 trans 0.46 0.67 - -
C18:1 (n-9) 33.87 49.11 21.8 45.78
C18:1 1.60 2.32 - -
C18:2 (n-6) 24.23 35.13 47.0 98.70
C18:3(n-6) 0.01 0.01 - -
C18:3 (n-3) 0.71 1.03 6.0 12.60
C20:0 0.23 0.33 - -
C20:1 0.55 0.80 - -
C20:2 0.29 0.42 - -
C20:3(n-6) 0.05 0.07 - -
C22:0 0.06 0.09 - -
C20:3(n-3) 0.20 0.29 - -
C24:0 0.06 0.09 - -
Not identified 1.41 2.04 - -
Total  
saturated FA
35.1 50.9 24.9 52.3
Total MUFA 38.0 55.1 21.8 45.8
Total PUFA 25.5 37.0 53.0 111.3
Total lipids 100 145 29.8 1305 100 210 40.2 1890
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table s4.1 Continued
components previous studya present studyb
% of total 
amount of lipids, 
proteins or 
carbohydrates 
g/kg  
diet
en% kcal/
kg  
diet
% of total 
amount of lipids, 
proteins or 
carbohydrates 
g/kg  
diet
en% kcal/
kg  
diet
Proteins
Casein 98.7 220 98.9 267
L-Cystein 1.4 3 1.1 3
Total protein 100 223 20.4 892 100 270 23.0 1080
Carbohydrates
Maltodextrin 20.6 112.2 23.1 100
Dextrose - - 11.6 50
Sucrose 15.7 85.5 23.1 100
Vit mix 1.8 10 2.3 10
Starch (70-30) 61.9 336.7 40.0 172.5
Total  
carbohydrates
100 544.4 49.8 2178 100 432.5 36.8 1730
Others
Mineral mix 35 35
Cellulose 50 50
Choline  
bitartrate
2.5 2.5
Cholesterol 97 mgc 97 mg
total 4375 4700
aLipids from previous study originated from 70% lard and 30% corn oil, presented lipid composition 
is analysed with GC 6. bLipids from present study are calculated amount of fatty acids originating 
from 70% sunflower, 18% coconut oil, and 12% flaxseed oil 19. cBased on theoretically present 
amount of cholesterol in lard.
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table s4.3 Taurine measurements in serum and in liver.
control Quercetin
Serum (µM) 564.9 ± 114.08 509.4 ± 62.93
Liver (µmol/g protein). 376.4 ± 96.6 332.8 ± 127.1
Data are presented as mean ± SD. 
figure s4.1 cumulative feed intake during the 12 weeks intervention period (a) and total 
energy content of faeces in two weeks (b). Faeces was collected in weeks 10 and 11. Data are 
presented as mean ± SEM. White bars indicate the control group (C) and black bars indicate the 
quercetin group (Q). 
?????
??
??
???
???
???
??
? ? ? ? ? ? ? ? ? ?? ?? ??
?
???
???
???
???????
?????????
??
??
??
???
??
??
???
??
??
???
??
?
? ?
?
??
??
??
??
A
B
73

chapter
direct comparison 
of metabolic health effects 
of the flavonoids QUercetin, 
hesperetin, epicatechin, 
apigenin and anthocyanins 
in high-fat diet fed mice 
Elise F. Hoek-van den Hil1,2,3, 
Evert M. van Schothorst1, Inge van der Stelt1, 
Hans J.M. Swarts1, Marjanne van Vliet1, 
Tom Amolo1, Jacques J.M. Vervoort4, 
Dini Venema3, Peter C.H. Hollman3, 
Ivonne M.C.M. Rietjens2, and Jaap Keijer1.
1 Human and Animal Physiology, Wageningen University, 
Wageningen, The Netherlands 
2 Division of Toxicology, Wageningen University, 
Wageningen, The Netherlands 
3 rIKIlt, Wageningen ur, Wageningen, The Netherlands 
4 Laboratory of Biochemistry, Wageningen University, 
Wageningen, The Netherlands
Submitted for publication
5
Chapter 5
5
abstract
Dietary flavonoid intake is associated with reduced risk of cardiovascular diseases, 
possibly by affecting metabolic health. The relative potency of different flavonoids in 
causing beneficial effects on energy and lipid metabolism has not been investigated.
Effects of quercetin, hesperetin, epicatechin, apigenin and anthocyanins, in mice 
fed a high-fat diet (HF) for 12 weeks were compared, relative to normal-fat diet. 
HF-induced body weight gain was significantly lowered by all flavonoids (17-29%), 
but most by quercetin. Quercetin significantly lowered HF-induced hepatic lipid 
accumulation (71%). Mesenteric adipose tissue weight and serum leptin levels were 
significantly lowered by quercetin, hesperetin, and anthocyanins. Adipocyte cell size 
and adipose tissue inflammation were not affected. 
The effect on body weight and composition could not be explained by individual 
significant effects on energy intake, energy expenditure or activity. Lipid metabolism 
was not changed as measured by indirect calorimetry or expression of known lipid 
metabolic genes in liver and white adipose tissue. Hepatic expression of Cyp2b9 was 
strongly down regulated by all flavonoids. 
In conclusion, all flavonoids lowered parameters of HF-induced adiposity, with 
quercetin being most effective. 
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5.1 introdUction
Fruit and vegetable consumption is regarded as protective against cardiovascular diseases 
(CVD) 1. Flavonoids in fruits and vegetables are suggested to be responsible, at least 
partly, for these protective effects. This is supported by epidemiological studies that have 
shown that an increased intake of flavonoids is associated with a reduction of CVD risk 2. 
Nowadays flavonoid supplements are widely available resulting in even increasing intakes 
of flavonoids. Elevated circulating lipid levels, a fatty liver and obesity are associated with 
a higher risk of CVD 3-5. Previously, we have shown that the flavonoid quercetin can lower 
serum lipid levels by affecting hepatic lipid metabolism 6, and that quercetin reduced 
high-fat diet-induced body weight gain and hepatic lipid accumulation 7. 
Quercetin is one of the many flavonoids in our diet and is the major representative 
of the flavonoid subclass of flavonols. Other flavonoid subclasses are flavanones, 
flavan-3-ols, flavones, isoflavones, and anthocyanins, which all are present in our diet. 
However, it is not known whether these flavonoids exert similar effects as quercetin 
on body weight homeostasis and lipid metabolism, and if so, whether they affect the 
same metabolic pathways. Human intervention studies with fruits or vegetables or 
extracts rich in flavonols, flavanones, flavan-3-ols, or anthocyanins showed beneficial 
effects on CVD related parameters such as blood pressure, vascular function or blood 
lipid profiles 8-10. Also, flavones, mostly present in herbs and cereals, are suggested to 
have beneficial effects on CVD risk factors 11. Therefore, it is interesting to compare 
the effects of flavonoids from different subclasses on CVD risk factors. 
The observed potential beneficial effects of flavonoids in humans are mostly based 
on studies using flavonoid-rich foods or extracts 12,13. Therefore, also other components 
can be responsible for the observed effects. For instance, caffeine was presumably 
present in studies with green tea catechin extracts, which could be underlying the 
reduction in body weight gain 14. Functional effects of flavonoids should therefore be 
investigated with fully characterized pure compounds. Furthermore, we have shown that 
effects of quercetin on body weight depended on the percentage and/or composition 
of fat in the background diet 7. It is therefore important to directly compare effects 
using the same diet. A high-fat diet that induces body weight gain and hepatic lipid 
accumulation seems best suited to reveal the lipid lowering properties of flavonoids.
Flavonoids were selected from five subclasses, based on potential CVD protective 
effects, and presence in food 8-11,15. In addition to quercetin (flavonol), hesperetin 
(flavanone), epicatechin (flavan-3-ol), apigenin (flavone), and a purified extract of 
mainly cyanindin-3-O-β-glucoside and delphinidin-3-O- β-glucoside (anthocyanins) 
were selected. The aim of this study was to investigate whether other flavonoids 
exert similar effects as quercetin, which reduced high-fat induced body weight gain 
and hepatic lipid accumulation 7. To better understand the effects, we extend the 
assessment with analysis of whole body energy balance and other metabolic health 
related analyses. A comprehensive analysis of whole body energy balance was 
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performed, including quantification of parameters such as body weight gain, faecal 
energy loss, energy intake, and activity. Indirect calorimetry was used to evaluate 
the type and rate of substrate utilization and energy expenditure (EE). Furthermore, 
circulating lipids, hepatic lipid accumulation and hepatic gene expression patterns 
were studied. Additionally, the effects of the flavonoids on gene expression in white 
adipose tissue (WAT) were assessed, together with WAT-secreted serum leptin levels. 
Leptin is a peptide hormone which regulates body weight gain.
5.2 materials and methods
Animals and treatments 
Eighty-four male C57BL/6JOlaHsd mice (Harlan Laboratories, Horst, The Netherlands) 
were individually housed and maintained under environmentally controlled conditions 
(temperature 21°C, 12h/12h light-dark cycle, 55 ± 15 % humidity), with ad-libitum access 
to food and water. At arrival, the mice were 9 weeks of age. During the first five days of a 
three weeks adaptation period, mice were fed a standard Harlan chow diet, followed by 
a standardized semi-synthetic normal-fat diet (NF, 10 energy % (en%) fat) with the same 
dietary constituents as the intervention high-fat diet (HF, 40en%) in which carbohydrates 
were substituted with fats 16 (Research Diets Services B.V., Wijk bij Duurstede, The 
Netherlands). At the start of the 12-week intervention period, mice were stratified based 
on body weight over 7 groups (n=12). One group of mice continued on NF, while the other 
six groups of mice received HF with or without supplementation of different flavonoids 
(HF+flavonoids). A subset of data of the control HF and HF+quercetin group were published 
before (body weight, energy intake, serum quercetin levels, and serum and hepatic lipid 
levels) 7. Flavonoids were added in equimolar amounts to HF (0.01 mol/kg diet), amounts 
were based on our previous results, which showed effectiveness of quercetin at this 
concentration 6,17; 0.33% (w/w) quercetin (Sigma, Zwijndrecht, The Netherlands), 0.33% 
hesperetin (Bioconnect, Huissen, The Netherlands), 0.32% epicatechin (Sigma), 0.29% 
apigenin (Fuzhou Corona Science & Technology Development Co., Ltd., Fuzhou Fujian, 
China), and 0.5% anthocyanins, a purified anthocyanin extract from bilberry and black 
currant consisting of mainly cyanindin-3-O-β-glucoside and delphinidin-3-O- β-glucoside 
(18, Medox, Polyphenols Laboratories, Sandnes, Norway). Sufficient amounts of individual 
anthocyanins were not available. Body weight and food intake were monitored weekly. 
Faeces were collected in weeks 11 and 12. One HF+quercetin (HF+Q) fed mouse was 
excluded from all analyses, because of a nasal abscess. At the end of the intervention, all 
mice were fasted for 2-4 h during the light phase and anesthetized by inhalation of 5% 
isoflurane using O2 as a carrier. Blood was sampled via orbital extraction in collect serum 
tubes (Greiner Bio-one, Longwood, USA) and stored at -80°C after obtaining serum. 
After blood collection, mice were killed by cervical dislocation, and liver, epididymal and 
mesenteric white adipose tissues (epiWAT and mesWAT, resp.) were dissected, weighted 
and snap frozen in liquid nitrogen and stored at -80°C. The experiment was performed 
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according to the Dutch Animal Experimentation Act (1996) and the experimental 
protocol was approved by the Animal Welfare Committee of Wageningen University, 
Wageningen, The Netherlands (DEC 2011079). 
hPLc analysis of flavonoid levels in serum and diet
Flavonoid levels in serum were measured using HPLC with coulometric array detection 
as described 6. Anthocyanins could not be detected by our method. Before analysis, 
samples were hydrolyzed by β-glucuronidase/sulfatase to obtain deconjugated 
flavonoids. Flavonoid levels in the diets were also measured with HPLC to confirm 
presence and stability. 
energy content of faeces and diet
Bomb calorimetry was used to determine energy content of diet and faeces 
(Calorimeter C7000, IKA, Staufen, Germany) as described 7. Total digestible energy 
intake over 12 weeks was calculated based on weekly energy intake and faecal energy 
loss, by multiplying weekly food intake by the measured dietary gross energy content 
minus the extrapolated faecal energy loss. Digestible energy intake was assumed to 
be comparable with metabolisable energy intake, as dietary protein content was equal 
for all diets and no differences in urinary energy losses were expected.
indirect calorimetric and activity measurements
Indirect calorimetry and activity were measured in weeks 1, 5 and 11. Indirect 
calorimetry was performed by an open circuit LabMaster Metabolism Research 
Platform (TSE systems GmbH, Bad Homburg, Germany) and analysed as described 
previously 19 with minor adaptations. A reference cage was measured and then rates 
of oxygen consumption (VO2) and carbon dioxide production (VCO2) were measured 
during 1 minute every 12 minutes for 48h, of which the last 24h were used. To avoid 
any influence of initial stress and adaptation, only the data of the last 24h of a 48h 
measurement were used for analysis. Respiratory exchange ratio (RER) is defined as 
VCO2 divided by VO2, and EE was calculated using the equation [3.815 + (1.232 x 
RER)] x VO2 
20. Carbohydrate and lipid oxidation rates were calculated using 21. During 
indirect calorimetry measurements, activity was continuously measured with the 
ActiMot system (TSE systems GmbH) in eight cages. Infrared beam breaks in horizontal 
plane (x and y direction) over the last 24hof a 48h period were used. 
motor performance
Balance and motor coordination was assessed by rotarod (IITC life science, Woodland 
Hills, USA) in week 9. Latency to fall was recorded on an accelerating rod (3-38 rpm 
in 300s); mice were placed on the rod four times with an inter trial rest period of 30 
minutes; the average of two longest runs per animal were used for analysis.
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Several parameters of gait were assessed in week 10 by CatWalk analysis (Noldus 
Information Technology, Wageningen, The Netherlands) using the reflection of light 
projected on a glass walking area. Each mouse made at least six compliant runs, 
being defined as a maximum speed variation of 40%, a minimum run duration of 0.5 
seconds and a maximum run duration of 10 seconds. Quantitative gait parameters 
were analysed using the CatWalk XT 10.0 software (Noldus Information Technology). 
Lipid determination in serum and liver 
Because flavonoids were previously shown to interfere with commonly used 
commercially available enzymatic lipid assays 22, alternative methods were used to 
measure the amount of lipids in serum and liver, as described 6. Serum lipids were 
extracted and analysed with 1H nuclear magnetic resonance (1H-NMR), and neutral 
lipids were stained in frozen liver sections with Oil red O (Sigma) and quantified.
RT-qPcR
RNA from liver was isolated using RNeasy columns (Qiagen, Venlo, The 
Netherlands),RNA from epiWAT was extracted with Trizol (Invitrogen, Breda, The 
Netherlands) and quality was verified (as published 6,7). RT-qPCR was performed 
and analysed as described 6. Data were normalized using reference genes beta-2 
microglobulin (B2m) and hypoxanthine phophoribosyltransferase 1 (hprt1) for liver and 
hprt1 and Ribosomal protein S15 (rps15) for epiWAT, chosen based on stable gene 
expression levels as determined with GeNorm (GeNorm, Ghent University Hospital, 
Ghent, Belgium). Primer sequences can be found in Supplementary Table S5.1.
serum leptin levels
Serum leptin levels were determined using a leptin ELISA kit (Crystal Chem Inc., 
Chicago, IL, USA) according to the manufacturer’s instructions. 
histology of epididymal white adipose tissue 
Paraffin embedded epididymal white adipose tissue (epiWAT) was cut into 5 µm sections 
and stained using Periodic Acid Schiff Haematoxylin (PASH). Per animal, circumference 
of at least 400 adipocytes was measured using AxioVision software v4.8 (Carl Zeiss 
Microscopy GmbH, Jena, Germany). To estimate macrophage infiltration as a marker 
for tissue inflammation, a MAC-2 staining was performed and analysed as published 23. 
Macrophage infiltration is expressed as total number of crown likes structures (CLS) per 
100 adipocytes; CLS are formed by macrophages around dying or dead adipocytes.
statistical analysis
All statistical analyses were in principle done based on all 12 mice per group with the 
following exceptions: HF+Q only for 11 mice; for indirect calorimetry measurements (n=9), 
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histological stainings (n=6), faeces collection (n=4), and serum flavonoid measurements 
(n=6), subsets of mice as indicated between the brackets were randomly selected, because 
of limited equipment or practical reasons. GraphPad Prism version 5.03 (Graphpad 
Software, San Diego, CA, USA) was used for statistical analysis. Data were checked for 
normality and if needed log transformed (Acot3, Cyp4a14, Por, Fasn and Cyp2b9 in liver 
and Cpt1a in EpiWAT). One-Way ANOVA was used to compare the groups, followed by 
Dunnett’s post hoc test to compare the different HF+flavonoid groups to HF, and HF to 
NF. For the analysis of data of liver weight, hepatic gene expression of Acacb and Cpt1a, 
and WAT gene expression of Pparg, a Kruskal-Wallis test was used, because also after 
log transformation these data were not normally distributed. Curve fitting was used to 
analyse body weight gain during the 12 week intervention period using Proast software 24. 
Two-way ANOVA (no repeated measures) was used for analysis of the lipid profiles in 
serum and for 24h indirect calorimetry data in time. Pearson correlation analyses were 
performed using all HF+flavonoids groups and HF group. NF was excluded for these 
correlation analyses, to avoid false positive strong correlations due to NF. P-values smaller 
than 0.05 were considered significantly different.
5.3 resUlts
Flavonoid quantification in diets and serum
Flavonoids in the diets were measured at the start of the experiment and were 
between 87%-99% of the theoretical amounts. After one week at room temperature in 
the cages, contents of flavonoids in the diets did not change; and varied between 90 
and 100% of the theoretical flavonoid amounts (Supplementary Table S5.2).
After 12 weeks on the HF+quercetin diet (HF+Q), the sum of quercetin and 
isorhamnetin in serum was 6.5 ± 1.4 µM 7. After the HF+hesperetin diet (HF+H), 
hesperetin was detectable in half of the measured serum samples (with a detection 
limit of 150 nM), for which the mean concentration was 0.5 ± 0.8 µM. Epicatechin, and 
apigenin, were not detectable in serum of HF+epicatechin (HF+E) and HF+apigenin 
(HF+Ap) mice (with detection limits of 300 nM). 
Body weight, metabolisable energy intake and feed efficiency
Body weight was significantly increased due to HF compared to NF feeding during 
the whole intervention period, with a cumulative body weight gain of HF mice being 
four times higher than the weight gain of NF mice (Figure 5.1). Supplementation of HF 
with any of the flavonoids (HF+flavonoids) reduced the body weight gain significantly, 
as analyzed by curve fitting analysis (Figure 5.1a). Cumulative body weight gain over 
12 weeks was for HF+Q mice 29% lower (p<0.001) 7 and for HF+H mice 21% lower 
(p<0.05) than for HF mice (Figure 5.1b). The cumulative metabolisable energy intake 
over 12 weeks was not significantly different for all HF+flavonoid groups compared to 
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figure 5.1. Flavonoids reduce HF-induced body weight gain and feed efficiency. Body weight of 
the mice during 12 weeks on a normal-fat diet (NF, 10 en% fat) or a high-fat diet (HF, 40%) with 
or without supplementation of the flavonoids quercetin (HF+Q), hesperetin (HF+H), epicatechin 
(HF+E), apigenin (HF+Ap) or anthocyanins (HF+An) (A). Total body weight gain over 12 weeks 
(B). Total metabolisable energy intake over 12 weeks (C). Total food efficiency, which is the ratio 
of body weight gain over metabolisable energy intake (D). Data are presented as mean ± SEM. * 
indicates a significant difference of HF+flavonoid to HF (p<0.05), **p<0.01, ***p<0.001, # indicates 
a significant difference of HF to NF (p<0.05), ###p<0.001. 
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HF, but it was significant different for HF vs NF (Figure 5.1c). As a result, feed efficiency 
was significant lower for HF+Q, HF+H and NF compared to HF (Figure 5.1d).
indirect calorimetry and activity 
Respiratory exchange ratio (RER) and EE were not significantly different between any 
HF+flavonoid group and HF in week 11, the 24h patterns are shown in Figure 5.2a and 
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5.2b. Mean 12h light and dark phase RER and EE values are in Supplementary Table 
S5.3. Mean RER values varied from 0.84-0.87, which implies that 48.3%-58.5% of the 
energy comes from glucose oxidation and 51.7%-41.5% from fat oxidation. HF mice had 
a significant lower RER compared to NF, which is caused by the lower carbohydrate and 
higher fat levels present in HF. EE was not significant different between HF and NF mice. 
HF mice were significantly less active during the dark phase compared to NF mice. No 
differences were observed for activity of HF+flavonoids groups compared to HF during 
the dark phase as well as the light phase (Figure 5.2c). RER, EE and activity for weeks 1 
and 5 were all comparable to those of week 11 (Supplementary Figure S5.1). 
motor performance
HF mice performed significantly poorer on the rotarod than NF mice, likely due to their 
higher body weight. Performance on rotarod was, however, not significantly different 
between any HF+flavonoid group and HF (Supplementary Figure S5.2). There were also 
no significant differences between the HF+flavonoid groups and HF in the measured gait 
parameters (Supplementary Table S5.4), however some parameters showed significant 
differences between HF and NF, also likely related to the large body weight differences. 
serum lipids
HF significantly induced higher levels of ‘MUFA and PUFA’, ‘PUFA’, ‘18:2 fatty acids’, ‘18:1 
and 16:1 fatty acids’ and ‘omega 3 fatty acids’ in serum compared to NF. No significant 
differences between HF and HF+flavonoid were observed in the serum lipid levels; however, 
some of the flavonoids showed a small trend towards the levels found for NF (Figure 5.3a).
hepatic lipid accumulation 
HF-feeding significantly induced hepatic lipid accumulation as is apparent from an 
increase in liver weight (Figure 5.3b), area of lipids (Figure 5.3c) and lipid droplet 
number (Figure 5.3d) compared to values for NF-feeding. Liver weight was not affected 
by the flavonoid supplementations to the diets. Only supplementation with quercetin 
(HF+Q) significantly reduced the HF-induced lipid accumulation. As compared to HF, 
quercetin lowered the area of lipids by 71%, and the lipid droplet number by 31%. 
Representative pictures of hepatic lipid stainings are presented in Figure 5.3e. 
hepatic gene expression
Hepatic expression levels of genes involved in fatty acid omega-oxidation were studied 
based on our previous observations that quercetin supplementation to a mild high-fat 
(30en%) diet-induced this pathway in liver 6. HF feeding compared to NF revealed 
significant induction of omega-oxidation by regulation of Acot3, Cyp4a10, and 
Cyp4a14. However, no significant regulation of these genes, nor Por was observed in 
any of the HF+flavonoid groups compared to HF (Table 5.1). Subsequently, also other 
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figure 5.2 Whole body rer, ee, and activity levels were not affected by flavonoid supplementation. 
Indirect calorimetry measurements of 24h RER (A) and EE (B) in week 11. Activity measured during 
indirect calorimetry measurements for light (12 h) and dark (12h) period (C). Data are presented as 
mean ± SEM. ## indicates a significant difference of HF to NF (p<0.001). RER; respiratory exchange 
ratio, EE; energy expenditure, NF; normal fat diet, HF; high-fat diet; HF supplemented with quercetin; 
HF+Q, hesperetin; HF+H, epicatechin; HF+E, apigenin; HF+Ap, anthocyanins; HF+An. 
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figure 5.3 effects of flavonoids on hf-induced effects on serum lipids, liver weight and hepatic 
lipid accumulation. Serum lipid fractions are shown as ratio of HF+flavonoid or NF over the average 
value of the HF-control (A). Liver weight at the end of the dietary intervention of 12 weeks (B). 
Quantification of total area of lipids per picture (C) and mean lipid droplet number per picture (D) in 
liver. Representative pictures of stained hepatic lipids by Oil red O (E). Hepatic Cyp2b9 expression 
(F). Data are presented as mean ± SEM. * indicates a significant difference of HF+flavonoid to HF, # 
indicates a significant difference of HF to NF (p<0.05), ##p<0.01. PUFA; poly unsaturated fatty acids, 
MUFA; mono unsaturated fatty acids, FA; fatty acids, TG; triglycerides, PGLY; phosphoglycerides, 
PC; phosphatidylcholine, EC; esterified cholesterol, TC; total cholesterol, NF; normal fat diet, HF; 
high-fat diet; HF+Q, HF supplemented with quercetin; HF+Q, hesperetin; HF+H, epicatechin; 
HF+E, apigenin; HF+Ap, anthocyanins; HF+An. 
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genes involved in lipid metabolism were studied. Acacb and Ppargc1a were significantly 
regulated by HF vs NF. However, Acacb, Fasn, Cpt1a, Ppara, and Ppargc1a were not 
significantly different for any of the HF+flavonoid diets compared to HF (Table 5.1). 
Cyp2b9, a target gene of the transcription factor CAR, was strongly up regulated 
by HF vs NF. Interestingly, this gene was significantly lower expressed upon 
supplementation of HF with all of the flavonoids (FC between -5.9 and -9.1, Table 5.1). 
Cyp2b9 expression levels for all groups are shown in Figure 5.3f. 
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Gene expression in white adipose tissue
Based on the above described results, it was decided to study gene expression in epiWAT 
only for NF, HF, HF+Q and HF+H groups. Genes were selected by their functions related 
to lipid metabolism. This showed significant regulation of Fasn, Cpt1α, Ppargc1α, Pnpla2, 
and lep due to HF compared to NF feeding. lep gene expression showed significant 
down regulation for HF+Q and HF+H mice compared to HF. No significant regulation by 
quercetin or hesperetin was observed for the other genes (Table 5.2). 
White adipose tissue and leptin
HF feeding significantly induced relative mesWAT and epiWAT weights compared to 
NF feeding. Supplementation with the flavonoids prevented this induction of relative 
mesWAT weight, which was significantly lower for HF+quercetin, HF+hesperetin and 
HF+anthocyanins compared to HF (Figure 5.4a). Relative epiWAT was only significantly 
decreased for HF+quercetin vs HF (Figure 5.4b). A trend for decreased relative WAT 
weights was seen for most of the HF+flavonoid diets compared to HF, in line with their 
reduced body weights. 
Likewise, serum leptin levels, which are known to be correlated to total adipose 
tissue mass, showed significant higher values for HF mice compared to NF mice. 
Quercetin, hesperetin and anthocyanins supplementation to HF significantly lowered 
serum leptin levels compared to HF (Figure 5.4c), which also corresponds to the gene 
expression results of lep.
table 5.1 Hepatic gene expression (RT-qPCR).
gene 
symbol
hf hf+Q hf+h hf+e hf+ap hf+an
vs nf vs hf
Lipid
Omega- 
Oxidation
Acot3 2.67## 1.07 -1.07 1.07 1.16 1.05
Cyp4a10 2.06## -1.09 1.15 1.05 -1.12 1.05
Cyp4a14 2.39### 1.11 1.23 1.09 1.06 1.04
Por 1.34 1.08 1.14 1.12 1.07 1.02
Lipid
Metabolism
Acacb -1.76## 1.07 1.01 1.11 -1.10 1.12
Fasn -1.10 1.10 1.05 1.17 -1.05 1.02
Cpt1a 1.25 -1.06 1.05 -1.02 -1.12 -1.01
Ppara 1.29 -1.07 1.09 1.02 -1.09 1.01
Ppargc1a -1.51## -1.06 1.05 1.10 1.18 -1.09
CAR target Cyp2b9 40.60### -8.22*** -8.02*** -5.85** -6.33** -9.05***
Data are presented as mean fold change of HF vs NF and HF+flavonoids vs HF. ## indicates significant 
difference of HF to NF (p<0.01), ###p<0.001, ** indicates a significant difference of HF+flavonoid to HF 
(p<0.01), ***P<0.001. NF; normal fat diet, HF; high-fat diet; HF supplemented with quercetin; HF+Q, 
hesperetin; HF+H, epicatechin; HF+E, apigenin; HF+Ap, anthocyanins; HF+An. 
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table 5.2 Gene expression in white adipose tissue.
gene 
symbol
function hf hf+Q hf+h
vs nf vs hf
Fasn Fatty acids synthesis -4.19### 1.05 -1.18
Cpt1α Fatty acid beta-oxidation 1.83### -1.32 -1.22
Ppargc1α mitochondrial biogenesis -2.13### 1.10 -1.10
Lipe Lipolysis -1.10 1.02 -1.05
Pnpla2 Lipolysis -1.66### 1.27 1.14
Lep Leptin 5.80### -1.70*** -1.52**
Pparg Adipocyte differentiation -1.48 -1.00 -1.14
Clmp Adipocyte differentiation 1.25 -1.13 -1.20
Data are presented as mean fold change of HF vs NF and HF+flavonoids vs HF. ### indicates 
significant difference of HF to NF (p<0.001),** indicates a significant difference of HF+flavonoid 
to HF (p<0.01), ***P<0.001. NF; normal-fat diet, HF; high-fat diet, HF+Q; HF supplemented with 
quercetin, HF+H; hesperetin.
Adipocyte size (Figure 5.4d) and macrophage infiltration (Figure 5.4e) in epiWAT were 
determined, and representative pictures of adipocyte stainings are shown in figure 5.4f. 
Mean adipocyte size was significantly higher for HF mice vs NF mice. Remarkably, 
supplementation of flavonoids to the HF diet did not significantly affect the HF-induced 
increased adipocyte size, indicating that the lower observed WAT weights were not due 
to smaller adipocytes; consequently, the number of adipocytes should be decreased. 
MAC-2 staining as a marker of macrophage infiltration of epiWAT revealed no 
indication for inflammation 25 for all groups. 
correlations
Pearson correlations between all parameters measured showed significant correlations 
between body weight gain and all parameters for HF and all HF+flavonoid groups 
(Figure 5.5a), except for the indirect calorimetry measurements (RER and EE). Strongest 
correlation was found between body weight gain and leptin (r=0.94, p<.0001, 
Figure 5.5b). Interestingly, Cyp2b9 expression showed also a strong correlation 
(p<0.001) with body weight gain (Figure 5.5c), metabolisable energy intake, relative 
weights of epiWAT and mesWAT, and with serum leptin levels. The correlation plots 
shown in Figure 5.5b and 5.5c indicate quercetin as most potent flavonoid to modify 
the HF-induced effects in the direction of NF effects.
5.4 discUssion
As expected, HF (40 en% fat) induced adiposity, as seen by body weight gain, more visceral 
adipose tissue and hepatic lipid accumulation, compared to NF (10 en% fat). We examined 
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figure 5.4 effects of flavonoids on hf-induced effects on white adipose tissue weights, serum 
leptin levels, adipocyte size and crown like structures in epiWat. Mesenteric white adipose 
tissue (mesWAT, A) and epididymal tissue (epiWAT, B) relative weight (gram/gram body weight) 
at the end of the dietary intervention. Serum leptin levels (C). Quantification of adipocyte sizes 
(D) and crown like structures (CLS) by macrophage staining (E) in epiWAT. Representative pictures 
of adipocyte stainings (F). Data are presented as mean ± SEM. * indicates a significant difference 
of HF+flavonoid to HF (p<0.05), **p<0.01, ***p<0.001, ### indicates a significant difference of HF 
to NF (p<0.001). NF; normal fat diet, HF; high-fat diet; HF supplemented with quercetin; HF+Q, 
hesperetin; HF+H, epicatechin; HF+E, apigenin; HF+Ap, anthocyanins; HF+An. 
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whether this unfavourable change could be prevented by individual supplementation of HF 
with five different flavonoids: quercetin, hesperetin, epicatechin, apigenin, or anthocyanins. 
All flavonoids reduced HF-induced body weight gain and hepatic Cyp2b9 expression. 
Quercetin was the most potent flavonoid in beneficially affecting the HF-disturbed whole 
body energy balance and lipid handling. In addition to quercetin, also hesperetin and 
anthocyanins decreased relative mesWAT weights and serum leptin levels. None of the 
flavonoids affected energy intake, substrate use, and energy expenditure.
The reduced body weight gain by all flavonoids was not caused by reduced intake 
of metabolisable energy. As an example, for HF+quercetin fed mice metabolisable 
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figure 5.5 correlations between measured parameters. Pearson correlations between body 
weight gain, metabolisable energy intake, RER, EE, liver weight, hepatic lipid accumulation, Cyp2b9 
expression, weight and area of WAT, and serum leptin levels were analysed for HF and all HF+flavonoids 
groups (A). Pearson r values are presented, with underneath the significance of the correlation; *p<0.05, 
**p<0.01, ***P<0.001, ****P<0.0001. Correlation plot of BW gain to leptin for HF, HF+flavonoids and 
NF (B). Correlation plot of BW gain to cyp2b9 expression (log2) for HF, HF+flavonoids and NF (C). Large 
symbols indicate the mean of the value per group, small symbols indicate the individual mice. 
????????????????????
??
??
???
??
???
??
? ? ?? ?? ?? ??
?
??
??
??
??
??
????
??
????????????????????
??
??
??
???
??
??
???
?
? ? ?? ?? ?? ??
??????
?????
????
???
?
??
??
????
?? ??
????
??
????
?????
?????
????
?
? ?
????
????
????? ?????
?? ??
????? ????? ????
?? ?? ????
???? ???? ????? ?????
?? ?? ???? ???
???? ???? ????? ????? ????
?? ? ???? ???? ????
???? ???? ????? ????? ???? ????
???? ?? ? ?? ?? ?
???? ???? ????? ????? ????? ????? ?????
??? ?? ?? ?? ?? ?? ??
???? ???? ???? ???? ????? ????? ???? ????
? ?? ?? ?? ?? ?? ?? ??
???? ???? ????? ????? ???? ???? ???? ???? ????
???? ???? ?? ?? ?? ?? ?? ?? ?
???? ???? ????? ????? ???? ???? ???? ???? ???? ????
???? ???? ?? ?? ?? ?? ?? ??? ?? ????
???? ???? ????? ????? ???? ???? ???? ???? ???? ???? ????
???? ???? ?? ?? ?? ?? ??? ?? ?? ???? ????
???? ???? ????? ????? ????? ????? ????? ???? ???? ???? ???? ????
?? ?? ?? ?? ?? ?? ?? ???? ?? ?? ?? ?
??
????
??
??
???
??
??
???
??
?
??
??
??
??
??
??????????
?????????
?????????
?????????????????????????
?????????????????????
??
??
??
???
??
???
???
??
?
???????????????????????
???????????
??????????
?????? ???????????
??? ??????
??????????
?????????????????????
??
????
??
??
??
???
??
??
??
??
????
??
?
???
??
???
?
??
??
???
????
???
???
??
???
??
?
??
??
???
????
???
??
??
??
??
??
??
???
??
??
???
?
??
??
??
???
?
??
??
??
???
?
intake was marginally lower than for HF mice, but this difference can only explain a 
lower body weight of ~0.5 gram, based on the observed feed efficiency, instead of the 
observed reduction of 4.6 gram after 12 weeks. Also activity and energy expenditure 
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measurements in weeks 1, 5, and 11 of the intervention showed no differences between 
the HF+flavonoid groups and HF, and could therefore not explain the differences in 
final body weight. These results correspond with previous data which showed that 
changes in energy expenditure could not explain weight differences due to quercetin 
supplementation in mice 26,27. Overall, energy intake, energy demand or energy loss, 
were not different between the HF+flavonoid groups and the HF control group and 
therefore cannot explain the flavonoid-induced body weight differences.
The flavonoid-induced body weight differences could neither be explained by an 
increase in lipid oxidation, as suggested earlier 6,28. Our indirect calorimetry measurements 
showed no indication for differences in substrate use between the different HF+flavonoid 
groups and HF. There was no lowering of the RER value, which would indicate increased 
fatty acid versus glucose oxidation. This confirms an earlier observation for quercetin 
supplementation showing an absence of effects on RER values 26. Also serum lipid fractions 
were not significantly changed by the flavonoids; only some lipid fractions showed a small 
tendency to decrease into the direction of values observed for NF mice. Furthermore, 
except Cyp2b9, all studied lipid metabolism genes, in liver and WAT for any of the flavonoid 
supplementations showed no significant differences in expression levels compared to HF. 
This indicates that the flavonoids did not induce measurable changes in lipid metabolism, 
which therefore cannot serve as an explanation for the observed body weight differences. 
Since individual parameters alone cannot explain the effect of the flavonoids on 
HF-induced increases in body weight, this effect may possibly be explained by several 
smaller changes that cumulatively contribute to the total body weight balance. Besides 
reduction of body weight gain, also lowering of serum leptin levels and relative mesenteric 
adipose tissue weights were found by supplementation of quercetin, epicatechin and 
anthocyanins. We therefore analysed to which extent the various parameters measured 
were correlated to each other. Body weight gain, WAT weights, and leptin levels 
were strongly correlated (Figure 5.5c, R>0.85, p<0.001). Also, significant correlations 
were found for metabolisable energy intake, serum leptin levels, WAT percentages, 
adipocytes area, hepatic lipid accumulation, and hepatic Cyp2b9 expression with 
many of the measured parameters, including body weight gain. In contrast, energy 
expenditure or RER were not correlated with body weight gain. Overall, these correlation 
analyses confirm that energy expenditure and lipid oxidation alone cannot explain the 
body weight gain lowering effect of the flavonoids. These correlations imply that several 
effects occur, which are related to the body weight gain differences, and these effects 
could possibly cumulatively contribute to the weight lowering effects. 
It is of interest to note that whole body energy balance was studied throughout 
the experiment at several time points. Total energy intake, which was corrected for 
faecal losses, activity, and energy expenditure were taken into account, providing a 
comprehensive picture of whole body energy balance, a major strength of this study. 
In addition, liver as well as white adipose tissue were investigated, which gives an 
extensive overview in comparing the effects of the different flavonoids. 
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Additionally, the effects of flavonoid supplementations on the motor and 
gait performances was studied, because flavonoids are also suggested to have 
neuroprotective actions 29, which could lead to improved motor performance. No 
improvement was observed, however, also no indication for adverse effects on these 
performance parameters was obtained.
Furthermore, we measured the presence of the flavonoids in the diets and in 
serum, which showed absorption of quercetin and hesperetin. The other flavonoids 
were not detectable in serum, which could be ascribed to their pharmacokinetics 
known to include a relatively fast rate of elimination 15,30,31. 
Interestingly, hepatic Cyp2b9 transcript levels were strongly down regulated by all 
flavonoids compared to HF (p<0.01). Cyp2b9 and Cyp2b10 are the major mice homologs 
of human CYP2B6. These P450 enzymes are involved in metabolism of exogenous and 
endogenous compounds, such as steroid hormones, prostaglandins, and fatty acids. 
Furthermore, Cyp2b9 is known to be regulated by the transcription factor CAR 32,33, which 
we previously proposed as a possible target of quercetin 6,7. Importantly, HF increased 
Cyp2b9 expression 40-fold compared to NF. This strong up regulation of Cyp2b9 by 
HF suggests that the amount of lipids in the diet influenced the transcription level of 
Cyp2b9. In a HF dietary context, flavonoids down regulated Cyp2b9 with fold changes 
ranging from 6 to 9. This decreased expression of Cyp2b9 in the various HF+flavonoid 
groups as compared to the HF group positively correlated with reduced body weight 
gain, mesenteric WAT weight, serum leptin levels, and hepatic lipid accumulation. These 
results suggest a relation of the effects of flavonoids on Cyp2b9 with lipid homeostasis, 
which could be possibly regulated via CAR. Overall, the reduced Cyp2b9 transcript levels 
by all flavonoids indicate a relation between Cyp2b9 and the preventive effects of the 
flavonoids on the HF-induced effects. This suggests that Cyp2b9 expression can be a 
marker in a possible common mode of action of the flavonoids. It is tempting to speculate 
that the newly observed common effects of the flavonoids on hepatic Cyp2b9 expression 
and adiposity are mechanistically related, but this requires further investigation.
Of all studied flavonoids, quercetin showed the strongest lowering effects on HF-
induced parameters. Quercetin not only affected most parameters, but also showed 
the most prominent effects. This is supported by correlation analysis (Figure 5.5a). It 
is particularly illustrated by the correlation plot of leptin vs. body weight gain (Figure 
5.5b) and of Cyp2b9 vs body weight gain (Figure 5.5c), which indicate that quercetin 
better prevented the HF-induced effects resulting in values closer to those observed 
for mice fed NF. 
Furthermore, the strong correlation of leptin and body weight gain for all 
HF+flavonoid groups suggests that leptin can be used as a sensitive marker for the 
effects on adiposity. This is especially of interest given that leptin, known to regulate 
body weight gain, can be measured easily and rapidly in circulation. This positions 
leptin as a potential practical and useful marker to quantify flavonoid effects on HF-
induced adiposity, to be used in animal as well as human studies. 
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In conclusion, a direct comparison of metabolic effects of quercetin, hesperetin, 
epicatechin, apigenin and anthocyanins, indicated that all flavonoids beneficially 
affected HF-induced disturbance of whole body energy balance and lipid handling, 
with serum leptin levels as a sensitive marker. This confirms the suggested potential 
of these flavonoids in lowering CVD risk factors. Furthermore, the reduction of hepatic 
Cyp2b9 transcript levels was shown for all flavonoids. Overall, quercetin appeared to 
be the most potent flavonoid in preventing HF-induced effects.
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table s5.2 Flavonoid quantification in diets at the start of the experiment 
stored at -20 °C and after one week at room temperature (RT).
  flavonoid  
start levels (%)
flavonoid levels  
after one week at rt (%)
Quercetin 88 92
Hesperetin 97 93
Epicatechin 99 100
Apigenin 92 95
Anthocyanins 87 90
Data are presented as percentage of the theoretical amount of flavonoids 
added to the diets.
table s5.3 Gait analysis with catwalk in week 10.
parameter nf hf hf+Q hf+h hf+e hf+ap hf+an
Run Duration (s) 2.89 3.35 3.28 3.09 3.21 3.09 3.06
RF Stand (s) 0.17 0.20 0.19 0.19 0.19 0.19 0.19
RF StandIndex -4.79 -3.84 -3.88 -4.08 -3.97 -4.15 -4.12
RF MaxContactAt (%) 35.80 35.83 34.95 36.73 35.16 35.78 37.83
RF MaxContactArea (cm²) 0.22 0.25 0.24 0.25 0.25 0.24 0.24
RF MaxContactMaxIntensity 139.78 145.70 142.61 145.27 143.50 143.00 147.11
RF MaxContactIntensity 71.09 72.95 71.45 72.41 72.81 71.69 72.94
RF PrintLength (cm) 0.84 0.87 0.84 0.84 0.86 0.84 0.86
RF PrintWidth (cm) 0.75 0.78 0.76 0.76 0.79 0.76 0.75
RF PrintArea (cm²) 0.30 0.33 0.32 0.32 0.32 0.31 0.32
RF MaxIntensityAt (%) 55.19 61.04 57.58 61.06 59.83 60.23 61.34
RF MaxIntensity 148.73 157.95 153.53 157.14 155.60 155.13 159.49
RF MinIntensity 36.52 36.34 36.49 36.38 36.48 36.37 36.44
RF Intensity 74.70 77.34 75.61 76.92 77.01 75.86 76.82
RF IntensityOfThe15MostIntensePixels 114.00 120.52 116.98 119.92 119.54 116.59 120.82
RF Swing (s) 0.13 0.14 0.14 0.14 0.14 0.14 0.14
RF SwingSpeed (cm/s) 53.67 51.58 49.04 48.65 49.74 48.66 47.79
RF StrideLength (cm) 6.88 6.79 6.69 6.59 6.72 6.40 6.55
RF StepCycle (s) 0.30 0.33 0.34 0.33 0.33 0.32 0.33
RF DutyCycle (%) 55.15 58.46 56.65 56.64 56.97 57.45 56.50
RF SingleStance (s) 0.13 0.14 0.14 0.14 0.14 0.14 0.14
RF InitialDualStance (s) 0.02 0.03 0.03 0.03 0.03 0.03 0.02
RF TerminalDualStance (s) 0.02 0.03 0.02 0.03 0.02 0.03 0.03
RH Stand (s) 0.14### 0.18 0.17 0.17 0.17 0.17 0.17
RH StandIndex -8.72### -6.37 -6.72 -6.78 -6.60 -7.02 -6.62
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continuing of supplementary table s5.3 
parameter nf hf hf+Q hf+h hf+e hf+ap hf+an
RH MaxContactAt (%) 28.28 27.02 26.75 25.78 27.12 28.10 27.40
RH MaxContactArea (cm²) 0.20# 0.24 0.25 0.25 0.25 0.24 0.25
RH MaxContactMaxIntensity 162.92 172.67 173.94 170.76 169.42 171.17 168.14
RH MaxContactIntensity 79.27 82.09 82.87 82.49 80.98 80.97 81.57
RH PrintLength (cm) 0.79# 0.86 0.88 0.83 0.87 0.86 0.86
RH PrintWidth (cm) 0.68 0.75 0.74 0.72 0.76 0.75 0.76
RH PrintArea (cm²) 0.26## 0.32 0.33 0.31 0.32 0.31 0.32
RH MaxIntensityAt (%) 45.71 52.42 52.44 48.88 52.16 52.45 52.23
RH MaxIntensity 172.38# 182.99 184.92 179.76 179.63 180.92 178.84
RH MinIntensity 39.45 38.31 38.82 39.22 39.35 38.40 38.99
RH Intensity 83.99 87.22 87.60 87.73 86.24 85.92 86.83
RH IntensityOfThe15MostIntensePixels 132.83 146.12 147.84 144.97 144.10 143.35 144.04
RH Swing (s) 0.13 0.14 0.14 0.13 0.13 0.14 0.13
RH SwingSpeed (cm/s) 46.73 46.56 44.61 44.30 46.58 43.98 44.80
RH StrideLength (cm) 6.10 6.24 6.00 5.89 5.91 5.94 5.95
RH StepCycle (s) 0.27 0.31 0.30 0.30 0.29 0.30 0.30
RH DutyCycle (%) 49.77## 54.71 53.73 53.87 54.90 53.21 53.80
RH SingleStance (s) 0.12 0.13 0.13 0.13 0.12 0.12 0.12
RH InitialDualStance (s) 0.01 0.02 0.02 0.02 0.02 0.02 0.02
RH TerminalDualStance (s) 0.01 0.03 0.03 0.03 0.02 0.02 0.03
LF Stand (s) 0.17 0.19 0.19 0.19 0.19 0.19 0.19
LF StandIndex -4.48 -4.16 -3.89 -3.94 -3.87 -4.02 -3.82
LF MaxContactAt (%) 34.41 34.55 34.73 35.89 35.32 34.45 34.01
LF MaxContactArea (cm²) 0.22## 0.26 0.24 0.25 0.24 0.24 0.24
LF MaxContactMaxIntensity 136.84 145.75 142.53 146.92 145.99 143.82 144.91
LF MaxContactIntensity 70.40 72.39 71.61 72.87 72.52 71.50 72.00
LF PrintLength (cm) 0.82 0.86 0.83 0.86 0.84 0.84 0.84
LF PrintWidth (cm) 0.74 0.76 0.76 0.76 0.75 0.76 0.79
LF PrintArea (cm²) 0.30 0.33 0.31 0.33 0.31 0.31 0.31
LF MaxIntensityAt (%) 57.58 61.34 59.85 61.03 59.17 60.41 60.56
LF MaxIntensity 148.27 158.10 155.26 158.92 157.39 156.20 156.83
LF MinIntensity 36.69 36.28 36.36 36.55 36.36 36.37 36.40
LF Intensity 74.54 76.73 75.80 77.22 76.66 75.82 75.88
LF IntensityOfThe15MostIntensePixels 113.01 120.18 117.42 120.85 119.28 117.27 118.14
LF Swing (s) 0.14 0.14 0.14 0.14 0.14 0.14 0.14
LF SwingSpeed (cm/s) 52.78 49.44 48.25 49.67 49.72 47.88 48.89
LF StrideLength (cm) 6.84 6.80 6.63 6.54 6.71 6.44 6.55
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continuing of supplementary table s5.3 
parameter nf hf hf+Q hf+h hf+e hf+ap hf+an
LF StepCycle (s) 0.30 0.34 0.33 0.33 0.33 0.33 0.33
LF DutyCycle (%) 54.48 56.90 56.21 57.46 57.02 56.51 57.30
LF SingleStance (s) 0.13 0.14 0.14 0.14 0.14 0.14 0.14
LF InitialDualStance (s) 0.02 0.03 0.02 0.03 0.02 0.03 0.03
LF TerminalDualStance (s) 0.02 0.03 0.02 0.03 0.03 0.03 0.02
LH Stand (s) 0.14## 0.17 0.16 0.17 0.17 0.17 0.17
LH StandIndex -9.49## -7.13 -6.69 -7.43 -6.65 -6.67 -6.48
LH MaxContactAt (%) 29.10 28.82 27.01 27.45 26.04 26.46 26.87
LH MaxContactArea (cm²) 0.21## 0.24 0.25 0.27 0.26 0.24 0.23
LH MaxContactMaxIntensity 167.66 174.38 171.56 178.64 174.68 171.47 165.12
LH MaxContactIntensity 82.46 82.72 82.00 84.02 82.49 82.22 79.47
LH PrintLength (cm) 0.81 0.84 0.86 0.87 0.87 0.83 0.85
LH PrintWidth (cm) 0.67 0.74 0.76 0.76 0.77 0.74 0.75
LH PrintArea (cm²) 0.26# 0.31 0.32 0.34 0.33 0.31 0.31
LH MaxIntensityAt (%) 47.27 51.38 52.68 48.95 53.20 49.70 51.83
LH MaxIntensity 176.53 183.79 181.55 186.84 184.83 180.92 176.39
LH MinIntensity 39.74 38.16 38.25 38.72 38.48 39.37 38.63
LH Intensity 87.05 87.91 86.84 89.33 87.40 87.30 85.20
LH IntensityOfThe15MostIntensePixels 137.75 147.96 145.69 151.88 148.60 144.29 140.91
LH Swing (s) 0.14 0.14 0.13 0.14 0.14 0.13 0.13
LH SwingSpeed (cm/s) 44.07 45.62 44.41 44.62 44.90 44.18 45.78
LH StrideLength (cm) 6.13 6.17 5.93 6.04 6.12 5.68 5.82
LH StepCycle (s) 0.27 0.30 0.30 0.31 0.30 0.29 0.29
LH DutyCycle (%) 48.48## 53.62 53.46 53.39 53.26 54.13 54.77
LH SingleStance (s) 0.12 0.12 0.12 0.13 0.12 0.12 0.12
LH InitialDualStance (s) 0.01 0.03 0.02 0.02 0.02 0.02 0.02
LH TerminalDualStance (s) 0.01 0.02 0.02 0.02 0.03 0.03 0.02
StepSequence NumberOfPatterns 29.42 30.92 30.83 31.83 30.83 32.08 31.75
StepSequence CA (%) 23.15 18.25 22.07 27.74 17.81 24.65 27.37
StepSequence CB (%) 19.25 25.14 28.57 19.55 26.36 22.58 18.02
StepSequence AA (%) 10.19 9.05 9.85 11.63 11.74 9.85 10.80
StepSequence AB (%) 42.88 46.23 37.14 38.97 39.71 37.94 40.98
StepSequence RA (%) 1.87 1.04 1.08 1.06 1.35 3.19 2.04
StepSequence RB (%) 2.65# 0.28 1.29 1.05 3.05* 1.79 0.78
StepSequence RegularityIndex (%) 92.64 92.92 92.30 92.33 93.47 92.12 93.12
BOS FrontPaws (cm) 1.20 1.21 1.20 1.22 1.27 1.20 1.26
BOS HindPaws (cm) 2.66 2.96 2.76 2.78 2.85 2.87 2.85
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continuing of supplementary table s5.3 
parameter nf hf hf+Q hf+h hf+e hf+ap hf+an
Average Speed 22.49 20.03 19.91 20.06 19.87 19.33 19.65
Maximum Variation (%) 20.89 21.46 23.27 21.19 22.21 23.74 21.25
Cadence 13.65 12.21 12.33 12.37 12.41 12.58 12.46
NumberOfSteps 148.00 152.00 152.58 158.75 151.25 159.08 156.17
PrintPositions RightPaws (cm) 1.23 1.12 1.25 1.23 1.29 1.13 1.33
PrintPositions LeftPaws (cm) 1.12 1.27 1.21 1.16 1.14 1.53 1.46
PhaseDispersions RF->LH 16.41 24.67 8.35 14.74 8.71 10.40 15.65
PhaseDispersions LF->RH 9.45 24.40 16.64 14.98 15.33 7.66 8.77
PhaseDispersions LH->RH 38.70 39.85 38.88 38.11 37.97 38.85 38.08
PhaseDispersions LF->RF 50.03 49.02 50.01 50.56 49.12 49.44 51.21
PhaseDispersions RF->RH 47.29 50.66 47.73 48.17 47.48 49.22 48.01
PhaseDispersions LF->LH 46.96 49.44 47.42 48.99 49.75 45.95 47.57
Couplings RF->LH 21.35 28.60 13.79 20.54 12.91 16.22 21.53
Couplings LF->RH 14.31 29.96 22.47 19.69 22.48 13.57 13.31
Couplings LH->RF 17.81 26.75 24.39 25.42 31.06 15.32 16.92
Couplings RH->LF 25.87 27.48 25.00 24.20 25.03 17.47 8.38
Couplings LH->RH 45.65 45.28 44.69 46.24 43.22 45.07 45.02
Couplings LF->RF 49.57 48.64 49.85 50.75 48.89 48.83 50.78
Couplings RH->LH 44.48 45.79 44.79 45.57 46.97 43.38 43.69
Couplings RF->LH 50.08 51.17 49.80 49.11 50.84 50.35 49.00
Couplings RF->RH 49.59 50.93 48.84 49.86 48.66 50.44 49.52
Couplings LF->LH 49.87 50.14 49.20 50.51 50.70 46.71 48.43
Couplings RH->RF 44.51 45.74 47.83 46.55 47.07 45.18 45.87
Couplings LH->LF 45.63 47.10 46.74 45.81 46.26 47.65 46.82
Support Zero (%) 0.15 0.06 0.05 0.02 0.03 0.03 0.02
Support Single (%) 5.90### 2.02 2.94 1.90 2.64 2.78 2.21
Support Diagonal (%) 73.54 69.45 71.44 70.70 70.24 69.06 71.57
Support Girdle (%) 3.44# 2.08 2.47 2.23 1.43 2.67 1.65
Support Lateral (%) 2.09 1.19 1.14 1.33 1.48 1.61 1.02
Support Three (%) 13.48## 21.97 19.10 20.25 20.53 19.90 20.02
Support Four (%) 1.39 3.23 2.87 3.56 3.65 3.94 3.52
Parameters were not significantly different between HF+flavonoids groups and HF. Some 
parameters were significantly different between HF and NF, which are indicates with #(p<0.05), 
##(p<0.01), ###(p<0.001). RF; right front paw, RH; right hind paw, LF; left front paw, LH; left hind 
paw, BOS; base of support.
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figure s5.1 Whole body rer, energy expenditure, and activity levels were not affected by 
flavonoid supplementation in week 1 and 5. Indirect calorimetry measurements of 24 hour RER 
in week 1 (A) and in week 5 (B) and energy expenditure in week 1 (C) and in week 5 (D). Activity 
measured during indirect calorimetry measurements for light (12 h) and dark (12h) period in week 
1 (E) and in week 5 (f). Data are presented as mean ± SEM. # indicates a significant difference of 
NF to HF. NF, normal fat diet; HF, high-fat diet; HF+Q, HF supplemented with quercetin; HF+H, HF 
supplemented with hesperetin; HF+E, HF supplemented with epicatechin; HF+Ap, HF supplemented 
with apigenin; HF+An, HF supplemented with anthocyanins; RER, respiration exchange ratio.
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figure s5.2. Rotarod measurements in week 9. Data is presented as latency to fall in seconds. 
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abstract
Given the positive results of quercetin in in vitro genotoxicity studies, in vivo 
genotoxicity of this dietary flavonoid was studied in liver and small intestine, where 
highest exposure to quercetin is expected. This is especially of interest considering 
high intake by widely available food supplements.
Quercetin (0.33%) supplemented to a high-fat diet was administered to mice during 
12 weeks. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
levels revealed no indications for hepatotoxicity. General microarray pathway analysis 
of liver and small intestinal tissue samples showed no regulation of genotoxicity 
related pathways. In addition, analysis of DNA damage pathways in these tissues did 
also did point at genotoxicity. Furthermore, comparison with a published classifier set 
of transcripts for identifying genotoxic compounds did not reveal any similarities with 
the regulation of this classifier set of transcripts by quercetin. Available microarray 
datasets of known genotoxic compounds, 2-acetylaminofluorene (2-AAF) and aflatoxin 
B1 (AFB1) in mice were taken along as positive controls for comparison, and indeed 
showed genotoxic properties (regulation of genotoxic related genes) in the analyses. 
This transcriptomic study showed that supplementation with quercetin at ~350 mg/kg 
bw/day for 12 weeks in mice gave no indications of quercetin-induced genotoxicity in 
liver and small intestine.
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6.1 introdUction
Flavonoids present in foods of plant origin like fruits, vegetables, and tea, are thought 
to play a role in the beneficial effects of these foods 1. Apples, onion and tea are major 
dietary sources of one of these flavonoids, quercetin, and in addition quercetin is 
widely available as a dietary supplement in Western countries. However, the safety of 
quercetin has been under discussion for several decades, since also possible adverse 
effects of quercetin, including genotoxicity, have been reported 2-4.
Genotoxicity results in DNA damage and when not repaired, this will result in 
lasting mutations, which can ultimately lead to cancer. Quercetin tested positive in 
various in vitro genotoxicity tests. For example genotoxic properties of quercetin 
were shown in bacterial systems including the Ames test, with and without metabolic 
activation 4-8. This genotoxicity has been related to the quinone-quinone methide 
chemistry of quercetin 5. Furthermore, in several cultured human and rodent cells, 
formation of micronuclei, DNA single strand breaks and chromosomal aberrations 
were observed after quercetin exposure 7,9-12. It was also shown that quercetin can 
generate DNA adducts in different cell types in vitro 13. 
However, genotoxicity was not shown in rodents after oral quercetin administration 
measured by among others micronuclei, chromosomal aberrations and unscheduled DNA 
synthesis in bone marrow, liver, and gastric mucosa cells 14-18. Several long-term (ranging 
from 64 weeks to lifespan) in vivo studies showed no carcinogenicity after quercetin 
exposure ranging from 0.2-10% (providing ~60-3500 mg/kg bw/day in rodents) 19-22. 
Other in vivo studies have shown, however, an indication for higher incidence of tumours 
after quercetin exposure. In rats fed a 0.1% (providing ~50 mg/kg bw/day) quercetin diet 
for 58 weeks, tumours in intestine and bladder were found 3. A 2-year study with 0.1-4% 
(providing ~50-2000 mg/kg bw/day) quercetin within the National Toxicology Program 
reported carcinogenicity in kidneys of male rats induced by the highest dose of quercetin 2. 
These indications of genotoxicity in vitro and the non-conclusive results on carcinogenicity 
in vivo, have raised concerns regarding the safety of quercetin. The genotoxicity of 
quercetin, even without metabolic activation, may specifically be of concern for organs of 
first contact, especially upon intake of highly dosed food supplements. Supplements with 
intakes as high as 1000-1500 mg/day represent dose levels far beyond average dietary 
intake (20 mg/day). At these high dose levels detoxification of quercetin via metabolism 
may be saturated resulting in exposure of the intestine and possibly liver to un-metabolised 
quercetin. This implies that in vivo genotoxicity studies in these first pass tissues could 
provide further insight in the possible hazards of high dose quercetin supplements.
Nowadays, transcriptomic analysis has been shown to be an informative tool to 
predict genotoxicity 23,24. Therefore, the aim of the present study was to characterise 
the potential genotoxicity of quercetin in the small intestine as well as in the liver of 
mice by transcriptomic analysis, in order to provide new additional information to 
evaluate the safety of quercetin. 
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6.2 material & methods
Animals and treatment
The experiment was performed according to the Dutch Animal Experimentation Act 
(1996) and the experimental protocol was approved by the Animal Welfare Committee 
of Wageningen University, Wageningen, The Netherlands (DEC 2011079). In brief, 
24 male C57BL/6JOlaHsd mice (Harlan Laboratories, Horst, The Netherlands) were 
individually housed and maintained under environmentally controlled conditions 
(temperature 21°C, 12 h/12 h light-dark cycle, 55 ± 15 % humidity), with ad-libitum 
access to food and water. At arrival, the mice were 9 weeks old and after adaptation 
for 3 weeks the mice (n=12) received a standardized high-fat diet (40en% fat; 25) 
without or with supplementation of 0.33% (w/w) quercetin (~325 mg/kg bw/day) 
(Sigma, Zwijndrecht, The Netherlands). Effects on body weight and lipid and energy 
metabolism have been reported before 26. One quercetin fed mouse was excluded 
from all analyses, because a nasal abscess developed in week 6. After 12 weeks of 
intervention, all mice were fasted for 2-4 hours during the light phase and anesthetized 
by inhalation of 5% isoflurane using O2 as a carrier. Blood was sampled via orbital 
extraction in collect serum tubes (Greiner Bio-one, Longwood, USA), kept on ice for 
max 2 hours, and centrifuged for 10 min at 3000g at 4 °C to obtain serum, aliquoted, 
and stored at -80°C. After blood collection, mice were killed by cervical dislocation, 
and liver was dissected and weighted, and small intestinal scrapings were snap frozen 
in liquid nitrogen and stored at -80°C. 
ALT and AsT measurements
Possible hepatotoxicity was analysed by measuring serum alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) levels using enzymatic assay kits (Bioo 
Scientific Corporation, Austin, USA; MaxDiscoveryTM ALT and AST Enzymatic Assay, 
resp.), according to the manufacturer’s instructions. Five µl of fresh serum was used 
per well and samples were measured in duplicate and averaged. Students’ t-test was 
used to compare the two normal distributed groups (GraphPad Prism version 5.03, 
San Diego, CA, USA). 
microarrays
RNA from liver and small intestinal scrapings was isolated using RNeasy columns 
(Qiagen, Venlo, The Netherlands) and used for microarray analysis. For global 
transcriptome analysis liver and small intestinal samples of individual mice and 
8x60K Agilent whole-mouse genome microarrays (G4852A, Agilent Technologies 
Inc., Santa Clara, CA) were used according to the manufacturer’s protocol with a few 
modifications as described previously 27. cDNA was synthesized for each animal from 
200 ng RNA. Normalisation and data analysis were performed as published 28 using 
Feature Extraction version 10.7.3.1 (Agilent Technologies). Based on visual inspection 
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three arrays of liver were excluded in which hybridization was not homogenous, and 
no arrays of small intestine were excluded. Microarray data have been deposited in 
NCBI Gene Expression Omnibus (GEO) under accession number GSE51343 (liver) and 
GSE63227 (small intestine).
microarray data analysis
First, Student’s t-tests were used with false discovery rate (FDR) adjustment for multiple 
testing correction according to Benjamini-Hochberg 29. Of the 34,373 and 31,718 probes 
being expressed in liver and small intestine respectively, no significantly differently 
expressed genes between the quercetin and the control group were found (FDR p<0.05). 
Follow-up analyses were performed based on a t-test without FDR adjustment, 
to prevent to discard data which could possibly indicate genotoxicity by using too 
stringent criteria (p<0.05). Fold changes were expressed as ratio of intervention 
group versus control group. General pathway analysis was performed using MetaCore 
(Thomson Reuters, US). Furthermore, regulated genes (p<0.05) present in ‘DNA 
damage’ specific marked pathways in Metacore were studied. 
For comparison with known genotoxic compounds, published microarray data (NCBI 
GEO, accession number GSE43977) of genotoxic compounds 2-acetylaminofluorene 
(2-AAF) and aflatoxin B1 (AFB1) in C57BL/6J mice were taken along. These specific 
gene sets were selected based on availability of microarray data of studies in mice 
with known genotoxic compounds given via the diet for at least 7 days and a sufficient 
number of arrays per group (n>6). These mice received 2-AAF (300 ppm, ~40 mg/
kg bw/day) and AFB1 (1ppm, ~0.15 mg/kg bw/day) via feed for 7 days, afterwards 
microarrays were performed with RNA from liver tissue 23. The doses were identified 
as suitable sub toxic doses to identify gene expression patterns 23. In addition, these 
doses were at least 5 times higher than the benchmark dose (BMD10), the dose that 
induces 10% extra tumour incidence above background levels 30. 
Moreover, regulation of a published classifier set of transcripts, reported to 
predict the genotoxic potential of compounds 23, was used to investigate the possible 
genotoxicity of quercetin. 
6.3 resUlts and discUssion
hepatotoxicity
General hepatotoxicity markers being ALT and AST levels in serum revealed a 
significantly lower level of ALT in serum of quercetin fed mice and no significant 
differences for AST between quercetin and control mice (Figure 6.1). Higher levels of 
ALT and AST are indications for hepatotoxicity, but all observed values in quercetin 
mice were within the normal range for ALT and AST levels 31. Overall, this indicates 
that the tested dose of quercetin did not cause hepatotoxicity. 
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General microarray analysis
Significantly expressed genes (p<0.05) resulted in 1,648 regulated probes in liver and 
1,230 in small intestine. Previous pathway analysis in Metacore with these regulated 
transcripts in liver revealed no pathways regulated by quercetin (FDR<0.01) 26. For the 
small intestine, pathway analysis revealed several pathways regulated by quercetin 
(FDR<0.01), but these regulated pathways were not involved in or related to possible 
genotoxicity or DNA damage (Supplementary Table 1). For comparison, the data 
obtained with the positive genotoxic controls 2-AAF and AFB1 revealed regulated 
pathways involved in DNA damage in mice 23. Therefore, for both liver and small 
intestine, we concluded that general pathway analysis of the transcriptomic data 
revealed no genotoxic effects of quercetin in liver and small intestine of mice after 12 
weeks exposure. 
DNA damage pathways 
Subsequently, the gene expression pattern was studied in more detail focussing on 
genotoxicity of quercetin in liver or small intestine, to confirm our conclusion of the 
general pathway analysis. A comparison was made with hepatic microarray data of 
the known genotoxic compounds 2-AAF and AFB1 23. Transcripts in the 11 pathways 
related to DNA damage in the pathway analysis program Metacore were investigated. 
2-AAF regulated 32 different transcripts and AFB1 regulated 40 transcripts in these 
DNA damage pathways (Figure 6.2). For quercetin in liver, only eight regulated 
transcripts were found in these DNA damage pathways, and nine in small intestine 
(Figure 6.2). Interestingly, all four overlapping transcripts for quercetin in liver 
responded in the opposite direction as was seen for the genotoxic compounds. Two 
overlapping transcripts in the small intestine responded in the same direction as the 
genotoxic compounds. 
figure 6.1. ALT and AST activity in serum of mice exposed to ~350 mg/kg bw/day quercetin for 12 
weeks as compared to controls. Data are presented as mean ± SEM. Alanine aminotransferase; ALT, 
aspartate aminotransferase; AST.
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figure 6.2 regulated transcripts by genotoxins 
(2-aaf and afb1) versus quercetin present in ‘dna 
damage’ pathways. Gene expression of quercetin is 
studied in liver and small intestine. Gene expression 
in liver of the known genotoxic compounds 2-AAF 
and AFB1 is taken along for comparison. Fold changes 
are presented as gene expression of intervention diet 
over control diet. Significant up-regulation is indicated 
in yellow, down regulation in blue (p<0.05) and 
non-significant regulation in white (p>0.05). 2-AAF; 
acetylaminofluorene, AFB1; aflatoxin B1.
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A small subset of four transcripts was only regulated by quercetin in the liver and 
seven transcripts in the small intestine. These transcripts were not regulated by the 
known genotoxic compounds. In liver, all four of these transcripts were related to 
DNA damage response, but they were both up and  down regulated and involved 
in different DNA repair mechanisms, like DNA mismatch repair, DNA double strand 
break repair, and checkpoint mediated cell cycle arrest. This therefore provided no 
clear indication of regulation of one mechanism into the same direction; furthermore, 
this can also be a protective action of quercetin to DNA damage. The seven transcripts 
specifically regulated by quercetin in the small intestine were all up-regulated. Up-
regulation of Cops8, ercc3, and Sirt6 is associated with a protective response against 
DNA damage 32-34. Inactivation of rbl1 is related to tumorigenesis 35. Therefore, the 
up-regulation of these four transcripts suggested a protective response of quercetin. 
There are no reports in the literature on genotoxic or carcinogenic responses related 
to regulation of the genes nfkbib and Pol2r, while up-regulation of Cdk7 is associated 
with carcinogenesis 32. It should also be taken in consideration that 5% of the transcripts 
will be regulated by chance, since a statistical threshold at p-value of 0.05 was used. 
Also given the fact that the number of regulated transcripts by quercetin in the 
DNA damage pathways is rather low and the gene expression in these pathways is 
mostly the opposite of the gene expression of the genotoxic 2-AAF and AFB1, this 
analysis suggests that there was no clear indication for genotoxicity of quercetin in 
liver and small intestine. 
classifier set of transcripts to identify genotoxic compounds
Next, a published classifier set of hepatic transcripts to identify genotoxic compounds 23 
was used to compare expression patterns induced by 2-AAF and AFB1 to the pattern 
induced by quercetin (Figure 6.3). Most of the transcripts were not regulated by 
quercetin in liver or small intestine. Only two transcripts were significantly regulated, 
however, these were regulated in the opposite direction compared to 2-AAF and 
AFB1. This further supports that quercetin did not exert genotoxic effects in liver and 
small intestine in this study. 
Carcinogenicity of quercetin in vitro and in vivo 
The only two studies that previously showed genotoxicity of quercetin in rodents 2,3 have 
been criticized. Re-evaluations of the study of the National Toxicology Program which 
showed an increase of kidney tumours only in male F344/N rats 2 led to the conclusions 
that the observed tumours were specific for the rat strain used and probably related to 
α2u-globulin nephropathy, which occurs only in male rats 36,37. The other in vivo study 3 
was also criticized 38 because the observed carcinogenicity could possibly be ascribed 
to the use of a specific rat strain and a whole grain diet in the study, which is however 
not fully understood. As mentioned in the introduction, the other long term studies 
with even higher doses of quercetin showed no carcinogenicity of quercetin 19-22. Even 
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figure 6.3 regulated transcripts of the genotoxicity classifier set by 2-aaf and afb1 23 versus 
by quercetin. Gene expression of quercetin is studied in liver and small intestine. Gene expression 
in liver of the known genotoxic compounds 2-AAF and AFB1 is taken along for comparison. Fold 
changes are presented as gene expression of intervention diet over control diet. Significant up-
regulation is indicated in yellow, down regulation in blue (p<0.05), non-significant regulation in white 
(p>0.05), and not determined regulation with nd 2-AAF; acetylaminofluorene, AFB1; aflatoxin B1. 
so, no genotoxicity was observed after oral quercetin administration in rodents 14-18. 
Thus overall, carcinogenic and genotoxic properties of quercetin have not been 
conclusively shown in vivo.
In contrast, the genotoxicity of quercetin has been demonstrated in vitro in multiple 
studies. The interpretation of these in vitro studies is uncertain, because the exposure 
of cells with quercetin in vitro differs from what really happens in the body. Apart from 
the intestinal cells, other cells in the body are exposed to much lower concentrations 
of quercetin, because metabolism in the intestinal wall and liver will modify quercetin 
resulting in low systemic availability of quercetin itself (Kroon et al. 2004). The quercetin 
metabolites or conjugates, e.g. glucuronides and sulfates, circulating in the blood are 
chemically distinct from their parent compound and their biological effects are likely 
to be different from that of the native compound 39. Furthermore, under cell culture 
conditions, flavonoids are rapidly oxidized resulting in oxidation products and H2O2 
40, 
which, when not properly controlled, can also explain the observed DNA damage. 
This discrepancy between in vitro and in vivo exposure, as is also seen for other 
flavonoid mediated effects 41, may explain why we and most other authors did not 
found in vivo genotoxic effects.
In this study the dose of quercetin was ~350 mg/kg bw/day for 12 weeks, which is 
about 1,000 times higher than human dietary intake and 15 times higher than human 
supplementary intake of quercetin.
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However, our results should also be seen in the light of the recent studies in which 
was shown in rats that quercetin exposure (0.03% quercetin diet, ~40 mg/kg bw/day) 
during pregnancy had effects on the foetus as quercetin can cross the placenta and 
can accumulate in the foetus. This could increase the risk on rearrangements in a gene 
which can be linked to childhood leukaemia. It was concluded that guidelines for 
using quercetin supplements during pregnancy are needed 42,43.
conclusions
In the present transcriptomics study, supplementation with quercetin at ~350 mg/kg bw/
day for 12 weeks gave no indications of quercetin-induced genotoxicity in liver and small 
intestine of mice. The small intestine is of special interest, because upon oral intake it 
is exposed to the highest amount of quercetin. We conclude that there is no reason for 
concern of genotoxicity in liver and small intestine after dietary intake of quercetin.
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7General Discussion
7.1 main findings and oUtline
main findings
The aim of this thesis was to identify mechanisms of beneficial health effects of flavonoids 
related to lipid metabolism and to characterise if high intake of these compounds would 
pose a risk for possible genotoxic effects. Elevated serum lipid levels, which were one of 
the important markers in our research, are known risk factors for cardiovascular diseases 
(CVD). Circulating and hepatic lipids are usually determined with fast and simple 
peroxidase-based assays. However, we have observed that flavonoids interfere in these 
assays, most likely due to inhibition of the peroxidase of these assays, as described 
in chapter 2. This means that the observed lipid lowering effects of flavonoids could 
have been overestimated in research when such peroxidase-based methods have been 
used, and therefore we have used alternative methods to adequately investigate lipid 
lowering effects of flavonoids. In chapter 3 we described that quercetin intake increased 
hepatic lipid omega-oxidation and lowered corresponding circulating lipid levels. In 
this study, a mild high-fat (MHF) background diet was used. We have suggested a 
possible role of the transcription factor constitutive androstane receptor (CAr) in these 
effects. Subsequently, high-fat (HF) diet-induced serum and hepatic lipids and body 
weight gain were found to be reduced by quercetin, which is described in chapter 4. 
The differences in the observed effects seen in chapter 3 and 4 suggested that the 
background diet that was used modified the effects induced by quercetin. In chapter 
5 the effects of quercetin were compared to other flavonoids from different flavonoid 
subclasses. Overall, quercetin was the most potent flavonoid in reducing the HF diet-
induced effects, but all studied flavonoids showed effects on HF diet-induced body 
weight gain. Furthermore, decreased expression of hepatic Cyp2b9, a known target 
gene of CAr, was found for all studied flavonoids. Given that possible beneficial 
effects of flavonoids may encourage higher flavonoid intakes, safety aspects have to 
be considered. Quercetin, the flavonoid shown to be the most active in our studies, 
has been linked to genotoxicity. Therefore, the genotoxic properties of quercetin were 
studied based on transcriptome profiling in small intestine and liver as described in 
chapter 6. This transcriptomic analysis showed no indication of genotoxicity of quercetin 
in either tissue at dose levels that were far above normal dietary intake.
outline of the discussion
The following sections will discuss a number of factors that might potentially influence 
observed health effects of flavonoids. Positive health effects are found in several 
epidemiological studies, however confirmation in intervention trials with flavonoid 
containing food supplements is scarce, and also discrepancies between animal studies 
and between human studies are found. This chapter will discuss our studies in relation 
to each other and in relation to other studies to gain insight in differences in outcomes 
that have been observed. The first paragraph describes differences between the in 
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vitro and in vivo situation (paragraph 7.2). The importance of choosing the right 
methods for studying flavonoid-mediated effects is discussed in paragraph 7.3. The 
dietary context (paragraph 7.4), and the doses used could also affect flavonoid-
mediated effects (paragraph 7.5). Next, some additional factors that may affect the 
ultimate results of studies characterising health effects of flavonoids, like gender and 
microbiota (paragraph 7.6). The implications of these factors for studying flavonoid-
mediated effect in humans are subsequently discussed in paragraph 7.7. Finally, this 
chapter will present the main conclusions of this thesis (paragraph 7.8).
7.2 In vItro versUs In vIvo
When considering experimental data on flavonoid-mediated effects it is important 
to realise that the in vitro situation may differ from the in vivo situation. For example, 
genotoxic effects of quercetin have been often found in vitro 1-4, while these genotoxic 
effects were not observed in vivo 5-7. In chapter 6 we have shown with transcriptome 
analyses that genotoxicity of quercetin was absent in liver and small intestine. Similarly, 
for example for flavonoid-mediated antioxidant effects, it was shown that although 
flavonoids are strong antioxidants in vitro, these effects could not explain disease 
prevention in vivo, given the low in vivo concentrations 8.
The interpretation of in vitro studies can be questionable when cells are being exposed 
to high concentrations of flavonoid aglycones, which differs from what is encountered 
in the body. With the possible exception of intestinal cells, other cells in the body are 
only exposed to very low concentrations of flavonoid aglycones. Metabolism in the 
intestinal epithelial cells and liver will modify the flavonoids entering the circulation 9. 
The metabolites formed, conjugates e.g. glucuronides and sulfates, circulating in the 
blood, are chemically distinct from their parent aglycones. The biological effects of 
these conjugates are very likely to be different from that of the native aglycones 10. 
Furthermore, under cell culture conditions, flavonoids are rapidly oxidized 
resulting in oxidation products and H2O2, especially when not properly controlled in 
the experiment 11. These oxidation products can affect cells and that may wrongly 
suggest functional effects on health or damage parameters.
In general, several other conditions are usually not taken into account in vitro; 
for example the crosstalk between organs, and influences of hormones. Cell culture 
conditions are physiologically different from in vivo conditions, for example the use of 
high glucose concentrations in cell culture medium can influence energy metabolism 
of the cells 12. Cell culturing may also result in loss of functions, with the loss of p450 
enzyme activity in the human hepatic cell line HepG2 as an example 13.
Therefore, several factors make that the in vitro situation differs from the in vivo 
situation. This discrepancy may explain why sometimes contradictory beneficial health 
effects or genotoxic effects of flavonoids are reported. In this thesis, the underlying 
mechanisms of flavonoid-mediated health effects is investigated, mainly in mouse 
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models. Further research could be performed in vitro, by selecting a model where 
the identified flavonoid targets are present. These experiments have to be properly 
controlled for auto-oxidation of flavonoids and should be performed including the 
naturally occurring metabolites of flavonoids.
7.3 analytical methods
The methods used to analyse flavonoid-mediated effects can also influence the 
observed effects. First of all interference of flavonoids in enzyme-based assays will 
be discussed in this paragraph. Subsequently, the use of transcriptomics in flavonoid 
research will be discussed. 
enzyme-based assays
Enzyme-based assays are generally accepted and used in research, including flavonoid 
research. In chapter 2, flavonoids were shown to interfere with enzyme-based assays 
for the determination of triglycerides (TG) and free fatty acids (FFA). These assays are 
based on peroxidases that convert intermediate products into a coloured product. 
The absorbance of these coloured products is subsequently measured and related 
to the amount of TG and FFA. However, several flavonoids are known to be able 
to inhibit peroxidase activity 14-16, resulting in apparent lower detected levels of the 
primary product by using these peroxidase-based assays.
In chapter 3 of the present thesis, serum TG and FFA levels of mice on a 
0.33% quercetin diet for 12 weeks were measured with enzyme-based assays and 
two independent analytical methods. The results obtained showed that the lipid 
lowering effect in quercetin-fed mice detected with the enzyme-based assays were 
clearly stronger than the effects measured with gas chromatography and 1H-NMR 
(Figure 7.1). This confirmed the interference of flavonoids with these assays (chapter 2). 
Furthermore, these lipid measurements in serum of an in vivo experiment, a matrix 
that logically contains mainly metabolised quercetin, showed that this interference can 
play a role under physiologically relevant conditions. 
Besides the TG and FFA assays, there are many more assays where peroxidases 
are used for detection 17,18. Horseradish peroxidase is commonly used in assays such as 
ELISA, Western blots and immunohistochemistry. In these assays, the target binds to the 
primary antibody, which binds to the secondary antibody which is linked to horseradish 
peroxidase, and the peroxidase will convert a substrate for final detection into a coloured 
product. The reason that peroxidases are often used in these assays is because a variety 
of substrates is available 18. Importantly, this means that with the use of peroxidase-
based ELISAs and possibly with more methods used in flavonoid research vigilance is 
needed and alternative enzymes should be used in these assays or alternative methods 
should be chosen to prevent overestimation of the lowering effects by flavonoids. 
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figure 7.1. Serum lipid lowering measured in the same animals with enzyme-based assays (kits) 
versus other analytical methods. Values are presented as the delta of the lowering of serum lipids 
in percentage of the levels found for quercetin (black) vs. control (white) mice, mean ± SEM (n=12). 
Asterisks indicates statistical difference, *p<0.05. TG; triglycerides, FFA; free fatty acids, 1H-NMR; 
1H-nuclear magnetic resonance, GC; gas chromatography.
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These assays are also often used for hepatic lipid quantification, therefore, in this 
thesis hepatic lipids were quantified with an alternative method; Oil Red O staining. 
For serum lipid profiling, gas chromatography was used. Furthermore, we also have 
implemented a 1H-NMR method for serum lipid profiling. We have adjusted this 
method, which was known for human samples, for the use of much smaller volumes 
available from mouse experiments. 
Transcriptomics 
Transcriptomic tools are nowadays widely used to study whole genome gene 
expression. With transcriptome profiling it is possible to search unsupervised for 
changes that may identify as yet unknown underlying mechanisms, because it is not 
needed to select targets or processes beforehand 19. Since a clear hypothesis for a 
mechanism of action for flavonoid-mediated health effects was initially not available, 
this technique and type of analysis was used in chapters 3 and 4. 
The flavonoids induced relatively small effects on gene expression in our studies. 
In chapter 3 we have performed a correction for multiple testing. We did not use this 
correction in chapter 4, because the observed hepatic gene regulation was much 
smaller. This demands vigilance in the interpretation of the data. While differential 
expression of single genes can be coincidental, validity of the findings can be supported 
by functional coherence between regulated genes. This is the case in chapter 4, where 
all three known hepatic Cyp2b genes were down-regulated by quercetin. Furthermore, 
identified targets were confirmed by an independent technique (RT-qPCR).
In chapter 5, in contrast to chapters 3 and 4, we have performed transcriptome 
analysis in a focused manner to identify potential genotoxic effects of quercetin. In 
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essence, transcriptome profiling was used to assess whether quercetin induced a 
genotoxicity gene expression profile. 
Altogether, the results in this thesis show that the microarray technique can be 
used to identify flavonoid-mediated mechanistic effects, which could be related to 
biological relevant physiological effects. In addition, transcriptome profiling can be 
used to develop or assess novel biomarkers or biomarker profiles 19,20, analogous to 
the genotoxicity profiling utilised in chapter 5. 
7.4 dietary context
The dietary context used in experiments studying flavonoid-mediated effects, can also 
influence the observed effects of flavonoids. Both chapter 3 and chapter 4 describe 
a dietary intervention in mice supplemented with the same dose of quercetin and 
with a similar set-up of the experiment. There was only one important difference 
between these studies; the background diet used was different. The difference of 
the diet was in fat energy % as well as in fat composition. In chapter 3, we report 
that quercetin in a MHF diet (30 en% fat) increased hepatic lipid omega-oxidation 
and lowered corresponding circulating lipid levels, while body weight gain, hepatic 
lipid accumulation and serum leptin levels were not significantly different. In chapter 
4, quercetin reduced HF (40 en%) diet-induced body weight gain, hepatic and serum 
lipids, and serum leptin levels, while no effects on omega-oxidation were found. The 
diet thus seemed to have an effect on the induced mechanism of action of quercetin 
and on the diet-induced body weight gain, hepatic lipid accumulation and leptin levels. 
These differences and the possible dietary effects on bioavailability and genotoxic 
properties of flavonoids will be discussed below. 
Dietary context and the underlying mechanism of flavonoid-mediated  
effects 
In chapter 3, increased hepatic lipid omega-oxidation is proposed as the underlying 
mechanism for the lowered serum lipid levels induced by quercetin. We have 
performed a similar study at 28°C. this study was not included in the preceding 
chapters of this thesis (unpublished data). The housing temperature 28°C is within 
the thermoneutral zone of mice. At thermoneutrality the energy requirements are 
the lowest, facilitating induction of diet-induced obesity in mice 21,22. In both studies 
exactly the same background diet, mouse strain, age, sex, individual housing and food 
accessibility were used, but the temperature was either 21 °C (the study reported in 
this thesis) or 28°C (unpublished data). Interestingly, the gene expression showed the 
same pattern of regulation of genes related to lipid omega-oxidation, the effects were 
smaller when the mice were housed at thermoneutral temperature, but showed the 
same trend of up-regulation of genes related to omega-oxidation (Table 7.1). 
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The serum lipid profiling showed lowered levels of palmitic acid (16:0) and oleic 
acid (18:1(n-9)) for the quercetin versus control group at 21°C, and the experiment at 
28°C showed the same trend (Figure 7.2). Palmitic acid (16:0) and oleic acid (18:1(n-9) 
are fatty acids, which specifically can be oxidised via omega-oxidation. The effects 
on gene expression level and on serum lipids in the experiment where the mice were 
housed at thermoneutral temperature were smaller, but followed the same trend as 
found in the experiment with housing at room temperature. This is in agreement with 
other data that suggest that thermoneutrality diminishes diet-induced metabolic 
differences 23. Nevertheless, these data indicate that with the same background diet, 
the same underlying effects were induced by quercetin. 
In chapter 3 we have suggested that the transcription factor CAR could have an 
important role in the quercetin-mediated regulation of lipid omega-oxidation. The 
omega-oxidation related Cyp4a genes, are also known to be targets of peroxisome 
proliferator-activated receptor alpha (PPARA). However, the connection of the 
differentially expressed genes, the up-regulation of Car and the known influence of 
CAR on lipid metabolism 24,25, suggested a relation of the transcription factor CAR 
with omega-oxidation in our experiment. Interestingly, in chapters 4 and 5 we have 
shown that HF-induced expression of Cyp2b9 was lowered by quercetin and other 
flavonoids. Cyp2b9 is a known target gene of CAR and not of PPARA. 
figure 7.2 relative serum palmitic (16:0) and oleic acid (18:1(n-9)) originating from total 
lipids. Serum lipids of the study described in chapter 3, 30 en% MHF diet housing at 21°C (A) and 
unpublished data of a study with the same setup and 30en% MHF diet, but animals were housed 
at 28°C (B). Data is presented as mean ± SEM (n=12). Asterisks indicate a significant difference 
between the control (C, white) and the quercetin (Q, black) group, *p<0.05.
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In chapter 3 where the MHF diet was used, an increased expression of omega-
oxidation by quercetin supplementation was shown, while using a HF diet (chapter 
4), no regulation of omega-oxidation was found (Table 7.1). The difference might be 
explained by the fact that HF diets induced omega-oxidation 26, which possibly masks 
further stimulation by quercetin. 
The regulation of Car and its Cyp2b target genes are all oppositely regulated in the 
experiment with the MHF diet compared to the experiment with the HF diet (chapter 3 vs. 
chapter 4). This is also the case for Fabp5, encoding a protein that can bind and transport 
PUFAs, including linoleic acid, into the liver 27. Linoleic acid was abundantly present in the 
HF diet (chapter 4), the amount was twofold higher than in the MHF diet (chapter 3). It 
was shown in vitro that linoleic acid can attenuate the activation of CAR and induction of 
Cyp2b9 mRNA 28,29. We have also studied the induction of CYP2B6 (the human homolog 
of Cyp2b10) in human liver HepaRG cells by the known CAR inducer CITCO. We observed 
that the induction CYP2B6 by CITCO (0.5 µM) was attenuated by addition of linoleic acid 
(100 µM) (Figure 7.3). Together this suggests that the background diet, and particularly 
the linoleic acid content, modulated the hepatic gene expression response to quercetin. 
Next to reduced body weight gain, all flavonoids showed reduced expression of 
hepatic Cyp2b9 (chapter 5). It has also been shown that many flavonoids can induce 
activation of CAR 30,31. This similar regulation by all flavonoids suggests a common 
mode of action of the flavonoids studied, and suggests that the results as shown in 
chapter 3 and 4 could possibly be similar for other flavonoids. Overall, CAR seems to 
play a role in flavonoid-mediated effects on lipid metabolism. 
Dietary context and flavonoid-mediated effects on hepatic lipid 
accumulation and body weight gain
In the previous section, it is discussed that the energy % of fat in the diet and/or the 
fat composition could affect the molecular effects of quercetin. The physiological 
figure 7.3 gene expression of cyp2b6 in heparg cells 
after exposure to linoleic acid (la) (100 µm) and citco 
(0.5 µm). Fold Changes are depicted as the expression 
values of exposed cells over control cells. Results 
are presented as mean ± SEM of three independent 
experiments (n=3). One-way ANOVA followed by a 
Bonferonni’s post hoc test was used to compare the 
different exposures. Different letters indicate a significant 
difference, p<0.05.
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effects found, e.g. body weight gain and hepatic lipid accumulation may also be 
modulated by the diet. In the MHF experiment we did not find any effect of quercetin 
on body weight gain or hepatic lipid accumulation (chapter 3), while in the HF-
experiment quercetin reduced the HF diet-induced hepatic lipid accumulation and 
body weight gain (chapter 4). In table 7 experiments in rodents are listed where 
quercetin was added to the diet. There are differences in the dose, duration and the 
background diet used. Strikingly, in most cases when a diet was used that induced 
body weight gain and/or hepatic lipid accumulation, this effect was reduced by 
quercetin supplementation. Next to our own observation 32, two other studies using 
a 40 en% HF diet in mice with quercetin supplementation of 0.025-0.05% reduced 
diet-induced body weight gain and hepatic lipid accumulation after supplementation 
during respectively 9 and 20 weeks. 33,34. Also the hepatic lipid accumulation induced 
with high cholesterol or methionine and choline deficient (MCD) diets was decreased 
by quercetin supplementation 35,36. Only one study that used a HF diet of 45 en% 
for 8 weeks did not show effects of quercetin on diet-induced body weight gain and 
hepatic lipid accumulation 37. The other studies presented in table 7.2 used diets 
that did not induce abundant body weight gain and/or hepatic lipid accumulation 
and indeed no effects of quercetin were observed on body weight gain or hepatic 
lipids. This indicates that quercetin may prevent body weight gain and hepatic lipid 
accumulation only under adverse dietary conditions which induce adiposity, but not 
with relatively healthy normal diets. 
table 7.2 Rodent studies using quercetin supplementation in different diets.
Quercetin 
in diet (%)
diet  
(en% fat)
Weeks animals body 
weight
hepatic 
lipids
ref
0.025 High-fat (40en%) 9 C57BL/6J mice ↓ ↓ 33
0.05 High-fat (40 en%) 4, 8, 20 C57BL/6J mice ↓ (wk 20) ↓ (wk 20) 34
0.33 High-fat(40en%) 12 C57BL/6JOlaHsd mice ↓ ↓ Chapter 4 / 32 
~1 High cholesterol 8 Swiss albino mice ND ↓ 36
~0.04, 0.2 unknown 10 Lean and obese  
Zucker rats
↓ (0.2%) ND 38
0.005 MCD 2, 4 C57BL/6J mice ↔ ↓ 35
0.05 Normal (16.7 en%) 4, 8, 20 C57BL/6J mice ↔ ↔ 34
0.005 Normal 2, 4 C57BL/6J mice ↔ ↔ 35
0.33 Mild High-fat (30 en%) 12 C57BL/6JOlaHsd mice ↔ ↔ Chapter 3 / 39
0.1, 1 Normal (11.5en%) 10, 41 Fisher 344 rats ↔ ND 40
0.8 High-fat (45 en%) 3, 8 C57BL/6J mice ↔ ND 37
0.03 Mild High-fat (35en%) 4 Wistar rats ↔ ND 41
1 Normal (20en%) 2 ICR mice ↔ ND 42
MCD; methionine and choline deficient, ND; not determined.
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Dietary effects on leptin
In chapter 5, a strong correlation between leptin and body weight gain was observed. 
Leptin is secreted by white adipose tissue and is a peptide hormone which regulates 
body weight gain. Serum leptin levels were significantly reduced by quercetin as shown 
in the HF-experiment (chapter 5), while serum leptin levels in the MHF-study (chapter 3), 
where the diet did not induce abundant adiposity, were not significantly different (data 
not shown). This corresponds with the found differences in body weight gain (chapters 4 
and 5), and the absence of body weight differences (chapter 3) between quercetin and 
control mice. Significant reductions in body weight gain and serum leptin levels were 
also shown for mice fed with a diet with hesperetin and anthocyanins supplementation 
(chapter 5). Effects on serum leptin levels were also found by others when studying 
the effect of anthocyanins on body weight gain. Supplementation with anthocyanins 
for 12 weeks significantly reduced HF diet-induced body weight gain, hepatic lipid 
accumulation, and serum leptin levels 43,44. HF diet-induced body weight gain and serum 
leptin levels were also reduced by blueberry anthocyanins in mice after 10 weeks 45, 
while black raspberry anthocyanins showed no effects on HF diet-induced body weight 
gain and serum leptin levels 46. Quercetin also induced reduced body weight gain and 
serum leptin levels by monosodium glutamate induced obesity in rats 47. It was also 
shown that quercetin had no effects on body weight and serum leptin levels after 4 
weeks of quercetin supplementation to a MHF diet 41. Together these results reveal that 
when flavonoid-mediated effects on body weight gain and adiposity were found, serum 
leptin levels were even more sensitively affected. The effects of flavonoids on diet-
induced adiposity seemed to be related to serum leptin levels. Leptin can be easily and 
rapidly measured in plasma or serum, and can therefore be used as an easy and useful 
early biomarker in humans for the effects of flavonoids on adiposity.
Dietary effects on bioavailability of flavonoids
For flavonoids it is known that bioavailability can also be influenced by dietary factors. 
Dietary fibres are suggested to decrease flavonoid absorption several folds 48, while 
dietary lipids are shown to increase the bioavailability of flavonoids. For example, in 
humans bioavailability of quercetin was increased by a fat-rich breakfast compared 
to a fat-free breakfast, the area under the curve for 24 h plasma concentrations was 
increased between 19-43% 49. Dietary proteins, carbohydrates and micronutrients 
are also suggested to have inhibitory or enhancing effects on the bioavailability 
of flavonoids 48. Therefore, the dietary context can influence the bioavailability of 
flavonoids, which can thereby influence the flavonoid-mediated effects. 
effects of dietary flavonoids on genotoxicity
The dietary flavonoids can also influence the bioavailability of genotoxic compounds, 
thereby influencing the genotoxic effects. The influence of flavonoids on the 
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bioavailability of genotoxic compounds can be via effects on transport proteins in 
the intestinal tract. Mostly this will result in a reduced absorption of carcinogenic 
compounds 50. However, for example, the trans cellular transport of the pro-carcinogen 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was increased by addition of 
flavonoids in Caco-2 monolayers 51. 
Furthermore, flavonoids can also affect metabolism, via interaction with phase 1 
and phase 2 enzymes 52. Flavonoids are known to inhibit cytochrome P450 (CYPs) 
enzymes involved in phase 1 metabolism. For example the flavonoid naringenin, mainly 
present in grapefruit juice, is a known inhibitor of CYP3A4. This phase 2 enzyme is, 
among others, involved in the biotransformation of the carcinogen aflatoxin B1 (AFB1) 
into its genotoxic epoxide metabolite 53.
Direct effects on phase 1 enzyme sulfotransferaxe (SULT) activity with the flavonoid 
nevadensin is for example also observed, this enzyme is involved in the bio-activation 
of allylalkoxybenzenes to carcinogens 54,55. 
Together this indicates that flavonoids can affect absorption and metabolism 
of genotoxic compounds, and this can result in detoxification or bioactivation of 
genotoxic compounds. 
7.5 doses 
The doses used in the experiments could also be of influence on the flavonoid-
mediated effects. First of all, this section will discuss the flavonoid doses used in our 
experiments compared to human intake. Then, the effects of the dose on the efficacy, 
bioavailability and genotoxicity of flavonoids will be presented. 
Flavonoid doses used as compared to human intake 
The dose of quercetin in the studies described in this thesis was 0.33% (w/w) of the 
diet, because previous findings showed that this was in the efficacy range for quercetin 
(between 0.1% and 1%) 40. The other flavonoids were added in equimolar amounts to 
the diet, which means supplementation of 0.29 to 0.5% (w/w) to the diets. The doses 
used were also within the range which is normally used in rodent flavonoid interventions 
as shown in table 1.2 of the general introduction and table 7.2 of this chapter. The 
doses of the individual flavonoids in the mice experiments provided ~350 to 500 mg/
kg bw/day for 12 weeks. In humans, the total estimated intake of flavonoids via food 
is between 1.5 and 15 mg/kg bw/day 56. Thus, the intake of the individual flavonoids 
that we have used in our mice interventions is between 200 and 1000 times higher than 
the estimated human dietary intake and about 15-100 times higher than the estimated 
human intake resulting from the use of flavonoid supplements. Thus, the doses used in 
the experiments were much higher than the average human dietary or supplementary 
intake, and it is of interest to elaborate if lower doses can also be effective.
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Dose and efficacy of flavonoids
Interestingly, in the experiment described in chapter 5, next to the HF-diet and the HF-diet 
with anthocyanins supplementation (HF+An10, 0.5%), we took along another group, 
which received a ten times lower dose of anthocyanins (HF+An1, 0.05%, unpublished 
data). This ten times lower dose of anthocyanins was shown to result in at least the same 
effect on HF diet-induced body weight gain, mesenteric white adipose tissue mass and 
hepatic lipid accumulation (Figure 7.4). The higher dose of anthocyanins did not directly 
result in stronger effects, this could probably be caused by saturation of uptake of 
flavonoids in some organs. Some other studies also did not find a dose-response relation 
when studying the efficacy of flavonoids. In a study in rats where three doses (10, 20 or 30 
mg/kg bw/day) of hesperetin were given in combination with 1,2-dimethylhydrazine for 
induction of colon carcinogenesis, all doses of hesperetin showed significant reduction 
of colon cancer indications. However, the effect was suppressed formation of more 
indicators of colon cancer 58,59. For the polyphenol resveratrol, it was also shown that 
of the three doses used (6, 30 and 60 mg/kg bw/day), the intermediate dose showed 
the highest potency for anti-obesity, and this dose showed significant effects on more 
parameters than the other doses 60. In this experiment, tissue distribution was also studied 
for these three doses of resveratrol. In liver, a dose-dependent amount of resveratrol 
metabolites was found. But in adipose tissue, the metabolites increased only between 
the two lowest doses, and were similar for the middle and highest dose. In muscle, also 
similar amounts were detected for the middle and highest dose. It was suggested that 
there is a maximum in the capacity of certain tissues for metabolite incorporation, which 
cannot be exceeded by supplementation with higher doses 61. 
Most likely there will be an optimal beneficial intake for flavonoids, this concept 
was also described for bioactive food components in general 62. Based on the data 
presented in Figure 7.4 it is concluded that the beneficial health effects on hepatic 
lipid metabolism as observed in our mice experiments, could probably be translated to 
humans by using doses which can be obtained with flavonoid supplements. However, 
even by taking this optimal beneficial intake concept into account, these beneficial 
health effects could possibly not translated to humans by dietary intake of flavonoids. 
For further research it is important to determine the optimal effective dose of flavonoids.
Dose and genotoxicity
The traditional dose-response relation, that a higher dose will be more effective, can 
also be expected for genotoxic effects of flavonoids. Indeed, dose-dependent effects 
on carcinogenicity of quercetin were shown in rodents: when different doses were 
used (providing ~50-2000 mg/kg bw/day), the highest doses showed more tumour 
formation 63. Furthermore, DNA adduct formation was shown to be dose-dependent 
for known genotoxic compounds 64, which suggests that stronger genotoxic effects 
can be expected at higher doses of flavonoids, as long as the bioavailability of the 
flavonoids is also dose-dependent.
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The dose of quercetin used, in the experiment where we have studied the 
genotoxicity, was ~350 mg/kg bw/day for 12 weeks, which is about 1,000 times the 
human dietary intake of quercetin. This gave no indications of quercetin-induced 
genotoxicity in liver and small intestine of mice. Genotoxicity was also not found in 
rodents after oral quercetin administration measured by among others micronuclei, 
chromosomal aberrations and unscheduled DNA synthesis in bone marrow, liver, and 
gastric mucosa cells 5-7,65,66. Furthermore, several other long-term (ranging from 64 
weeks to lifespan) in vivo studies showed no carcinogenicity after quercetin exposure 
figure 7.4 effects of two different doses of anthocyanins on body weight gain, relative 
mesWat weight and lipid accumulation in liver. Anthocyanins were added to a HF diet with 
0.033% (HF+An1) and 0.33% (HF+An10). Curve fitting was used to analyze body weight gain 
using Proast software 57. One-way ANOVA with a Dunnett’s post hoc test was used the compare 
the relative mesWAT weight and area of hepatic lipids between the HF+An groups and the HF 
control group. Data is presented as mean ± SEM (n=8-12), asterisks indicate significant differences, 
*p<0.05, **P<0.01, ***p<0.001. MesWAT, mesenteric white adipose tissue.
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providing ~60-3500 mg/kg bw/day in rodents 67-70. Hence, there is no reason for 
concern over genotoxicity in liver and intestine after dietary intake of quercetin. 
The quercetin doses used in this mouse experiment are 15 times higher than human 
supplementary intake of quercetin. For non-genotoxic substances a safety factor of 100 
is normally used to correct for inter-species differences and human variability. Of note, 
recent studies in rats showed that a quercetin exposure of ~40 mg/kg bw/day during 
pregnancy can affect the foetus, as quercetin can cross the placenta and accumulates 
in the foetus. These studies also reported that the rearrangements in a gene which 
can be linked to childhood leukaemia was increased 71,72. Therefore, the safety of high 
supplementary intake of flavonoids should be further studied, and possibly specific 
guidelines for using quercetin supplements during pregnancy are needed.
7.6 other potential factors inflUencing 
efficacy of flavonoids
In this paragraph two more factors will be discussed which could potentially influence 
flavonoid-mediated effects, namely gender and colonic microbiota.
Gender 
The rodent studies of the present thesis and other studies investigating effects of 
quercetin as mentioned in table 7.2, were performed only with male mice. Data in 
female rodents are lacking, while the effects could be different between males and 
females. It is for example shown for the dietary compound beta-carotene that it can 
induce opposite effects in gene expression for male and female mice 73. Also the 
flavonoids genistein and quercetin-3-O-rutinoside (rutin) have shown sex-dependent 
differences in effects in kidney and on serum markers of cardiovascular health, 
respectively 74,75. Furthermore, sensitivity for activation of CAR and CYP4A, involved 
in the suggested mechanisms of action of quercetin in chapter 3, is known to be sex-
dependent 76,77. For further research it is important to also study effects in females and 
to analyse if sex dependent differences in flavonoid mechanisms of action exist. 
colonic microbiota
Flavonoids are extensively metabolised by bacteria in the colon. Individual differences 
in microbiota could have an influence on the extent and kind of metabolism of 
flavonoids that predominantly occurs. This will influence the amount and composition 
of the colonic metabolites, which also could have effects on health outcomes 78. 
Excessive amounts of flavonoids entering the colon could also inhibit the growth 
of colonic microbiota, and thus influencing the metabolite profile in the colon and 
subsequently in the circulation79. The exact implications of colonic microbiota for the 
effects of flavonoids are not known and need to be further investigated 80. 
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7.7 implications for stUdying flavonoid-
mediated effects in hUmans
For the translation of the flavonoid-mediated effects found in animals to humans several 
factors should be taken into account. Many of the factors mentioned above have 
specific implications when performing flavonoid research in humans and contribute to 
the explanation of discrepancies that are found between human and animal studies 81. 
Factors which have specific implications for studying flavonoid-mediated effects in 
humans compared to animals are discussed below.
mouse as a model
Identifying mechanisms of actions in specific organs, e.g. liver, is not easily done in 
humans, therefore the mouse is widely used as a model for studying diet-induced obesity, 
insulin resistance, cardiovascular diseases, and hepatic lipid accumulation 82-84. The effects 
of flavonoids on lipid metabolism as shown in this thesis, have been studied before in a 
mouse model 85-87. However, for the translation to humans, these specific effects on lipid 
metabolism should be confirmed in humans. Apart from physiological differences between 
humans and mice in lipid metabolism, the following factors should be considered.
Flavonoid metabolism
The metabolism of flavonoids can also be different between mice and humans. It is 
described that various mono-, di- and tri-conjugates are found for quercetin in the 
circulation of rodents as well as in humans 88, suggesting an overall comparable pattern 
of conjugates formed after flavonoid metabolism in mice and humans. However, the 
amount of specific conjugates of quercetin for example can be different between mice 
and humans 89-95 and also the biological effects of conjugates can be different 10,89. 
Therefore, possible differences in the major flavonoid conjugates present in the 
systemic circulation could affect the observed physiological effects. 
Dietary context
The dietary context can modulate the molecular and physiological effects of 
flavonoids, as discussed above. In human intervention studies, mostly no controlled 
defined background diet is used. Moreover, in observational studies flavonoid 
intake is estimated on the basis of general dietary intake 96-100, not corrected for the 
differences in dietary background intake between subjects. This can contribute to the 
explanation why more abundant effects are found in animal studies than in human 
interventions. Therefore, it is important to consider the dietary context in detail in 
flavonoid research. Ideally a fully-controlled dietary background should be used in 
further research, alternatively the dietary intake could be measured, which can be 
used for correction for possible confounding effects of the dietary context.
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Purity of flavonoids
Human intervention studies that showed beneficial effects on functional markers for 
CVD, are almost exclusively based on administration of flavonoid-rich foods, such as 
cocoa, tea, berries or wine 96-100. These flavonoid-rich foods or extracts also contain 
many other substances that may have an effect, such as for example theobromine and 
caffeine. For instance, caffeine was present in many human intervention studies with 
green tea flavan-3-ol containing extracts. Effects on body weight were only seen in 
green tea extracts that also contained caffeine 101. Therefore, it is important that pure 
individual flavonoids will be studied, since now there is only very limited information 
on effects of individual flavonoids in humans. In rodents, pure flavonoids have been 
studied more often, and these studies could give important clues for human research.
Taken together, for the design of effective flavonoid studies in humans, we have 
to control or correct for several factors like dietary context, dose, purity of flavonoids, 
flavonoid bioavailability and flavonoid metabolism. In addition, it may be advisable 
to characterize participants with respect to microbiota and genetic constitution (for 
example polymorphisms in metabolizing enzymes). This will lead to more reliable and 
relevant experiments, which contribute to the unravelling of the potential beneficial 
effects on lipid metabolism of flavonoids.
7.8 conclUsions
In this thesis several effects of flavonoids in mice are described. Interference of 
flavonoids in peroxidase-based assays was demonstrated, which will overestimate 
the effects of flavonoids. Therefore, vigilance is needed in using these and other 
peroxidase-based assays in flavonoid research. The flavonoid quercetin showed effects 
on hepatic lipid metabolism and on whole body energy balance. The mechanistic and 
physiological effects of quercetin appeared to be modulated by the fat content and 
fat composition of the dietary background. The effects on hepatic lipid metabolism 
seemed to be related or influenced by the transcription factor CAR. All five studied 
flavonoids, quercetin, hesperetin, epicatechin, apigenin and anthocyanins showed 
reduction of HF diet-induced body weight gain, with quercetin showing the strongest 
effects in preventing adiposity. No genotoxic effects of quercetin were found in our 
transcriptomic analysis in small intestine and liver of mice. 
Our studies revealed beneficial health effects of flavonoids in mice on hepatic 
lipid metabolism, which could probably be translated to humans by using doses which 
can be obtained with flavonoid supplements, but possibly not by dietary intake of 
flavonoids. Individual differences in consumed diet, colonic microbiota, and gender, 
also contributing to differences in flavonoid bioavailability and metabolism, probably 
hampered observations of flavonoid effects on lipid metabolism in human experiments. 
Fully-controlled experiments using pure flavonoids, with fixed background conditions in 
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animals and humans, could contribute to better understanding of underlying mechanisms 
of the health effects of flavonoids on lipid metabolism, and these studies would help to 
better evaluate flavonoids as potential functional healthy dietary compounds. 
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Consumption of foods containing flavonoids is associated with a reduced risk of 
cardiovascular diseases (CVD), possibly by lipid-lowering effects. On the other hand, 
for one of these flavonoids, quercetin, also genotoxicity was shown especially in 
in vitro bioassays. Therefore, the first aim of this thesis was to identify mechanisms 
underlying potential beneficial health effects of flavonoids. The focus was on hepatic 
lipid metabolism and circulating lipids and a molecular and physiological approach was 
used. Secondly, we aimed to study the potential in vivo genotoxic effects of quercetin 
by transcriptome analyses in liver and small intestine, since these represent the tissues 
of first contact exposed to relatively high levels upon oral intake of flavonoids.
Circulating lipids are important CVD-related risk markers, which are in general 
determined with commercially available enzyme-based assays. However, the usual 
enzyme in these assays, peroxidase, has previously been reported to be inhibited 
by flavonoids. Therefore, we have studied in chapter 2 whether these assays can 
adequately be used in flavonoid research. We observed that various flavonoid 
aglycones interfere with peroxidase used in triglycerides (TG) and free fatty acids 
(FFA) enzymatic assays, reporting incorrect lower TG and FFA levels than actually 
present. Furthermore, addition of metabolites such as isorhamnetin or quercetin-3-
O-glucuronide, the major metabolite of quercetin in human and rat plasma, to murine 
serum also resulted in a significant reduction of the detected TG levels, while a trend 
was seen towards reduced FFA levels. It can be concluded that when applying these 
biochemical assays, vigilance is needed and alternative analytical methods assessing 
FFA or TG levels should preferably be applied for studying the biological effects of 
flavonoids on TG and FFA levels.
In chapter 3 mechanistic and physiological effects of quercetin on hepatic lipid 
metabolism were studied. C57BL/6JOlaHsd male adult mice received a mild high-fat 
(30 en%) diet without or with supplementation of 0.33% (w/w) quercetin for 12 weeks. 
Gas chromatography and 1H-NMR were used to quantitatively measure serum lipid 
profiles. Whole genome microarray analysis of liver tissue was used to identify potential 
mechanisms underlying altered circulating lipid levels by quercetin supplementation. 
Body weight, energy intake and hepatic lipid accumulation did not differ significantly 
between the quercetin and the control group. In serum of quercetin-fed mice, TG 
levels were decreased by 14% (p<0.001) and total poly unsaturated fatty acids (PUFA) 
levels were increased by 13% (p<0.01). Levels of palmitic acid, oleic acid, and linoleic 
acid were all decreased by 9-15% (p<0.05) in quercetin-fed mice. Both palmitic acid 
and oleic acid can be oxidized by omega-oxidation. Gene expression profiling showed 
indeed that quercetin increased hepatic lipid metabolism, especially omega-oxidation. 
At the gene level, this was reflected by the up-regulation of cytochrome P450 (Cyp) 
4a10, Cyp4a14, Cyp4a31 and Acyl-CoA thioesterase 3 (Acot3). Two relevant regulators, 
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cytochrome P450 oxidoreductase (Por, rate limiting for cytochrome P450 activities) 
and the transcription factor constitutive androstane receptor (Car; official symbol 
nr1i3) were also up- regulated in the quercetin-fed mice. We concluded that quercetin 
intake increased hepatic lipid omega-oxidation and lowered corresponding circulating 
lipid levels, which may contribute to potential beneficial effects of quercetin on CVD.
Subsequently, in chapter 4 effects of quercetin supplementation were studied in mice 
given a high-fat (40 en%) background diet. The set-up of the experiment was the same 
as in chapter 3, with the exception of the background diet that was used, which was 
different in fat content and composition. This high-fat diet-induced body weight gain, 
and serum and hepatic lipid accumulation, which are all known risk factors for CVD. The 
aim of this study was to investigate the effects and underlying molecular mechanisms 
of the effects of the flavonoid quercetin on hepatic lipid metabolism in mice given this 
high-fat diet background. C57BL/6JOlaHsd male adult mice received the high-fat diet 
without or with supplementation of 0.33% (w/w) quercetin for 12 weeks. Body weight 
gain was 29% lower in quercetin fed mice versus control mice (p<0.01), while the energy 
intake was not significantly different. Quercetin supplementation lowered high-fat 
diet-induced hepatic lipid accumulation to 29% of the amount present in the control 
mice (p<0.01). 1H-NMR serum lipid profiling revealed that the supplementation also 
significantly lowered high-fat diet-induced increases in serum lipid levels. Global gene 
expression profiling of liver showed that cytochrome P450 2b (Cyp2b) genes, key target 
genes of the transcription factor Car, were down-regulated. However, the induction of 
omega-oxidation observed by quercetin supplementation to a mild high-fat (30en%) 
diet (chapter 3), was not observed this time with the high-fat (40en%) diet. Cumulatively, 
quercetin decreased high-fat diet-induced body weight gain, hepatic lipid accumulation 
and serum lipid levels. This was accompanied by regulation of cytochrome P450 2b 
genes in liver, which are considered to be under transcriptional control of CAR. The 
quercetin effects are likely dependent on the fat content and composition of the diet.
In chapter 5 we investigated whether flavonoids from other flavonoid subclasses can 
exert the same effects as we observed for quercetin. Effects of quercetin, hesperetin, 
epicatechin, apigenin and anthocyanins, in C57BL/6JOlaHsd male adult mice fed a 
high-fat diet for 12 weeks were compared, relative to a normal-fat diet. High-fat diet-
induced body weight gain was significantly lowered by all flavonoids (17-29%), but 
most by quercetin. Quercetin significantly lowered high-fat diet-induced hepatic lipid 
accumulation (by 71%). High-fat diet-induced increases of mesenteric adipose tissue 
weight and serum leptin levels were significantly lowered by quercetin, hesperetin, and 
anthocyanins. Adipocyte cell size and adipose tissue inflammation were not affected. 
The effects on body weight and adiposity could not be explained by individual significant 
differences in energy intake, energy expenditure, nor by differences in activity. Lipid 
metabolism was not changed as measured by indirect calorimetry or expression of known 
lipid metabolic genes in liver and white adipose tissue. Hepatic expression of Cyp2b9 was 
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strongly down-regulated by all flavonoids. Overall, all five flavonoids lowered parameters 
of high-fat diet-induced adiposity, with quercetin being most effective. 
Next to the beneficial health effects of flavonoids, the safety of flavonoids is under discussion, 
mainly because of potential genotoxic effects found for quercetin in vitro. Therefore, in 
chapter 6 the in vivo genotoxicity of this flavonoid was studied by transcriptome analyses 
in two tissues, small intestine and liver, where the highest exposure to quercetin is 
expected. This is especially of interest in view of high intake by widely available food 
supplements. Quercetin (0.33%) supplemented to a high-fat diet was administered to 
C57BL/6JOlaHsd male adult mice during 12 weeks. Serum alanine aminotransferase 
and aspartate aminotransferase levels revealed no indications for hepatotoxicity. 
General microarray pathway analysis of liver and small intestinal tissue samples showed 
no regulation of genotoxicity related pathways. In addition, analysis of DNA damage 
pathways in these tissues did also not point at genotoxicity. Furthermore, comparison with 
a published classifier set of transcripts for identifying genotoxic compounds did not reveal 
any similarities in the regulation of these classifier set by quercetin. Available microarray 
datasets of known genotoxic liver carcinogens, 2-acetylaminofluorene and aflatoxin B1 in 
mice were taken along as positive controls for comparison, and indeed showed genotoxic 
properties (regulation of genotoxic related genes) in the analyses. This transcriptomic 
analysis showed that supplementation with quercetin at ~350 mg/kg bw/day for 12 weeks 
did not induce genotoxicity in liver and small intestine.
In conclusion, we have shown in vivo efficacy of flavonoids reflected by effects on 
metabolic health parameters, including hepatic lipid metabolism. These effects on hepatic 
lipid metabolism seemed to be related or influenced by the transcription factor CAR. The 
dietary contexts appeared to modify the health effects. The five studied flavonoids in 
general showed the same effects, with quercetin being the most effective. No genotoxicity 
of quercetin was found by transcriptome analyses in liver and small intestine. Overall, we 
have obtained indications for beneficial health effects of flavonoids in mice, which makes 
it interesting to study if these effects can be extrapolated to humans to further explore 
their potential as functional compounds of dietary flavonoid intake.
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Het consumeren van voedingsmiddelen rijk aan flavonoïden wordt geassocieerd met 
een verminderd risico op hart- en vaatziekten, mogelijk als gevolg van een verlaagd 
lipide-gehalte in het bloed. Echter, voor één van deze flavonoïden, quercetine, geven 
in vitro proeven aanwijzingen voor mogelijke genotoxiciteit. Het eerste doel van dit 
proefschrift was het identificeren van mechanismen die ten grondslag liggen aan 
gezondheids-bevorderende effecten van flavonoïden. Hierbij lag de focus op het 
vetmetabolisme in de lever en het lipide-gehalte in het bloed. Het tweede doel was 
om de mogelijke genotoxische effecten van quercetine in de lever en dunne darm te 
onderzoeken. Deze twee weefsels werden gekozen omdat deze als eerste blootgesteld 
worden aan relatief hoge niveaus flavonoïden bij consumptie van voedingsmiddelen 
of supplementen rijk aan flavonoïden. 
Lipide-gehalten in het bloed zijn belangrijke risico-indicatoren voor hart- en vaatziekten. 
Lipiden in het bloed worden over het algemeen bepaald met behulp van commercieel 
beschikbare enzymatische assays. Deze assays zijn meestal gebaseerd op het gebruik 
van het enzym peroxidase. Echter, het is bekend dat het enzym peroxidase kan 
worden geremd door flavonoïden. Daarom hebben we in hoofdstuk 2 bestudeerd 
of deze assays op een adequate manier gebruikt kunnen worden in onderzoek met 
flavonoïden. We laten zien dat verschillende flavonoïden interfereren met peroxidase 
in triglyceriden- en vrije vetzuur-assays. Dit resulteerde in incorrecte, lagere gemeten 
waarden van triglyceriden en vrije vetzuren dan de daadwerkelijk aanwezige waarden. 
Verder resulteerde het toevoegen van metabolieten van quercetine aan muizenserum 
ook in een significante, maar incorrecte schijnbare afname van de gemeten waarden 
van triglyceriden. Deze afname werd ook waargenomen in de gemeten waarden van 
de vrije vetzuren, hoewel dit effect niet significant was. Daarom is voorzichtigheid 
geboden wanneer deze op peroxidase-gebaseerde assays worden gebruikt bij het 
bestuderen van de effecten van flavonoïden. Alternatieve methoden, zoals 1H-NMR, 
LC-MS of gas-chromatografie worden daarom aanbevolen voor het bestuderen van de 
effecten van flavonoïden op triglyceriden en vrije vetzuren in het bloed.
In hoofdstuk 3 hebben we de mechanistische en fysiologische effecten van quercetine op 
vetmetabolisme bestudeerd. Volwassen C57BL/6JOlaHsd muizen kregen een dieet met 
een mild hoog vetgehalte (30 en%) met of zonder toevoeging van 0.33% (w/w) quercetine 
gedurende een periode van 12 weken. Lichaamsgewicht en energie-inname waren niet 
verschillend tussen de quercetine en de controle groep. In het bloed werden lipide-
profielen bepaald door middel van gas-chromatografie en 1H-NMR. In het bloed van de 
muizen die het dieet verrijkt met quercetine kregen, was het triglyceride niveau 14% lager 
(p<0.001) en het gehalte meervoudig onverzadigde vetzuren was toegenomen met 13% 
(p<0.01) ten opzichte van de controle groep. Verder waren in het bloed van de muizen die 
het quercetine-dieet kregen, de niveaus van de 16:0, 18:1(n-9) en 18:2(n-6) vetzuren 9-15% 
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lager (p<0.05). Mogelijke onderliggende mechanismen voor de afname van de lipide-
gehalten in het bloed werden onderzocht m.b.v. genoom brede genexpressie analyse. We 
vonden op-regulatie van de genen Cyp4a10, Cyp4a14, Cyp4a31 en Acot3. Deze genen 
zijn betrokken bij omega-oxidatie van vetzuren, een proces waarbij de vetzuren 16:0 en 
18:1(n-9) kunnen worden geoxideerd. Twee andere relevante genen, Por en Car, waren 
ook op-gereguleerd in de muizen die waren blootgesteld aan quercetine. Inname van 
quercetine verhoogde in deze studie de vetzuur omega-oxidatie en verlaagde het gehalte 
van specifieke vetzuren (16:0 en 18:1(n-9). Deze effecten zouden ten grondslag kunnen 
liggen aan mogelijk preventieve effecten van quercetine op hart- en vaatziekten.
In hoofdstuk 4 hebben we de effecten van quercetine bestudeerd in een bredere 
context door het toe te voegen aan een dieet met een hoger vetgehalte (40 en%). 
De opzet van dit experiment was gelijk aan het experiment uit hoofdstuk 3, met 
uitzondering van het achtergrond dieet dat hier werd gebruikt. Dit dieet met hoog 
vetgehalte veroorzaakte een toename van het lichaamsgewicht, een toegenomen 
vervetting van de lever en een toename van het lipide-gehalte in het bloed. Deze 
effecten zijn risicofactoren voor hart- en vaatziekten. Het doel van deze studie was 
om de effecten van quercetine te onderzoeken op het vetmetabolisme in de lever 
en de onderliggende mechanismen die hieraan ten grondslag liggen in muizen die 
een dieet met een hoog vetgehalte kregen. Volwassen C57BL/6JOlaHsd muizen 
kregen het dieet met of zonder toevoeging van 0.33% (w/w) quercetine gedurende 
een periode van 12 weken. Na deze 12 weken was het lichaamsgewicht 29% minder 
toegenomen in de muizen waar quercetine was toegevoegd aan het dieet. Omdat de 
energie-inname tussen de groepen gelijk was, kan het verschil in energie-inname niet 
de verklaring zijn voor het verschil in gewichtstoename. De vervetting van de lever was 
ook afgenomen met 29% in vergelijking met de mate van leververvetting in de controle 
muizen. De bepaling van het lipide-profiel m.b.v. 1H-NMR liet ook zien dat quercetine 
de door het vet geïnduceerde serum lipide-gehaltes verminderde. Microarray analyse 
van leverweefsel liet een op-regulatie zien van Cyp2b genen, target genen van CAR. 
De inductie van omega-oxidatie zoals beschreven in hoofdstuk 3 waar quercetine werd 
toegevoegd aan een dieet met een mild hoog vetgehalte, zagen we niet terug in deze 
studie waarin gebruik gemaakt werd van een dieet met een hoog vetgehalte. Quercetine 
verminderde de door het hoog-vet-dieet geïnduceerde lichaamsgewichttoename, 
vervetting van de lever en de lipide-gehalten in het bloed. Dit ging gepaard met 
regulatie van Cyp2b genen in de lever. De door quercetine geïnduceerde effecten zijn 
waarschijnlijk afhankelijk van het vetgehalte en de samenstelling van het dieet. 
In hoofdstuk 5 hebben we onderzocht of flavonoïden van andere flavonoïde-
subklassen dezelfde effecten hebben als de effecten die we hebben gevonden voor 
quercetine. De effecten van quercetine, hesperetine, epicatechine, apigenine en 
anthocyaninen werden vergeleken in muizen die 12 weken een dieet met een hoog 
vetgehalte (40 en%) kregen waaraan deze flavonoïden werden toegevoegd. Het 
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controle dieet veroorzaakte een toename in lichaamsgewicht. Door toevoeging van de 
verschillende flavonoïden, verminderde de toename in lichaamsgewicht met 17-29%, 
afhankelijk van de specifieke flavonoide. De grootste effecten werden gevonden voor 
quercetine. Quercetine verlaagde de door het dieet geïnduceerde vervetting van de 
lever met 71%. De hoeveelheid mesenterisch vetweefsel en de leptine-waarden in het 
bloed werden significant minder verhoogd in de groep met het dieet met quercetine, 
hesperetine of anthocyaninen. De gemiddelde grootte van de adipocyten en de mate 
van inflammatie in het vetweefsel bleven onveranderd. De effecten op lichaamsgewicht 
en adipositas kunnen niet worden verklaard door individuele significante verschillen 
in de energie inname, het energieverbruik, of de lichaamsactiviteit van de muizen. 
Het vetmetabolisme werd gemeten met behulp van indirecte calorimetrie en 
expressie van genen die betrokken zijn bij vetmetabolisme in lever en vetweefsel. 
Het vetmetabolisme bleek niet veranderd te zijn door toevoeging van de flavonoïden 
aan het dieet. Genexpressie van Cyp2b9 was sterk omlaag gereguleerd door alle 
flavonoïden. Parameters van dieet-geïnduceerde adipositas werden verlaagd door alle 
vijf de flavonoïden, waarbij quercetine de sterkste effecten liet zien.
Naast de gezondheids-bevorderende effecten van flavonoïden, staat de veiligheid 
van flavonoïden ook ter discussie, vooral door de mogelijk genotoxische effecten 
van quercetine die werden gevonden in in vitro experimenten. Daarom hebben we 
in hoofdstuk 6 de in vivo genotoxiciteit van quercetine onderzocht door middel van 
genoom brede genexpressie analyses in weefsel afkomstig van de dunne darm en de 
lever van muizen blootgesteld aan quercetine. Dit zijn de organen die naar verwachting 
blootgesteld worden aan de relatief hoogste concentraties quercetine. Dit is relevant 
met het oog op breed beschikbare quercetine-supplementen, waarmee een hoge 
dosis quercetine kan worden ingenomen. Quercetine (0.33%, w/w) werd toegevoegd 
aan een dieet met een hoog vet gehalte, en werd gedurende 12 weken gegeven aan 
C57BL/6JOlaHsd muizen. Serum alanine aminotransferase en aspartaat aminotransferase 
waarden gaven geen indicatie voor leverschade. Genexpressie analyse in weefsel 
van zowel de lever als dunne darm toonde geen regulatie aan van processen die 
geassocieerd zijn met genotoxiciteit. Een analyse van processen gerelateerd aan DNA 
schade liet ook geen indicatie zien voor genotoxiciteit van quercetine. Verder liet een 
vergelijking met een bekende set van genen die gebruikt worden voor het identificeren 
van genotoxische stoffen zien dat er geen overeenkomt was met de door quercetine 
gereguleerde genen. Beschikbare lever microarray datasets van bekende genotoxische 
stoffen dienden als positieve controle en lieten inderdaad regulatie zien van genen 
die gerelateerd zijn aan genotoxiciteit. Hieruit concludeerden we dat toevoeging van 
quercetine aan het dieet (350 mg/kg bw per dag) van muizen gedurende 12 weken 
echter geen genotoxiciteit in de lever en dunne darm induceerde. 
Concluderend hebben we laten zien dat quercetine in vivo effecten heeft op 
parameters die gerelateerd zijn aan metabole gezondheid, zoals vetmetabolisme in 
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de lever. Deze effecten op vetmetabolisme in de lever lijken gerelateerd te zijn aan 
de transcriptiefactor CAr. De dieet-context kan deze gezondheids-bevorderende 
effecten beïnvloeden. Over het algemeen lieten de vijf flavonoïden vergelijkbare 
effecten zien, waarbij quercetine het meest effectief was. Er werden geen aanwijzingen 
voor genotoxiciteit van quercetine gevonden in de lever en de dunne darm. We 
hebben duidelijke aanwijzingen voor gezondheids-bevorderende effecten laten zien 
van flavonoïden in muizen. Daarom is het interessant om in de toekomst te bestuderen 
of deze effecten geëxtrapoleerd kunnen worden naar de mens, om zo de potentie van 
flavonoïden als functionele voedingscomponenten verder te onderzoeken. 
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